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Dissertation supervised by Dr. Aleem Gangjee 
This dissertation describes the design, synthesis and biological evaluation of 
monocyclic, bicyclic and tricyclic pyrimidine-based heterocycles as a) single agents with 
combination chemotherapy potential having dual antiangiogenic effects and cytotoxic 
effects or b) one-carbon metabolism inhibitors  for targeted tumor therapy; or c) selective 
Pneumocystis jirovecii (pj) dihydrofolate reductase (pjDHFR) inhibitors for pneumocystis 
pneumonia (PCP) infection.  
The work in this dissertation is centered on identifying structural features that are 
necessary for inhibition of tubulin polymerization or thymidylate synthase as well as for 
inhibition of one or more of the receptor tyrosine kinases (RTKs)- vascular endothelial 
growth factor receptor-2 (VEGFR2), epidermal growth factor receptor (EGFR) and/or 
platelet-derived growth factor receptor β (PDGFR- β) in single entities. Single agents with 
both antiangiogenic activities as well as cytotoxicity (via disruption of microtubule 
 v 
dynamics or thymidylate synthase inhibition) would afford agents that circumvent 
pharmacokinetic problems of multiple agents, avoid drug-drug interactions, could be used 
at lower doses to alleviate toxicity, be devoid of overlapping toxicities, and delay or prevent 
tumor cell resistance.  
Synthesis of substituted quinazoline and pyrido[3,2-d]pyrimidines is described. It 
also reviews the synthesis of multi-transporter (PCFT and FR) selective 5-substituted 
pyrrolo[2,3-d]/[3,2-d]pyrimidines as targeted one-carbon metabolism enzymes 
(GARFTase/AICARFTase and/or SHMT2) inhibitors circumventing both dose-limiting 
toxicity and tumor resistance associated with most prescribed antitumor agents like 
pemetrexed. 
PCP is a host species-specific infection. Current therapies such as trimethoprim-
sulfamethoxazole (TMP-SMX) combination, which has been used for PCP for decades, has 
major limitations due to low inhibitory potency of TMP, side-effects of SMX and emergence of 
resistant strains expressing mutated dihydropteroate synthase enzyme (target of SMX). For 
patients unresponsive or resistant to this treatment, newer drugs are critically needed. Structure-
based design, using a pjDHFR homology model and through the identification of amino acid 
differences between pjDHFR and hDHFR active sites, has been presented in the text. Synthesis 
of proposed 2,4-diaminopyrimidine analogs is presented here.  
This dissertation exemplifies the use of various structural features such as a pyridyl 
ring, fluoro, and methyl groups as high impact medicinal chemistry design tools. The pyridyl 
ring has been used to introduce both conformational flexibility and restriction, whereas the 
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I. BIOCHEMICAL REVIEW 
A.1 Microtubule Targeting Agents (MTAs) 
Microtubule targeting agents are an essential part of cancer chemotherapy.1 MTAs 
target microtubule dynamics not only during mitosis but also during interphase.2, 3  
A.1.1. Structure of Microtubules 
 
Figure 1. Structure and polymerization of microtubule (modified from ref. 1). 
Microtubules (MT) are highly dynamic intracellular polymers. The long, hollow, 
filamentous, tube-shaped protein polymers are essential for eukaryotic cells.4 They play crucial 
roles in the development and maintenance of cell shape, in the transport of vesicles, 
mitochondria and other components throughout cells, in cell signaling, and in cell division and 
mitosis. An alpha- (α) and a beta- (β) tubulin subunits form tubulin heterodimers arrange 
longitudinally in a polar head-to-tail fashion to form protofilaments. Thirteen protofilaments 
assemble laterally into tubules with a diameter of approximately 24 nm. The plus (+) end is 
crowned by β-tubulin and the minus (-) end is at α-tubulin (Fig. 1).5  
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Figure 2. Microtubule dynamics and the GTP cap (modified from ref. 1). 
Guanosine-5'-triphosphate (GTP) binding and hydrolysis by αβ-tubulin dimer drives 
growth and shrinkage of microtubules (Fig. 2).1 Two molecules of GTP bind to the 
heterodimers, and each monomer contains a GTP binding site. The α-tubulin binds irreversibly 
to GTP at the non-exchangeable site (N-site), and it does not hydrolyze whereas β-tubulin binds 
reversibly to GTP at the exchangeable site (E-site) and is prone to hydrolysis.6 The N-site is 
buried within the tubulin dimer at monomer-monomer interface whereas the E-site is exposed 
on the surface of an unpolymerized tubulin dimer and at the plus end of the microtubules. 
Exchange of GDP bound on E-site with GTP renders free αβ-tubulin dimer fit for 
polymerization. The α-tubulin of the incoming dimer contacts the E-site on the microtubule 
plus end which completes the binding site that enables hydrolysis. Therefore, microtubule 
growth and GTP hydrolysis are coupled. Microtubules keep growing at the plus end until it has 
GTP-bound tubulin at the tip, once GTP hydrolysis catches up to the top of the microtubule, 
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rapid depolymerization and shrinkage follows. The switch from growth to shrinkage is called 
catastrophe, and the reverse is called rescue.  
 
A.1.2. Binding sites of MTAs 
MTAs are mainly classified into two groups based on their mechanism of action.1  
I. Microtubule stabilizing agents (MSAs): MTAs such as paclitaxel, docetaxel, epothilones, and 
discodermolide promote tubulin polymerization and stabilize the polymer. These compounds 
stabilize GDP-bound tubulin to promote microtubule polymerization. 
II. Microtubule destabilizing agents (MDAs): MTAs such as Vinca alkaloids (vinblastine, 
vincristine, vinorelbine, vindesine and vinflunine), cryptophycins, halichondrins, estramustine, 
colchicine, and combretastatin promote depolymerization and prevent polymerization of 
tubulin are classified as microtubule destabilizing agents.  
 
Figure 3. Binding sites of different classes of MTAs depicted on αβ-tubulin heterodimer 
conformation seen in bovine brain tubulin crystal structure (modified from ref. 7).  
There are currently five structurally distinct and well-characterized sites on 





A.1.2.1. Taxoid binding site: 
  
Figure 4. Taxoid binding site and representative taxanes and epothilones (modified from ref. 
1).  
Paclitaxel (PTX, Fig. 4), approved by FDA in 1992, was the first agent to be identified 
as MTA.8, 9 Along with its semisynthetic derivative, docetaxel (DTX, Fig. 4, clinically 
available since 1996), these drugs are used to treat a variety of solid tumors and malignancies 
breast cancer,10 ovarian cancer,11 nonsmall cell lung cancer,12 gastroesophageal cancer,13 germ 
cell tumors,14 and cancers of the head and neck.15 The binding site of PTX and its derivatives 
is called the taxoid site, which lies in the luminal surface of β-tubulin of the microtubule. There 
is a secondary site named type-I pore site (Fig. 4) next to the taxoid site.16 Majority of data on 
the elucidation of the binding site of MSAs suggest that they bind to either taxoid site or pore 
site in unassembled tubulin; while in MT they first bind to the type I pore then diffuse to the 
luminal taxoid site. Epothilone class of MSAs share the same binding site with the taxoids.17 
Taxoid site binding agents cause restructuring of M-loop of β-tubulin, which increases the 
lateral tubulin interactions in microtubules, therefore, promoting the polymerization and 
tubulin assembly.16  
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A.1.2.2. Laulimalide/Peloruside Binding Site:  
 
Figure 5. Structures of Laulimalide and Peloruside A (modified from ref. 1). 
Laulimalide and peloruside A (Fig. 5), macrolide MTAs, bind to a non-taxane site on 
β-tubulin on the exterior surface of the microtubule. They bind at the interface of two adjacent 
β-tubulin subunits across the protofilaments. These MSAs allosterically stabilize the M-loop 
in the taxoid binding site.16  
A.1.2.3. Vinca-binding domain:  
   
Figure 6. Vinca binding site and representative vinca alkaloids (modified from ref. 1).  
The vinca alkaloids such as vinblastine and vincristine (Fig. 6) were once considered 
wonder drugs, which were used for various childhood hematological and solid malignancies 
and adult hematological malignancies.1 Other vinca derivatives like vindesine, vinorelbine, and 
vinflunine are in preclinical and clinical evaluation for various cancers. These drugs bind to 
the β-tubulin on the soluble heterodimers to a distinct region termed as a vinca-binding domain 
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(Fig. 6).18, 19 Other than vinca alkaloids various drugs like cryptophycins, halichondrins and 
dolastatins also bind at the same site.20  
A.1.2.4. Colchicine binding site:  
  
Figure 7. Colchicine binding site and combretastatins (modified form ref. 1). 
The colchicine site binding agents include podophyllotoxin, combretastatin21 (Fig. 7), 
and flavonols. The binding site lies at the interface of αβ-tubulin heterodimer.22 Upon binding 
these agents to prevent α- and β-subunits from arranging into the straight conformation, needed 
for microtubule formation, due to steric clashes with α-subunit, which results in a curved 
conformation of the heterodimers. Therefore, they cause rapid microtubule depolymerization 
and mitotic arrest. CA4P (Fosbretabulin) is under extensive investigation for platinum-resistant 
ovarian cancer, neuroendocrine tumors (NETs), hepatocellular carcinoma, and gastric cancer.23 
A.1.2.5. Maytansine binding site:  
 
Figure 8. Maytansine binding site and representative binding agents.  
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Maytansine was shown to bind to a recently discovered new binding site on β-tubulin 
reported by Prota et al.24 Binding of maytansine to the plus end of the microtubule led to 
microtubule depolymerization. Maytansine is also a component of the antibody-drug conjugate 
Trastuzumab emtansine that was recently approved by the FDA for the treatment of HER-2 
positive advanced breast cancer.25 
 
A.1.3. Mechanism of Cytotoxic Effects of MTAs  
MTAs have achieved phenomenal success as cancer chemotherapy not only due to their 
ability to induce mitotic arrest but also due to their role in the disruption of interphase cellular 
mechanisms. MTAs act on both mitotic and interphase cells and their vasculature.3 
A.1.3.1. Mitotic cells 
 MTAs act on proliferating cells (cancer as well as normal cells) by decreasing 
microtubule dynamics, thereby arresting mitosis.26 On mitotic arrest, cells either die due to 
apoptosis or arrest in a senescence-like G1 phase.27, 28 Classical MTAs such as paclitaxel and 
related drugs suffer from neurotoxicity and loss of neutrophils.29 MTAs were regarded as anti-
mitotic agents for a long time, which led to development of more specific anti-proliferative 
agents targeting mitotic kinases and kinesin spindle protein which might lack neurotoxicity of 
paclitaxel.2 These types of inhibitors showed equipotency to MTAs in in vitro and xenograft 
models of cancer but failed when they reached the clinic. Also, these agents caused reversible 
neutropenia in patients.30 Doubling time, an indication of the rate of mitosis, of tumor cells in 
in vitro (less than 24 h) and xenograft models (1.2 to 12.2 days) is rapid whereas, in patients, 
majority of tumors show median doubling time of approx. 147 days.31 Therefore mitosis-
specific antiproliferative agents failed in clinical trials, and at the same time showed toxicity 
against the bone marrow neutrophils, 28% of which are in mitosis at any one time.2 On the 
contrary, traditional MTAs such as taxanes, vinca alkaloids, and epothilones quickly shrink the 
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lesions in breast cancer, ovarian cancer, non-small-cell lung cancer, and in glioblastoma despite 
of slow and untimely proliferation rate of these cancer cells. This highlights that mitosis is not 
the only target of the MTAs.  
A.1.3.2. Interphase cells: 
  
Figure 9. Diverse anticancer interphase activities of MTAs (modified from ref. 3). 
An expanding body of research suggests that MTAs can cause derangement of 
activities of interphase cells (Fig. 9).3 This is because microtubules play a multitude of 
functions in interphase cells namely, a) centrosome clustering, b) induction of voltage-
dependent anion channel opening with release of Ca2+ and cytochrome c, c) disruption of 
delivery of mRNA along interphase microtubule tracks, d) induction of mRNA release from 
polysomes, e) improvement of major histocompatibility complex (MHC) class I expression, 
increased activation of f) dendritic cells, g) cytotoxic T lymphocytes and h) macrophages, i) 
impedes vesicular traffic to cell front, j) impeded timely endocytosis, k) interfere with 
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transcription factor transport by motors to the nucleus with l) up- or down-regulation of tumor 
suppressor or oncogenes, respectively. The major toxicity of the MTAs is neurotoxicity, which 
is the cytotoxic effects of MSAs on non-dividing neurons in the interphase stage, which further 
bolsters the idea that MTAs have a mechanism of action other than anti-mitotic. Currently, it 
is unknown which of these effects are the most important for cell death. It is possible that 
MTAs act by instigating “a thousand cuts” on the cancer cells essentially living on the brink of 
life and death, therefore, more susceptible than normal cells.  
 
A.1.3.3. Vascular Disrupting Effect: 
Figure 10. Differences between tumor VDAs and anti-angiogenic agents (modified from ref. 
33).  
Tumor vasculature is an attractive chemotherapeutic target as an intact vasculature is 
important for growth and survival of tumors. Microtubule destabilizing agents like 
combretastatin have been regarded as vascular disrupting agents (VDAs).32 Tumor-VDAs act 
by selectively disrupting tumor blood vessels, inhibiting tumor blood flow, and cause extensive 
necrosis (Fig. 10). Selectivity for tumor vasculature over normal cells arises from differences 
in endothelial cells and pericytes distribution among them. There is no lymphatic drainage in 
tumors, and hence, the cells have higher interstitial pressure. The endothelial cells depend on 
microtubule to maintain cell shape. Due to the porous nature of tumor vasculature, the tumor-
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VDAs can cause rapid disruption of tumor blood supply by the destruction of vascular 
endothelial-cadherin at the junction. This causes tumor ischemia and cell death.33 
Tumor-VDAs cause necrosis of tumor cell within the core of the tumor, whereas anti-
angiogenic agents impart their activity on the tumor periphery and in small tumor masses. Due 
to this major difference, tumor-VDAs and anti-angiogenic agents have different toxicity and 
tolerability profile, offering the potential for their use on combination chemotherapy. Triple 
therapy of the VDA (Dimethylxanthenone-4-Acetic Acid (DMXAA)), anti-angiogenic agent 
(bevacizumab) and MTA (paclitaxel) caused sustained tumor regression whereas none of the 
single agents alone caused tumor regression.34 
 
A.1.4. Resistance to MTAs 
Resistance to MTAs can occur at several stages of pharmacodynamics of the 
microtubule inhibition. Efflux through the membrane efflux pump of the ATP binding cassette 
(ABC) family is the primary mechanism of resistance towards MTAs.4 P-glycoprotein (Pgp), 
a product of a multidrug-resistant gene (MDR1 or ABCB1) is responsible for the efflux of 
MTAs. In Pgp-overexpressing SK-OV-3 MDR-1-6/6 cell line, the potency of paclitaxel was 
reduced 800-fold versus parental cell lines.35 Substrates of Pgp, in addition to drug efflux, 
cannot enter the CNS, when drugs are administered orally. Thus, agents which are less 
susceptible to efflux by Pgp could possess a novel pharmacodynamic and pharmacokinetic 
profile.  
Microtubules are assembled with more than 13 diverse isotypes of α and β tubulins.4 
Among them, increased levels of βIII-tubulin are associated with a reduced rate of responses 
to taxanes in tumors of the lung,36 breast37 and ovary.38 On the contrary to the effect of βIII-
tubulin with taxanes, epothilones are indifferent to expression of βIII-tubulin.39 
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A.2. Thymidylate synthase inhibitors 
A.2.1. Thymidylate synthase 
 
Figure 11. De novo synthesis of dTMP by the enzyme TS.  
One of the key enzymes of folate metabolism, thymidylate synthase (TS), is present in 
living organisms including humans, bacteria and protozoa.40 It catalyzes the reductive 
methylation of 2'-deoxyuridine 5'-monophosphate (dUMP) to 2'-deoxythymidine 5'-
monophosphate (dTMP), utilizing the coenzyme N5,N10-methylene tetrahydrofolate (5,10-
CH2THF) (Fig. 11). The dTMP is phosphorylated to 2'-deoxy-thymidine 5'-triphosphate 
(dTTP) by cellular kinases. The dTTP formed is utilized by deoxyribonucleic acid (DNA) 
polymerase and is incorporated into DNA. The TS catalyzed reaction is a key step in DNA 
biosynthesis and the only de novo biosynthetic pathway to dTMP.41 During TS catalysis, 5,10-
CH2THF acts as a one-carbon donor and is converted to dihydrofolate (DHF) (Fig. 11). 
A.2.2 Structure of TS 
The TS enzyme (EC 2.1.1.45) is a homodimer consisting of two identical subunits each 
having a molecular weight of 30‒35 kDa and a primary sequence of approximately 316 amino 
acids.40 It has two active sites, each formed by residues from monomers. The primary structures 
of several TS enzymes, including those of humans, bacteriophages, and plants, are known. TS 
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enzymes are highly conserved in different species both in terms of structure and mechanism: 
27 amino acids are completely conserved across all species, and 165 (80%) are conserved in 
more than 60% of the organisms. The active (dUMP) site of TS involves 32 amino acid 
residues, of which 16 are conserved in all species. 
Through site-directed mutagenesis, the function of each residue in the substrate-
binding site of TS has been studied. Cys198, Asn229, Arg178' and Arg179', Glu60 and Val316 
(lcTS numbering) were determined to be the most important residues in dUMP binding site.40 
During the TS catalysis, Cys198 is involved in the nucleophilic attack on C6 of the uracil ring 
resulting in the formation of a covalent bond between TS and dUMP. Thus no mutation is 
tolerated at Cys198. Asn229 (lcTS numbering), another important residue in the active site, is 
involved in hydrogen bonding with the 4-oxo of dUMP.40 Thus substitution of Asn229 by other 
amino acids resulted in reduced or complete loss of catalytic activity. Asn229 also plays an 
important role in enzyme specificity. When Asn229 is replaced with Asp229, the enzyme is no 
longer a deoxyuridylate methylase, but a cytidylate methylase, which catalyzes the 
methyltransferase reaction with 2'-deoxycytidine 5'-monophosphate (dCMP) instead of dUMP. 
Amino acid residues, Arg178' and Arg179' (lcTS numbering), belong to the opposite 
subunit and bind to the phosphate group of the deoxyribose ring.40 Replacement of these two 
amino acids reduced the catalytic activity. The importance of other amino acids in the active 
site has also been studied. The C-terminal residue Val316 participates in the conformational 
change of the enzyme, which occurs after the covalent binding of cofactor 5,10-CH2THF to 
the binary complex of TS‒dUMP. This conformational change is necessary for the catalytic 
reaction because it positions dUMP and the cofactor to facilitate the transfer of the methylene 
group. Pro196, Pro197, and His199 (lcTS numbering) are highly conserved amino acids, but 
their substitution with other amino acids is well tolerated. 
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A.2.3. Catalytic mechanism of TS 
 
Figure 12. The catalytic mechanism of human TS. 
The mechanism of catalysis by TS has been examined and is depicted in Fig. 12. 
Sequential binding of a substrate (dUMP) and cofactor 5,10-CH2THF with TS enzyme induces 
a conformational change to form a non-covalent ternary complex (TS‒dUMP‒cofactor). In 
step A, Cys195 of human TS (hTS) attacks C6 of dUMP to form the enol. Protonation at the 
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N10-position of 5,10-CH2THF results in the formation of the reactive N
5-iminium species in 
step (B). The C5-position of the enol of dUMP reacts with the iminium ion of the activated 
cofactor to form an unstable covalent ternary complex in step (C).42 The proton at the C5-
position of dUMP is abstracted by a base in the active site to provide enol in step (D). The 
abstraction of a proton from O4 of the enol results in the formation of exocyclic methylene and 
also the release of the reduced cofactor in step (E). The enzymatic reaction is completed by the 
hydride transfer from C6 of the reduced cofactor to form dTMP. The modified cofactor, which 
serves as a methylene donor and reductant, is released from the active site of TS followed by 
the release of the product, dTMP. 
A.2.4. Inhibition of TS 
Inhibition of TS depletes dTTP, one of the four building blocks required for DNA 
synthesis, thus leading to impaired DNA synthesis and repair.41 dTTP depletion also perturbs 
cellular levels of deoxynucleotides resulting in DNA damage.41, 43Alternatively, TS inhibition 
causes accumulation of dUMP and subsequent misincorporation of dUTP into DNA. These 
processes result in DNA double-strand breaks that lead to the initiation of apoptotic cell death, 
commonly referred to as “thymidine-less” cell death. 
A.2.5. TS inhibitors in cancer chemotherapy 
Inhibition of TS in tumor cells inhibits DNA biosynthesis resulting in thymidine-less 
cell death. Normal cells also require TS for DNA synthesis.40. Nonetheless, TS inhibitors are 
widely used in cancer chemotherapy, and the reason for their tumor selectivity is attributed to 
differences in transport, metabolism and the rates of cell division for normal and some tumor 
cells.41 As tumor cells replicate much more rapidly than normal cells, they have a higher need 
for a synthesis of deoxynucleotides than normal cells. Several TS inhibitors have been 
rationally designed to target the TS-binding site of either dUMP or cofactor 5,10-CH2THF. TS 
inhibitors are classified broadly into two classes: dUMP-based and folate-based TS inhibitors. 
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A.2.5.1. dUMP-based TS inhibitors 
dUMP-based TS inhibitors are antimetabolites that are analogs of dUMP, one of the 
substrates in TS catalysis.41 These inhibitors, upon bioactivation, either inhibit TS or are 
misincorporated into DNA and/or RNA resulting in the inhibition of DNA and/or RNA 
synthesis. 
 
Figure 13. dUMP and representative dUMP-based TS inhibitors. 
5-Fluorouracil (5-FU, Fig. 13) is a dUMP-based inhibitor and represents the first 
class of clinically used TS inhibitors.44 The mechanisms of action of 5-FU includes inhibition 
of TS, incorporation into DNA, and/or incorporation into RNA.40, 44 5-FU is a prodrug and 
must be bioactivated to various active nucleotides such as 5-fluoro-2'-deoxyuridine 5'-
monophosphate (5-F-dUMP, Fig. 13), 5-fluoro-2'-deoxyuridine 5'-triphosphate (5-F-dUTP) 
and 5-fluorouridine triphosphate (5-F-UTP). 5-F-dUMP is a mechanism-based inactivator of 
TS since it forms a covalent complex with TS and the cofactor. Alternatively, 5-F-dUMP can 
be phosphorylated by a series of enzymatic reactions to 5-F-UTP, which is misincorporated 
into RNA and causes inhibition of RNA processing and function. 
5-FU has been used for more than 50 years in the treatment of colorectal cancer.41 5- 
FU remains one of the most widely used anticancer agents with a broad-spectrum activity 
against many solid tumors, including pancreas, breast, head and neck, gastric, and ovarian 
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cancers. However, 5-FU causes toxicity to normal cells because the enzymes that activate it 
are not tumor selective.45 For instance, 5-FU causes diarrhea because of its activation in the 
intestines. Moreover, it is rapidly degraded by the dihydropyrimidine dehydrogenases in the 
liver, thereby limiting its oral bioavailability. 
Capecitabine (Xeloda®) and tegafur (Fig. 13) are prodrugs that are metabolized to 5-
FU, which then gets converted to active nucleotides involved in DNA and RNA damage.41, 45 
Rational drug design of capecitabine exploited the utilization of three tumor-overexpressing 
enzymes for its metabolism to 5-FU. Capecitabine is readily absorbed in the gastro-intestinal 
tract and is converted to 5-fluoro-5'-deoxycytidine (5-F-5'-dCR) by carboxylesterases in the 
liver. 5-F-5'-dCR is then converted to 5-fluoro-5'-deoxyuridine (5-F-5'-dUR) by cytidine 
deaminase, which is highly expressed in both liver and tumor tissues. The final step involves 
the conversion of 5-F-5'-dUR by either thymidine phosphorylase or uridine phosphorylase to 
form 5-FU. Both thymidine phosphorylase and uridine phosphorylase are highly active in 
tumors than in normal tissues, thus resulting in tumor specificity to capecitabine. This 
Medicinal Chemistry approach resulted in capecitabine with improved oral bioavailability and 
tumor selectivity over 5-FU. Capecitabine is used clinically in the treatment of metastatic breast 
and colorectal cancers.46 It has also shown promising anticancer activity in patients with 
prostate, pancreatic, and ovarian cancers. Tegafur (Fig. 13) is a prodrug that is bioactivated in 
the liver by cytochrome P-450 2A6 via 5'-hydroxylation to 5-FU. 
A.2.5.1. Folate-based TS inhibitors (Antifolates). 
 Antifolates are structurally related to natural cofactor 5,10-CH2THF and bind to the 
binding site of the cofactor. These are competitive inhibitors that do not take part in the 
catalysis, i.e. they do not form the iminium species. The benzoyl-L-glutamate side-chain 
containing antifolates are called classical antifolates, where as non-classical antifolates lack 
the benzoyl-L-glutamate side-chain.  
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Figure 14. Natural cofactor 5,10-CH2THF and representative antifolates as TS inhibitors.  
First specific folate-based TS inhibitor was N10-Propargyl-5,8-dideazafolate (PDDF, 
Fig. 14).47 and was also the first quinazoline-containing TS inhibitor that entered phase I 
clinical trials. However, its development was abandoned due to its poor aqueous solubility 
induced renal toxicity.45 Therefore, further derivatives containing the 2-methyl group 
(Raltitrexed (Tomudex®), Fig. 14) instead of a 2-amino group (PDDF) to improve water 
solubility and decrease renal toxicity. Raltitrexed is transported into cells via ubiquitously 
present reduced folate carrier (RFC) and needs to undergo polyglutamylation, via folypoly-γ-
glutamate synthetase (FPGS), to increase potency (by 100-fold) and cellular retention. 
Raltitrexed showed good activity against advanced colorectal and breast cancers in phase II 
and III trails. However, it caused life-threatening toxicities, such as gastrointestinal toxicity 
and myelosuppression. Raltitrexed was approved as first-line therapy for the treatment of 
advanced colorectal cancer in several European countries, Australia, Canada, and Japan.  
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 Clinical use of current classical antifolates is limited by resistance mechanisms such as 
decreased uptake by RFC and/or decreased FPGS activity.42 Nonclassical lipophilic antifolates, 
able to passively diffuse into cells, such as nolatrexed (Thymitaq®) and plevitrexed (Fig. 14) 
have been designed to circumvent these resistance mechanisms associated with classical 
antifolates. Bioisosteric replacement of the γ-carboxylic acid group with tetrazole moiety in 
plevitrexed results into transport into cells by RFC and passive diffusion and is no more a 
substrate for FPGS.42 Even though; nolatrexed was the first nonclassical TS inhibitor to reach 
phase II clinical trials, it showed minimal activity in patients with advanced hepatocellular 
carcinoma.48  
Pemetrexed ((Alimta®), Fig. 14) is claimed to be multitargeted antifolate that inhibits 
TS in addition to other folate-dependent enzymes including dihydrofolate reductase (DHFR) 
(very weakly), 5-aminoimidazole-4-carboxamide ribonucleotide transformylase 
(AICARTFase), and glycinamide ribonucleotide transformylase (GARTFase) (very weakly).49 
Unfortunately, it predominantly enters cells via the RFC under normal pHs and requires 
polyglutamylation for maximal inhibitory effects.45 Pemetrexed is approved in the USA for the 
treatment of advanced nonsquamous non-small cell lung cancer and malignant pleural 
mesothelioma. The main toxicities associated with pemetrexed are hematologic toxicity, 
gastrointestinal toxicity, fatigue, and skin rashes.50 
A.2.6. Thymidylate synthase inhibition in toxoplasmosis  
Toxoplasma gondii (T. gondii, tg), an intracellular protozoan parasite, causes 
toxoplasmosis, a disease that affects the brain and the eyes.51 Humans are infected by ingestion 
of food or water that is contaminated with oocysts shed by cats or by eating raw or undercooked 
meat containing tissue cysts.52 According to the Centers for Disease Control and Prevention 
(CDC), more than 40 million people in the US have been infected with T. gondii. While 
toxoplasmosis is generally benign and goes unnoticed in immunocompetent individuals, it is a 
 19 
major opportunistic infection in immune-compromised patients such as those with acquired 
immune deficiency syndrome (AIDS) and those receiving organ transplants or chemotherapy.51 
T. gondii infection is one of the major causes of morbidity and mortality in HIV patients.53 
Protozoa, including T. gondii, contain a bifunctional TS‒DHFR enzyme wherein the TS and 
DHFR exist on the same polypeptide.54 Sharma et al.55 solved the first three-dimensional 
structure of T. gondii TS‒DHFR (tgTS‒DHFR) with a resolution of 3.7 Å. The tgTS‒DHFR 
enzyme is a homodimer in which each monomer has a molecular mass of 69 kDa. Each 
monomer consists of a TS domain (289 residues) on the C-terminal and a DHFR domain (252 
residues) on the N-terminal. TS and DHFR domains are tethered together by a linker region 
(69 residues). The crystal structure and the overall sequence alignment also indicated that the 
active site of T. gondii TS (tgTS) is highly conserved. Cys489 of the TS domain is involved in 
the catalysis of dUMP to dTMP. The key residues important for the binding to PDDF 
(antifolate) are Ile402, Asp513, Leu516, Phe520, Arg603 and Met608. The tgTS‒DHFR 
exhibits substrate channeling, i.e. the dihydrofolate is directly transferred from the TS active 
site to the DHFR active site without entering the bulk solution. T. gondii relies on TS‒DHFR 
for the synthesis of nucleotides essential for its survival. Also, T. gondii, unlike humans, lacks 
salvage of thymidine; thus, tgTS function is necessary for survival of the parasite.54 Since the 
TS‒DHFR enzyme is crucial for T. gondii survival, selective inhibition of tgTS represents a 
valid target to combat T. gondii infection. However, achieving selective inhibition of tgTS over 
hTS is difficult because TS is highly conserved across species (much more than DHFR) and 
also there is significant homology between the active site residues of tgTS and hTS as there is 





A.3. Receptor tyrosine kinase inhibitors 
A.3.1. Angiogenesis  
 
Figure 15. Angiogenesis in tumors (modified from ref. 58). 
Angiogenesis is a process of sprouting new blood vessels from existing blood 
vasculature.57 Angiogenesis occurs during tumor development due to the stressful environment 
such as hypoxia, which forces tumors to express hypoxia-induced factors, which is primarily 
responsible for the recruitment of stromal cells. There is a balance between pro- and anti-
angiogenic factors in normal tissues. In cancer, as the tumor grows, it should obtain its own 
blood supply. To achieve this, the tumor tilts the balance towards pro-angiogenic factors to 
drive vascular growth by attracting and activating cells from within the microenvironment of 
the tumor (Fig. 15).58  
 The process of switching from anti-angiogenic factors to pro-angiogenic factors release 
is called angiogenic switching, which starts in the tumor when the tumor grows larger than 2 
mm in diameter.59, 60 Tumor cells exploit their microenvironment by releasing cytokines and 
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growth factors. These include vascular endothelial growth factor (VEGF), platelet-derived 
endothelial growth factor (PDGF) and epidermal growth factor (EGF), which promote 
endothelial cell proliferation/migration.61-63 Oxygen and nutrients supplied by newly infiltrated 
blood vessels help with tumor progression and metastases.64 The remodeled tumor vasculature 
is weak and leaky, with irregular blood flow. Therefore, tumor vasculature differs from normal 
tissue vasculature.65 
Antiangiogenic treatment is now an accepted mechanism, originally proposed by Judah 
Folkman approximately 48 years ago,66 with multiple anti-angiogenic agents approved by FDA 
as single agents or in combination with other cytotoxic drugs or radiation therapy. Most notable 
angiogenic inhibitors target receptor tyrosine kinases which are involved in the process of 
angiogenesis.67 
A.3.2. Receptor Tyrosine Kinase (RTK)   
Total of 518 protein kinases have been identified in the human genome, i.e., ~1.7% of 
the entire genome, of which 90 belong to tyrosine kinases (TKs).68 Of the 90 TKs, 58 are 
receptor tyrosine kinases (RTKs), and 32 are non-receptor tyrosine kinases (NRTKs). NRTKs 
carry out intracellular communication and RTKs are involved in signal transduction. RTKs 
catalyze the transfer of -phosphate group of adenosine triphosphate (ATP) to tyrosine residues 
in the activation loop, a process termed as autophosphorylation.69 RTKs exists as monomers in 
an inactive form, upon ligand binding dimerization of monomers takes place. RTK monomer 
consists of an N-terminal extracellular ligand-binding domain, a transmembrane domain, and 
a C-terminal intracellular domain with tyrosine kinase activity (Fig. 16). Kinase domain is bi-
lobar in nature with N-terminal lobe mainly made up of -sheets and C-terminal lobe which 
consists of -helices, which form a cleft at the center housing ATP binding region.70, 71 ATP 
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binding site is divided into the adenine region, the sugar region, and the phosphate binding 
region. 
 
Figure 16. Structure of receptor tyrosine kinase (vascular endothelial growth factor receptor 
(VEGFR)) and binding site of ATP (modified from refs. 69, 70, and 71). 
 
Figure 17. Types of inhibitor binding sites (modified from ref 71). 
The kinase domain contains a specific combination of amino acid residues aspartic 
acid, phenylalanine, and glycine (DFG) at the start of the activation loop in C-terminal lobe.71 
Based on the conformation of the binding pocket and the DFG motif, RTK inhibitors are 
divided into four major classes (Fig. 17). ATP-competitive inhibitors that bind to the active 
forms of kinases with the aspartate residue of the DFG motif facing into the active site of the 
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kinase are called Type I inhibitors. The inhibitors that bind to the inactive forms of the kinase 
with the aspartate residue of the DFG motif protruding outward from the ATP-binding site of 
the kinase are termed as Type II inhibitors. In type III binding mode, inhibitors bind in an 
allosteric pocket adjacent to ATP without making any interaction with the ATP-binding pocket 
whereas Type IV inhibitors bind to an allosteric site remote from the ATP-binding pocket.  
RTKs regulate various cellular processes such as proliferation, survival, apoptosis, 
metabolism, transcription, differentiation, etc. In cancers, dysregulation of RTKs creates the 
hallmark of cancer.72 Therefore, RTK inhibitors play a vital role as anticancer chemotherapy 
(Fig. 18). 
(a) Vascular endothelial growth factor receptor (VEGFR) 
The VEGFR family consists of three related RTKs- VEGFR-1, VEGFR-2, and 
VEGFR-3 The VEGF family has five members- VEGF-A, VEGF-B, VEGF-C, VEGF-D, and 
placental derived growth factor (P1GF).73 VEGF-A, a key regulator of blood vessel growth, 
binds to VEGFR-2 with Kd of 75 – 125 pM.
74 Activation of VEGFR-2 via VEGF results in 
signaling processes that include protein kinase activation, trans-autophosphorylation, and 
initiation of downstream signaling pathways, ultimately leading to angiogenesis. VEGF is 
expressed in a variety of cell lines derived from various hematologic malignancies, including 
multiple myeloma, T-cell lymphoma, acute lymphoblastic leukemia, Burkitt lymphoma, 
histiocytic lymphoma, and chronic myelocytic leukemia.75 Some examples of approved 
VEGFR inhibitors are bevacizumab (Avastin®) for colorectal cancer,76 sunitinib (Sutent®) 
(Fig. 18) for metastatic pancreatic neuroendocrine tumors77 and sorafenib (Nexavar®) (Fig. 
18) for advanced renal cell carcinoma.78 
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Figure 18. Structures of FDA-approved RTK inhibitors. 
 (b) Platelet-derived growth actor receptors (PDGFR) 
The PDGF has four different chains- PDGF-A, PDGF-B, PDGF-C and PDGF-D, 
which can bind to receptors PDGFRα and PDGFRβ to activate signaling pathways such as 
Ras-MAPK, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ (PLC-γ) to cause 
cell growth stimulation, differentiation, migration, and inhibition of apoptosis.79 PDGFs recruit 
pericytes to reduce endothelial cell proliferation and promote differentiation. PDGFR signaling 
complements VEGFR induced new vessel formation. Example of an approved PDGFR 
inhibitor is imatinib (Gleevec®) (Fig. 18) for chronic myeloid leukemia.80 
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(c) Epidermal growth factor receptor (EGFR) 
The EGF family is comprised of eleven members and four EGFR family receptors.81 
Overexpression of EGFR leads to an increased tumor cell proliferation, survival and 
invasiveness.82 EGFR gene is an oncogene-driven gene.83 EGF and EGFR aid in tumor growth 
and metastasis via several ways:  1) increasing tumor cell proliferation and migration  2) 
localization of EGFR to the nucleus to promote cell proliferation  3) dysregulation of 
autophage activity  4) stimulation of several matrix metalloproteinases that facilitate cancer 
invasion and metastasis  5) EGF‐mediated decrease in the abundance of mRNAs that restrain 
oncogenic transcription factors. Some examples of approved EGFR inhibitors are erlotinib 
(Tacreva®) (Fig. 18) for locally advanced or metastatic non-small cell lung cancer,84 gefitinib 
(Iressa®) (Fig. 18) for metastatic non-small cell lung cancer,85 and afatinib (Gilotrif®) (Fig. 
18) for squamous non-small cell lung cancer.86 
There are two major problems with the use of RTK inhibitors as anti-angiogenic agents. 
First, resistance to the therapy in preclinical and clinical settings is commonly observed.87 This 
resistance is either acquired or inherent in nature. Second, severe toxicities (bleeding, 
hypertension, fatigue) to the treatment have been reported.88 In patients, resistance to anti-
VEGF therapy occurs due to selection pressure on cancer cells which activates the 
compensatory mechanism for angiogenesis.67 Thus, a combination approach targeting different 
angiogenesis signaling could be highly effective. Additionally, a cross communication between 
multiple angiogenic signaling pathways can generate synergistic effects, e.g. Synergism was 
observed in signaling by fibroblast growth factor-2 (FGF-2) and PDGF-BB in tumor growth 
and metastasis.89 Another example of synergism is VEGF and basic fibroblast growth factor in 
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vitro and in vivo.90 Many molecules function as single agents with multi-RTK inhibition 
potential, e.g., Sorafenib is a multi-RTK inhibitor (VEGFR-2, VEGFR-3, PDGFR-β and 
Rapidly Accelerated Fibrosarcoma (RAF)) used in the treatment of renal,91 hepatocellular92 
and thyroid93 cancers. Sunitinib is a multi-RTK inhibitor (VEGFRs, PDGFRs, and c-kit) 
important in the treatment of renal,94 pancreatic,95, and gastrointestinal96 cancers. Erlotinib is 
an EGFR inhibitor used to treat pancreatic97 and non-small cell lung98 cancers. The success of 
these therapies in the clinic validates the development of single agents as multi-RTK inhibitors. 
 
A.4. Combination chemotherapy potential in cancer 
A.4.1. Combination potential of anti-angiogenic therapy with MTAs 
 Complex disease like cancer can only be tackled by combination therapy.99 The 
advantages attributed to a combination therapy include increased patient compliance, the 
emergence of an additive or synergistic interaction of the combined drugs, delay or overcome 
resistance, reduction of drug dosage with a consequence of diminished toxicity. Most of the 
tumors are heterogenic in nature. Therefore, combination therapy plays a significant role.100 
Inhibition of a single target or pathway is known to be of limited benefit to a cancer patient 
due to resistance and lack of efficacy. Optimal drug combination can provide an effective 
therapy to combat resistance and target tumor heterogeneity.101 
A.4.1.1 Vascular normalization 
Cytotoxic agents, such as MTAs or TS inhibitors can kill cancer cells directly, and 
antiangiogenic agents would kill cancer cells indirectly by depriving them of nutrients and 
oxygen. Clinical data has shown the success of using a combination of the cytotoxic drug with 
anti-angiogenic agents.102 The anti-angiogenic therapy instead of blocking delivery of the 
cytotoxic drug augments its effect. Based on this observation, Jain and coworkers formulated 
the “vascular normalization” hypothesis.103 
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Figure 19. Vascular normalization hypothesis (modified from ref. 103) 
 As illustrated in Fig. 19, the cancer cells have haphazard blood vessels, which are leaky 
and tortuous.104 This creates spatial heterogeneity in blood flow, increased interstitial fluid 
pressure, low pH, and hypoxia.105, 106 The heterogeneity in blood flow decreases delivery of the 
cytotoxic drug. Acidic pH decreases the activity of immune cells and hypoxia renders cells 
resistant to radiotherapy.107 Anti-angiogenic therapies can stabilize vessels by increasing 
pericyte coverage and reduce vascular permeability/leakiness, therefore, normalizing the blood 
vessels.108, 109 These changes inhibit intravasation of metastatic seeking cancer cells and 
increase the delivery of cytotoxic drugs.103, 110, 111  
The normalization of vasculature in tumors limited to a fixed time after the anti- 
angiogenic therapy is administered, is defined as the “vascular normalization window” (Fig. 
20).112 This window is short-lived and delivery of cytotoxic drugs in this time duration can 
provide a synergistic effect for the targeting the tumor.113 Lateral dosing, scheduling, 
sequencing, and studying the tumor vasculature is required to formulate a chemotherapy 
Antiangiogenic Treatment 
“Normal cells” “Tumor cells” 
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treatment for a patient. The careful consideration is mandatory to optimize the efficacy of a 
combination of cytotoxic drug and anti-angiogenic agent and to reduce negative side-effects. 
 
Figure 20. Dose and time-dependent vascular normalization window (modified from ref. 
112) 
 Combination of tumor-VDAs with anti-angiogenic therapies is effective for targeting 
both core and peripheral part of the tumors (ref. section A.1.3.3). 
A.4.2 Single agents with MTA and RTK inhibitory potential 
 Rationally designed single chemical entities capable of selectively targeting two or 
more biological targets or processes are called single agents.114 They are different than 
promiscuous drugs, which have a wide-spectrum of non-selective target activity and side-
effects. Multitargeted drugs offer various advantages over combination chemotherapy, namely 
(i) predictable pharmacodynamic and pharmacokinetic effects; (ii) improved patient 
compliance; and (iii) presence of multiple entities (in one agent) with multiple effects 
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simultaneously.114 A combination therapy requires a very careful selection of scheduling (Fig. 
20), which is avoided while designing a single agent.  
Docetaxel (MTA) plus nintedanib (Vargatef®, VEGFR, PDGFR, and FGFR inhibitor) 
versus docetaxel plus placebo in patients in non-small-cell lung cancer (LUME-Lung 1) phase 
3 trial displayed an increase in overall survival of 10.9 months for the drug combination, 
compared to 7.9 months for docetaxel monotherapy.115, 116 The clinical evidence prompted 
more investigation into the combination therapy of MTAs with multi-RTK inhibitors. 
 
Figure 21. Quinazoline MTAs with multi-tyrosine kinase inhibitory activity. 
Single agents (1a – 3a, Fig. 21) acting as MTAs along with inhibitors of VEGFR-2, 
PDGFRβ, and EGFR have been developed in our group previously by Shruti and Gangjee.117 
Compounds 1a and 2a showed excellent inhibition potential across all four targets with CAM 
angiogenesis assay activity comparable to Sunitinib and better than Erlotinib. Separately, 
various scaffolds such as furo[2,3-d]pyrimidines118-120 and pyrrolo[3,2-d]pyrimidines121, 122 
have been shown by Gangjee and coworkers to have dual acting antitubulin and multiple RTK 
inhibitory activities. These studies attest to the rationale of designing compounds with anti-





A.4.2 Combination potential of anti-angiogenic therapy with TS inhibition 
 
Figure 22. Single agents with dual RTK and TS inhibitory activity. 
2,4-Diamino-5-thioaryl-pyrimido[4,5-b]indoles 4a and 5a (Fig. 22) have been reported 
by Gangjee and coworkers123 as single agents with antiangiogenic and cytotoxic activities. 
These compounds inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects and TS for 
cytotoxic effects with inhibitory potencies comparable or better than the standard compounds: 
semaxanib (VEGFR-2 inhibitor), DMBI (PDGFR-β inhibitor) and raltitrexed (hTS inhibitor). 
In COLO-205 metastatic colon cancer xenograft mouse models, compound 4a significantly 
decreased tumor growth, liver metastases, and angiogenesis better than DMBI, remarkably 
without any toxicity. Antitumor activity of 5a was found to be partially due to reduced HIF-1α 
stabilization by increasing oxygen consumption in hypoxic conditions, which caused necrosis, 






A.5 Folate Receptors (FR) and/or Proton-Coupled Folate Transporter (PCFT) targeted 
(cytosolic and/or mitochondrial) one-carbon metabolism inhibitors  
A.5.1 Folates and its role in physiology 
 
Figure 23. The chemical structures of physiologically relevant folate derivatives with 
different carbon oxidation states. 
Water-soluble members of B9-class of vitamins are termed as folates which are 
involved in essential processes of growth and survival of all tissues. Folic acid can be described 
as the parent structure of folates (Fig. 23).126 The group encompasses of various substitutions 
attached at N5 and/or N10 of folic acid, and the presence of γ-linked glutamyl residues (2-8).127-
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130 Humans cannot physiologically synthesize them and are obtained only from the ingested 
food.131 Chemically these are hydrophilic and anionic structures which cannot cross biological 
membranes by passive diffusion. Hence, the human body has devised several sophisticated 
transporter systems to absorb folic acid and its derivatives.132 
Figure 24. Compartmentalization of mammalian one-carbon metabolism (modified from ref. 
141). 
Folates are extensively involved in cellular one-carbon transfer reactions. They act as 
cofactors for the transfer through several of its metabolites (Fig. 24).133-135 In the cytosol, the 
reduced cofactor 10-formyl-THF is used in the purine biosynthesis.133, 136 The enzyme 
glycinamide ribonucleotide formyl transferase (GARFTase) uses 10-formyl-THF for the 
formation of the imidazole ring of purines.136 
Folates are used as cofactors in several cellular one-carbon transfer reactions.133, 134 In 
the cytosol, the reduced cofactor 10-formyl-THF is used in the purine biosynthesis by the 
enzyme glycinamide ribonucleotide formyl transferase (GARFTase) for the formation of the 
imidazole ring of purines.133, 136 Downstream to the GARFTase enzyme in the purine 
biosynthesis pathway, 5-Aminoimidazole-4-carboxamide ribonucleotide formyl transferase 
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(AICARFTase) enzyme uses 10-formyl-THF to synthesize inosin-5ˊ-monophosphate (IMP).136 
TS catalyzes the conversion of 2ˊ-deoxyuridine monophosphate (dUMP) to 2ˊ-deoxythymidine 
monophosphate (dTMP) utilizing 5,10-CH2-THF.
44, 133 The conversion generates DHF which 
is recycled into THF by the enzyme dihydrofolate reductase (DHFR), which is abundantly 
expressed in the cytosol.1 Another form of folic acid, 5-CH3-THF synthesized by Methylene 
Tetrahydrofolate Reductase (MTHFR) from 5,10-methylene-THF in cytosol serves as a 
cofactor for the reaction catalyzed by Methionine Synthase (MS).137 MS produced methionine 
from cysteine, which later conjugates with Adenosine Triphosphate (ATP) to form, a methyl 
group donor, S-Adenosyl-Methionine (SAM). SAM causes methylation reactions on DNA, 
RNA, histones, and neurotransmitters, and thus can regulate transcription and translation of 
proteins, such as tumor suppressor genes or promoter genes.138 
THF cofactors can be transported into mitochondria from the cytosol via mitochondrial 
folate transporter (MFT/SLC25A32).139-141 In the mitochondria, it is used in the biosynthesis 
of formate and glycine (Fig. 24). The intermediate folic acid derivatives can be transferred to 
the cytosol for various cellular synthetic reactions.141 Mitochondria accumulates 40% of the 
folate in the cell.141, 142 Abnormalities in the nucleotide biosynthesis, methylation reactions, 
glycine biosynthesis, can affect DNA synthesis, DNA repair, DNA methylation, which can 
cause genomic instability of the cellular system, potentially leading to cell death. 
 
A.5.2 Cellular uptake of folates 
 Folate cofactors are hydrophilic anions at physiologic pH (7.2-7.4) and diffuse poorly 
across cell membranes. Consequently, folate transport systems have evolved in mammalian 
cells to facilitate cellular uptake. In mammalian cells, folate transport is facilitated by 
genetically distinct systems.132, 143-145 
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Figure 25. Transport of (anti)folates intracellularly and extracellularly (modified from ref 
133). 
1) Reduced Folate Carrier (RFC, SLC19A1): 
RFC belongs to solute carrier (SLC) family of facilitative carriers part of major 
facilitator superfamily (MFS) of the transporter.146 It is a 591- amino acid transmembrane 
protein with a molecular mass of approximately 85 kDa.147 It has 12 hydrophobic 
transmembrane domains (TMD) with a short hydrophilic N-terminus and long hydrophilic C-
terminus.147 RFC is devoid of ATP-binding site domain, and thus its transport is not ATP-
driven.147 It is a bidirectional antiporter that exchanges intracellularly stored adenosine 
nucleotides, thiamine monophosphate, and thiamine pyrophosphate (Fig. 25).148 Due to the low 
concentration of folates inside the cell, the transport of folates is uphill into the cell by the 
antiporter.148 It has a higher affinity for reduced folates (Km = 1-3 μM) and lower affinity for 
oxidized folates like folic acid (Km =200-400 μM).
149 In humans, RFC is ubiquitously 
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expressed in normal and malignant cells, including bone marrow, breast, lung, heart, small 
intestine, and lymphocytes.150-152 
2) Proton-Coupled Folate Transporter (PCFT, SLC46A1): 
PCFT functions as a unidirectional symporter that transports folates with protons into 
the cells (Fig. 25).153 For instance, in the upper small intestine, the concentration of protons is 
high due to the activity of Na+/H+ exchanger.154 Thus, the high extracellular H+ concentration 
acts as the driving force for the PCFT symport into the cell. It functions optimally at pH 5.5.153 
The transporter activity decreases as the pH increases. Unlike RFC, PCFT has equal affinity 
for both folic acid and reduced folates.153 Similar to RFC, PCFT is a MFS with 459 amino 
acids transmembrane protein with a molecular mass of 55 kDa.155 It has 12 TMDs and both of 
its N- and C-termini is in the cytosol.153 PCFT displays a 14% amino acid identity with RFC.132 
No X-ray crystal structures for PCFT and RFC have been resolved so far which impedes a 
structure-based drug design approach. 
 
3) Folate receptors (FRα, FRβ, FRγ): 
FRα and FRβ are the third routes of folate influx intracellularly. These are 
glycoproteins with high affinity for folates and are encoded by three different loci of FRα, FRβ, 
and FRγ. There is 70-80% amino acid homology among the FRs and have 245-257 amino acid 
residues.156 FRα and FRβ are glycosylphosphatidinylinositol (GPI)- anchored cell surface 
glycoproteins and FRγ is a secretory protein.156 The uptake of folates by FRα and FRβ is 
receptor-mediated endocytosis.157 FRα is mostly expressed in epithelial cells of uterus, 
placenta, choroid plexus, retina, and kidney. It is also expressed in cancers of epithelial origin- 
adenocarcinoma of ovary, cervix, uterus, kidney, lung, breast, bladder and pancreas.156, 158, 159 






Figure 26. X-ray co-crystal structure of FRα with AGF183 (cyan) (PDB: 5IZQ). 
X-ray crystal structures of FRα and FRβ have been resolved and published152, 160 and 
the binding of folate, an image of the co-crystal structure of a known antifolate AGF183, is 
displayed in Fig. 26. The 2-amino-4-oxo pyrimidine motif is commonly observed across 
folates and antifolates. The 2-NH2 forms an ion-dipole interaction with Asp81 side chain. The 
3-NH interacts with Ser174 side chain via hydrogen bonding interactions — the 4-oxo forms 
a hydrogen bonding interaction with the side chain of Arg103. The pyrrolo[2,3-d]pyrimidine 
scaffold is stabilized by π-π stacking interactions with Tyr85 and Trp171. The L-glutamate side 
chain extends into a pocket composed of hydrophilic side chains. The α-COOH forms ion-
dipole interactions with Trp140 side chain and backbone NHs of Trp138 and Gly137. The γ-
COOH forms ionic interactions with Lys136 and ion-dipole interactions with side chains of 
Trp102 and Gln100. 
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Figure 27. X-ray co-crystal structure of FRβ with PMX (pink) (PDB: 4KN2). 
The co-crystal structure of FRβ with pemetrexed has been resolved, which can be 
visualized in Fig. 27. The 2-amino-4-oxo pyrimidine scaffold is stabilized by π-π stacking 
interactions with Tyr101 and Trp187. The 2-NH2 forms hydrogen bonding interactions with 
Ser190 side chain and the 4-NH2 forms ion-dipole interaction with Asp97 side chain. The 
phenyl linker is also stabilized by π-π stacking interactions with Trp118. The L-glutamate NH 
forms a hydrogen bonding interaction with His151 backbone. The anionic side is oriented in a 
solvent exposed pocket. The α-COOH forms ion-dipole interactions with Trp156 side chain 
and backbone NH of Gly153.  
A.5.3 Retention and efflux of folates 
 Following uptake, folates may undergo folypolyglutamylation, catalyzed by folypoly-
γ-glutamate synthetase (FPGS).161 It catalyzes sequential addition of multiple equivalent of 
glutamic acid to γ-carboxyl chain of the folate cofactors. This causes an increased retention of 
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these polyanions intracellularly. FPGS has two forms: cytosolic and mitochondrial.162 It is also 
noted that polyglutamylated folates are much better substrates for various folate-dependent 
enzymes.163 The process of folypolyglutamylation can be reversed by enzyme γ-glutamyl 
hydrolase (GGH), which catalyzed hydrolysis of γ-glutamyl tail of polyglutamylated folates.164 
Several ABC transporters exist in humans. Among the multidrug resistance proteins 
(MRP), MRP1-5 are capable of exporting folate derivatives.165 Another exporter of folates is 
breast cancer resistance protein (BRCP/ABCG2).166 (Anti)Folates can get removed from the 
cell by overexpression of these transporters in cancer cells. 
 
Figure 28. Structures of clinical antifolates 
Clinically used antifolates include pemetrexed (PMX), raltitrexed, methotrexate, and 
pralatrexate (Fig. 28). Pemetrexed and raltitrexed are reviewed in previous section. 
Methotrexate is a DHFR inhibitor, which is taken up by cells via PCFT and RFC transport.133 
Pralatrexate is a DHFR inhibitor with an intracellular uptake through RFC.167 It has been 
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approved in patients with peripheral T-cell lymphoma.167 All the clinically used folates utilize 
RFC transport for entry into the cell. Because of the ubiquitous expression of RFC, these 
compounds do not have inherent selectivity into cancer cells and cause dose-limiting toxicities 
(severe myelosuppression).168, 169 The process of polyglutamylation decreases when the 
concentration of intracellular folates (e.g., 5-formyl-THF) increases. Thus, activity of PMX 
like antifolate will decrease when concentration of intracellular folates increases. Also, PMX-
resistant cancers have been identified which were developed due the mutagenesis in the FPGS 
active site.170-172 Since polyglutamylation is responsible for increased potency, loss of FPGS 
activity can lead to drug resistant cancer cell lines.171 Several studies have displayed a reduced 
activity of such FPGS-dependent antifolates in cancer cells lines, which have low FPGS 
activity or have mutated FPGS incapable of binding to the antifolate.170, 171 An increase in GGH 
activity also can cause decreased activity of antifolates and lead to a development of 
resistance.173 Overexpression of DHFR or TS, and mutations in the active site of DHFR or TS 
can also lead to resistance.170-172 As an approach to combat resistance and dose-limiting 
toxicities, there is a critical need to develop agents with (a) increased selectivity for transport 
via PCFT or FRs over RFC to eradicate dose-limiting toxicities; (b) ability to target two or 
more intracellular enzymes to decrease development of resistance; and (c) no dependence on 
FPGS for its activity against intracellular targets. Dies et al.174 and Wang et al.175 report 6-
substituted pyrrolo[2,3-d]pyrimidines with selectivity for transport through PCFT and FRs 
over RFC. These compounds are potent inhibitors of GARFTase (inhibit purine synthesis). 
They also display a strong inhibition of GARFTase in their monoglutamylated form and do not 
depend on FPGS to potentiate their activity. 
A.5.4 Inhibitors of one-carbon metabolism 
A.5.4.1 Inhibitors of de novo purine synthesis 
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 Purines serve as building blocks of DNA and RNA, and as a component of ATP, cyclic 
adenosine monophosphate (cAMP), nicotinamide adenine dinucleotide (NAD) and coenzyme 
A (CoA). The synthesis can occur through de novo synthetic pathway or salvage pathway.134 
The de novo synthetic pathway is a 10-step folate-dependent pathway (from phosphoribosyl 
pyrophosphate (PRPP) to IMP) (Fig. 29).132 
 
Figure 29. De novo purine nucleotide biosynthetic pathway132 
The enzymes catalyzing the reactions enumerated in Fig. 29 are: 1) glutamine 
phosphoribosylpyrophosphate amidotransferase (GPAT); 2) GAR synthase (GARS); 3) GAR 
formyl transferase (GARFTase); 4) formyl glycinamide ribonucleotide synthase (FGAM 
synthetase); 5) 5-amino-4-imidazole ribonucleotide synthase (AIRS); 6) 
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carboxyaminoimidazole ribonucleotide synthase (CAIRS); 7) 5-aminoimidazole-4-(N-
succinylocarboxamide) ribonucleotide synthase (SAICARS); 8) adenylosuccinate lyase 
(ASL); 9) 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR) formyl transferase 
(AICARFTase); and 10) IMP cyclohydrolase (ATIC). There are two steps that use 10-CHO 
THF and are folate-dependent in nature. They are glycinamide ribonucleotide formyl 
transferase (GARFTase, reaction 3) and aminoimidazole carboxamide ribonucleotide formyl-
transferase (AICARFTase, reaction 9). The reactions 2, 3 and 5 are catalyzed by the 
trifunctional glycinamide ribonucleotide (GAR) formyl transferase (GARFTase), which 
contains GARS (reaction 2), GARFTase (reaction 3) and AIRS (reaction 5) activities. 
Reactions 6 and 7 are catalyzed by the bifunctional phosphoribosyl aminoimidazole 
carboxylase/ phosphoribosyl aminoimidazole succinocarboxamide synthetase (PAICS) 
enzyme, which contains CAIRS (reaction 6) and SAICARS; (reaction 7) activities. Reactions 
9 and 10 are catalyzed by a bifunctional enzyme, 5-amino-4-imidazolecarboxamide 
ribonucleotide (AICAR) formyl transferase (AICARFTase)/IMP cyclohydrolase (ATIC). The 
two folate-dependent reactions (reactions 3 and 9) in which 10-CHO-THF serves as the one-
carbon donor are catalyzed by GARFTase and AICARFTase. 
Free purine bases which are derived from the turnover of nucleotides or from the diet, 
can be attached to PRPP to form purine nucleoside monophosphates. There are two types of 
phosphoribosyl transferases: adenine phosphoribosyl transferase (APRT) for AMP formation 
and hypoxanthine-guanine phosphoribosyl transferase (HGPRT) for IMP and GMP 
formation.176 Many enzymes required for salvage pathways get co-deleted in cancer cells, and 
cancer cells remain dependent on the de novo synthesis for obtaining purines.177 Further, 
methylthioadenosine phosphorylase (MTAP), another salvage enzyme that releases adenine 
from methylthioadenosine is abundantly expressed in normal tissues and is co-deleted with 
CDKN2A in many tumors.178-180 
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(a) GARFTase  
Gangjee and coworkers have reported 6-substituted pyrrolo[2,3-d]pyrimidines which 
displayed GARFTase inhibition (Table 1).174, 175, 181 Unlike PMX, which needs to be 
polyglutamylated for its activity, the reported compounds show potent inhibition of GARFTase 
in its monoglutamylated form.174  









Figure 30. X-ray co-crystal structure of GARFTase and antifolate AGF150 (PDB: 4ZZ1).175 
AGF150 is displayed in cyan color, and the substrate GAR is displayed in orange color. 
 
The binding mode of antifolates in GARFTase can be visualized by studying the X-ray 
co-crystal structure of GARFTase and antifolate AGF150 (PDB: 4ZZ1, 1.35 Å) (Fig. 30).175 
 n Ar Ki (nM) 
AGF23 4 1,4-phenyl 17 ± 3 
AGF71 4 2,5-thienyl 22 ± 3 
AGF94 3 2,5-thienyl 68 ± 11 
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The N1 of the pyrrolo[2,3-d]pyrimidine scaffold forms hydrogen bonding interaction with NH 
of the backbone of Leu899. The 2-NH2 displays hydrogen bonding interaction with backbone 
NH of Ala947 and Glu948. The 3-NH also forms hydrogen bonding interaction with backbone 
NH of Ala947. The 4-oxo forms hydrogen bonding interaction with backbone NH of Asp951. 
The glutamate side chain is oriented in a solvent-exposed pocket — the α-COOH forms ionic 
bonding with Arg871 and ion-dipole interaction with backbone NH of Ile898. 
 
(b) AICARFTase 
5-Aminoimidazole-4-carboxamide (AICA) and AICAR can be metabolized to AICAR 
monophosphate (ZMP) by adenine phosphoribosyl transferase (APRT) and adenosine kinase 
(AK).132 Thus, this can circumvent the reaction catalyzed by GARFTase. Moran and 
coworkers182 reported an interesting find on the effect of PMX on AICARFTase. Inhibition of 
AICARFTase causes accumulation of its substrate- AICAR (ZMP). The accumulated ZMP 
causes activation of AMP-dependent protein kinase (AMPK), the activation of AMPK causes 
inhibition of the mechanistic target of rapamycin (mTOR) as well as direct phosphorylation of 
the raptor component of mammalian target of rapamycin complex (mTORC1 complex). Thus, 
it inhibits cell growth through two distinct pathways. 
To understand the binding mode of compounds in AICARFTase, the X-ray cocrystal 
structure of AICARFTase with a bicyclic classical antifolate compound can be studied (Fig. 
31).183 The bicyclic scaffold is stabilized by π-π stacking interaction with Phe544. The 2-NH2 
displays hydrogen bonding interaction with the backbone carbonyl of Asn489 and ion-dipole 
interaction with the side chain of Asp546. The 3-NH also displays ion-dipole interaction with 
the side chain of Asp546. The 4-oxo group forms a hydrogen bonding interaction with the side 
chain of  
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Figure 31. X-ray co-crystal structure of AICARFTase with bicyclic classical antifolate 
BW1540U88UD (PDB: 1P4R).183 The ligand is displayed in cyan color, and the substrate 
AICAR is displayed in orange color. 
Asn547. The sulfone in the linker shows hydrogen bonding interaction with backbone NH of 
Arg541, the side chain of Asn431, and ion-dipole interaction with Lys266. The glutamate side 
chain is oriented in a hydrophilic and solvent exposed pocket. 
 
 
Figure 32. 5-substituted pyrrolo[2,3-d]pyrimidine compounds (AGF126 and AGF127) with 
inhibitory activity against both GARFTase and AICARFTase.184, 185 
Gangjee and coworkers184, 185 have reported 5-substituted pyrrolo[2,3-d]pyrimidines 
(AGF126 and AGF127) which displayed inhibition of both GARFTase and AICARFTase 
(Fig. 32). This dual inhibition is advantageous as it attacks the purine biosynthetic pathway at 
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two distinct sites and could overcome a tumor resistance due to lack of sensitivity at a single 
target. Such therapy will be effective for drug-resistant tumors.  
A.5.4.2 Inhibitors of serine hydroxymethyl transferase enzyme 
Figure 33. Compartmentalization of 1C metabolism (modified from ref. 126). 
One carbon units incorporated in various folate metabolism cofactors are primarily 
derived from serine catabolism occurring in mitochondria.126, 186 Therefore, serine catabolism 
plays essential role in cancer cell growth. Serine is catabolized in mitochondria and synthesized 
in cytosol by set of enzymes which allow not only for parallel metabolic processes, but also 
for a complete oxidative/reductive cycle.126 In mitochondria, serine is metabolized to formate 
via three enzymes: a) serine hydroxymethyl transferase 2 (SHMT2), b) methylene 
tetrahydrofolate dehydrogenase 2/L, and c) monofunctional tetrahydrofolate synthase 
(MTHFD1L) whereas serine is synthesized in cytosol via a) methylene tetrahydrofolate 
dehydrogenase, and formyltetrahydrofolate synthetase 1 (MTHFD1), and b) serine 
hydroxymethyl transferase 1 (SHMT1). The cycle that catabolizes serine in mitochondria and 
synthesizes serine in the cytosol is thermodynamically driven by the difference in 
electrochemical potential between mitochondrial NADH (NADPH) and cytosolic NADPH. 
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In rapidly proliferating cells such as cancer cells there is continuous need for 1C units, 
which results in consistent overexpression of SHMT2 and immediately downstream enzyme 
MTHFD2 in most of the cancers.187-189 The 1C unit generated from serine catabolism in the 
mitochondria is exported to cytosol as formate, which is incorporated in THF and subsequently 
by series of reactions catalyzed by GARFTase, AICARFTase and thymidylate synthase used 
for nucleotide synthesis.141, 190, 191 Even though SMHT2 and MTHFD2 deleted cells are viable, 
primarily due to 1C pool compensation by the cytosolic SHMT1 enzyme.191, 192 However, the 
flux carried through this enzyme is not sufficient to meet glycine demand and these cells are 
glycine auxotrophs.126 This lack of glycine becomes more pronounced in cancer cells which 
are not able to access serum glycine supply and rely primarily on intracellular synthesis.193 To 
achieve cytotoxic effect simultaneous inhibition of both cytosolic and mitochondrial SHMT 
enzymes is necessary. Khushbu and Gangjee194 have recently reported novel pyrrolo[3,2-
d]pyrimidine antifolates which inhibit both SHMT1 and 2 enzyme along with enzymes in de 
novo purine biosynthesis pathway and are transported selectively into the tumor cells. This 
resulted in excellent in vivo efficacy in pancreatic cancer model. These compounds are exciting 
prototypes for dual-targeting mitochondrial and cytosolic C1 metabolism for cancer, with 
substantial promise for overcoming resistance to current anticancer therapies. 
A.6. Selective pjDHFR inhibitors 
A.6.1. Pneumocystis jirovecii and pneumocystis pneumonia Infection 
Pneumocystis jirovecii (pj) is a fungus which is present in the lungs of a majority of 
the human population around the world.195 It is an atypical fungus, which differs from other 
fungi due to the presence of cholesterol, instead of ergosterol, in its cell membrane. The species 
affecting humans is very different than the species affecting other animals, such as rats and 
mice. The species that infects rats does not proliferate when passaged into mice, whereas the 
infection from rats to other rats causes severe infection.196 The immune system in healthy 
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individuals keeps the Pneumocystis jirovecii infection under control. In immunocompromised 
patients, Pneumocystis jirovecii infection causes Pneumocystis pneumonia (PCP). PCP can be 
fatal for patients with HIV/AIDS (most common), patients undergoing chemotherapy for 
cancer, patients on immunosuppressive medications, patients undergoing organ or bone-
marrow transplantation or those that are malnourished.195, 197 PCP presents itself when the 
patients’ CD4 count is below 200 cells/mm3. Although PCP prophylaxis and antiretroviral 
therapy (ART) has changed the face of the HIV/AIDS epidemic, the incidences of HIV cases 
persist due to non-adherence to the medication, toxicity to the medications, emergence of drug 
resistant HIV strains, late diagnosis of HIV and the rise of the number of cases in developing 
countries.198, 199 Thus, PCP continues to be a significant public health burden. In the US, 9% of 
the hospitalized HIV/AIDS and 1% of organ transplant patients develop PCP infection.200 In 
these patients, the mortality rate is from 5-40% while being treated for PCP and approaches 
100% if left untreated.200 
Both the prophylaxis and treatment for PCP involves the combination of trimethoprim 
(TMP)-sulfamethoxazole (SMX) (co-trimoxazole).201, 202 TMP (Fig. 34) is a selective, but 
weak inhibitor of dihydrofolate reductase (DHFR), the enzyme necessary for the reduction of 
dihydrofolate to tetrahydrofolate,203 while SMX is an inhibitor of the dihydropteroate synthase 
(DHPS), the enzyme necessary for the synthesis of folates in fungi.204 The low activity of TMP 
against DHFR is augmented by SMX, in the treatment regimen. The efficacy, low cost and 
activity in variety of infections has propelled cotrimoxazole to be used indiscriminately. Due 
to the rampant use, mutations in the DHPS locus of Pneumocystis jirovecii encoding DHPS 
have been documented as the cause of TMP/SMX resistant strains of PCP.204-207 
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 Figure 34. Clinical and non-clinical agents for the treatment for PCP 
 Various studies have also reported clinical and non-clinical mutations discovered in 
DHFR after treatment or prophylaxis using DHFR inhibitors.208-212 Treatment failure and 
discontinuation of co-trimoxazole occurs in several cases due to such resistant strains or 
toxicity/allergy by SMX.213, 214 In cases of treatment failure to TMP/SMX, the second-line 
treatment in mild to moderate PCP is TMP-dapsone or clindamycin-primaquine, which also 
leads to low efficacy and often lethal side-effects.201, 215, 216 Piritrexim (PTX) and trimetrexate 
(TMQ) are potent, but non-selective inhibitors of DHFR, which cause dose-limiting 
toxicities.201, 217, 218 These agents, combined with leucovorin (for rescue from 
myelosuppression) had high costs, drug toxicities, drug interactions and lack of efficacy. For 
patients that do not respond to first line treatment as well the inevitable recurrence of resistance, 





Figure 35. Reaction catalyzed by DHFR219 
Dihydrofolate reductase (DHFR) is an important target for several human diseases- 
protozoal, bacterial, fungal infections, and autoimmune diseases.219, 220 Folate metabolism has 
been investigated and validated for decades as a target in chemotherapy. Eukaryotic organisms 
synthesize thymidine via thymidylate cycle, which consists of enzymes: (a) Serine 
hydroxymethyl transferase (SHMT); (b) DHFR; and (c) Thymidylate synthase (TS). DHFR 
catalyzes NADPH-dependent reduction of 7,8-dihydrofolate to the 5,6,7,8-tetrahydrofolate 
(THF) (Fig. 35). The THF then acts as a cofactor in the conversion of deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), catalyzed by TS. This 
inhibition causes disruption in DNA, RNA and protein synthesis of the organism and 
eventually leads to death. Thus, inhibition of TS or DHFR causes a “thymineless death” and 




A.6.3. hDHFR, pcDHFR and pjDHFR 
Pneumocystis infection is host specific. Most of the drugs synthesized and evaluated 
thus far for PCP infections were tested against Pneumocystis carinii DHFR (pcDHFR), which 
was presumed to be the causative species of PCP infection in humans.203 Pneumocystis carinii 
(pc) however is a distinct species that infects rats, different from Pneumocystis jirovecii, 
responsible for human infections. The amino acid sequence of the DHFR of Pneumocystis 
carinii (pcDHFR) differs by 38% when compared to the DHFR of Pneumocystis jirovecii 
(pjDHFR).221 Hence, drugs evaluated against the surrogate pcDHFR in vitro, may not translate 
into activity in the treatment of PCP infection in humans.222 Rational design of pjDHFR 
inhibitors is hampered due to a lack of crystal structure information for pjDHFR. Another 
significant impediment in the drug discovery of inhibitors of pjDHFR is the inability to grow 
the organism outside the human lung and hence to develop a tissue culture for in vitro studies 
or an animal model for in vivo evaluation of the synthesized compounds. 
 
Figure 36. Previously reported pyrido[2,3-d]pyrimidines. 
Gangjee and coworkers222 reported pyrido[2,3-d]pyrimidines (Fig. 36) as selective and 
potent pjDHFR inhibitors (Table 2). To illustrate the interactions that defines the enhanced 
selectivity and potency, Cody et al.223 reported the X-ray co-crystal structures of 8a with 





Table 2. Inhibitory Concentrations (IC50, in nM) against Recombinant DHFR from 
pjDHFR and human DHFR (hDHFR) and Selectivity Ratios.211 
 pjDHFR (IC50, in nM) hDHFR (IC50, in nM) h/pj 
           6a 2.4 52 21 
7a 2.5 5.6 2 
8a 4.2 150 35 
TMP 120 32200 268 
PTX 1.6 3.0 2 
TMQ 2.1 2.6 1 
 
 
Figure 37. Sequence alignment of hDHFR (186 residues), pcDHFR and pjDHFR (both 206 
residues). Mutational sites are underlined and in red while key active site residues are 
numbered and colored cyan.  
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 The variability in pcDHFR, pjDHFR and hDHFR enzyme sequences have been 
investigated by Cody et al.212 The particular residues which seem to influence the active site 
(as seen in Fig. 37) are at positions 35 and 64 (hDHFR numbering). In hDHFR enzyme, these 
residues are Gln and Asn; in pcDHFR enzyme, these are Lys and Phe and in pjDHFR enzyme 
are Ser and Ser. Structural data for inhibitor binding to hDHFR and pcDHFR reveal that these 
residues interact with inhibitors and that inhibitors have been designed in the past to 
specifically target these residues.47, 211, 220 
 TMP is a moderate pcDHFR and pjDHFR inhibitor. The reason for its safety in PCP 
infection is its inactivity against hDHFR (Table 2). The importance of the positions 35 and 64 
in hDHFR was illustrated by evaluating the Ki of TMP against wild type and mutants of 
hDHFR (Table 3). The Q35S mutant hDHFR displays a 3-fold reduction in Ki for TMP, 
compared to hDHFR. The N64S mutant displays a 31-fold reduction in Ki compared to 
hDHFR. The Q35S/N64S double mutant displays a 4-fold reduction in Ki compared to 
hDHFR. Thus, selectivity of agents can be achieved for pjDHFR over hDHFR by rational 
design of compounds targeting the amino acid residues that are different in hDHFR and 
pjDHFR enzymes. 
Table 3. Kinetic constants (Ki) of TMP against pjDHFR, pcDHFR, and wild type and mutant 
hDHFR.212 
Enzyme Ki (nM) 
hDHFR 5200 ± 700 (n = 4) 
pcDHFR 800 ± 300 (n = 7) 
pjDHFR 43 ± 5 (n = 14) 
hDHFR Q35S 1800 ± 100 (n = 3) 
hDHFR N64S 170 ± 0.5 (n = 2) 




II. CHEMICAL REVIEW 
The chemistry related to the present work is reviewed and includes synthetic approaches to the 







Various synthetic methodologies have been employed in the synthesis of quinazolines. 
Few of them will be discussed here from substituted benzene precursors. 
Scheme 1. Synthesis of quinazoline from anilines 
 
Protection of the amino group of the aniline 1b with ethyl chloroformate (Scheme 
1) and subsequent reaction with hexamethylenetetramine (HMTA) in trifluoroacetic acid 
(TFA) resulted in the formation of cyclized dihydrobenzoquinazoline 3b. Oxidation of 3b 




Scheme 2. Synthesis of quinazoline from 2-aminoarylketones and benzylamines 
 
Graphite oxide was used as a recyclable heterogenous catalyst (Scheme 2) in the 
synthesis of 2-arylquinazoline 7b (84-93%), from 2-aminoarylketones 5b and benzylamines 
6b. To ensure complete oxidation t-butyl hydroperoxide (TBHP) was used.225, 226 
Scheme 3. Synthesis of quinazoline from 2-iodobenzaldehydes via Ullmann reaction 
 
Ligand-free Cu-catalyzed Ullmann reaction conditions (Scheme 3) were used for 
preparing substituted quinazolines 10b in 61-89%yield from 2-iodobenzaldehydes 8b and 
amidine hydrochloride 9b.225, 227 
Scheme 4. Synthesis of 2-aryl-4-methylquinazolines 
 
In a similar reaction, quinazolines 13b (Scheme 4) were synthesized substituted 2-
bromoacetophenone 11b, aldehyde 12b and aq. the  in the presence of Cu catalyst (CuI) and 
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N-methylpyrrolidone (NMP) as a solvent. The reaction was proposed to occur via Cu(I) 
catalyzed amination of 11b to yield substituted 2-aminobenzophenone that further reacted with 
the aldehyde 24.225, 228 
Scheme 5. Synthesis of 1(H)-quinazolin-2-one from alkynylanilines 
 
The synthesis of target compounds was accomplished in two steps (Scheme 5). In 
the first step, the urea derivative, 15b was obtained by reacting o-alkylnylaniline 14b with 
potassium isocyanate. In the subsequent step, acid catalyzed intramolecular cyclization of 15b 
yielded 16b in 28-98% yield.225, 229 
Scheme 6. Synthesis of quinazolin-4(3H)-one from anthranilic acid 
 
Treatment of anthranilic acid 17b (Scheme 6) with aliphatic anhydride yielded 
corresponding benzoxazinones 18b, which were used further without purification to form 
acylaminobenzamides 19b. Subsequent cyclization with formamide under microwave 
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irradiation conditions afforded the desired quinazolin-4-one 20b in 74-87% yield.225, 230 
In another method, 2-nitrobenzamide 33 was reacted with aromatic aldehyde 34 in 
the presence of sodium dithionate to yield quinazolin-4(3H)-one 26b (Scheme 7). 
Mechanistically, the reaction proceeded via reduction of nitro by sodium dithionate to amine 
23b that cyclized with the aldehyde to yield 2,3-dihydroquinazolin-4(1H)-one 24b. The sulfur 
dioxide from sodium dithionate subsequently participated in the oxidation to yield desired 
compound 26b.225, 231 
Scheme 7. Synthesis of quinazolin-4(3H)-one from 2-nitrobenzamides 
 
Scheme 8. Synthesis of quinazolin-4(3H)-one from isatoic anhydride 
 
In a one-pot three-component reaction (Scheme 8) with benzyl halides 27b, amines 
28b and isatoic anhydride 29b quinazolin-4(3H)-one 30b were synthesized via in situ 
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generations of aldehydes by DMSO mediated oxidation of benzyl halide in the presence of 




Scheme 9. Synthesis of 6-chloropyrido[3,2-d]pyrimidine-2,4-diamine from 2,6-
dichloropyridine 
 
The 2,4-diamino-6-chloropyrido[3,2-d]pyrimidine 35b (Scheme 9), was obtained from 
2,6-dichloropyridine 31b via a four-step synthetic procedure.233 The 2,6-dichloropyridine was 
nitrated with 90% nitric acid and sulfuric acid to afford 32b. This was followed by substitution 
of the 2-Cl moiety with cuprous cyanide at 180 °C to afford 2-cyano-3-nitro-6-chloropyridine 
33b. Following the reduction of 33b with iron powder in acidic methanol to afford the 3-amino-
6-chloropicolinonitrile 34b. The 2-cyano-3-amino function was set up to condense with 
chloroformamidine hydrochloride in dimethyl sulfone to afford the crucial intermediate 35b 
(85% over four steps). 
 Wang et al.234 have reported synthesis of (E)-6-styrylpyrido[3,2-d]pyrimidine-2,4- 
diamine derivative 41b from 5-aminopyrimidine-2,4-diol 36b (Scheme 10). Commercially 
available 5-aminouracil 36b and crotonaldehyde were cyclized in 20% HCl using the Skraup 
reaction to give 2,4-dihydroxy-6-methylpyrido[3,2-d]pyrimidine 38b. The 6-
methylpyrido[3,2-d]pyrimidine 38b was then reacted with substituted benzaldehyde in the 
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presence of p-toluenesulfonamide using N,N-dimethylacetamide as a solvent to form (E)-2,4-
dihydroxy-6-phenylethylenylpyrido[3,2-d]pyrimidine 39b. Chlorination of intermediate 39b 
with an excess of POCl3 in the presence of catalytic pyridine provided the 2,4-dichloro 
derivative 40b. Conversion of 40b to the corresponding 2,4-diamino derivative 41b was 
achieved using a saturated solution of ammonia in dry methanol in a sealed vessel at 150 ⁰C 
for 8 h. 
Scheme 10. Synthesis of (E)-6-styrylpyrido[3,2-d]pyrimidine-2,4-diamine from 5- 
aminopyrimidine-2,4-diol 
 
Mamouni et al.235 reported a four-step procedure for synthesis of pyrido[3,2-
d]pyrimidine-2,4-diones from furo[3,4-b]pyridine-5,7-dione (Scheme 11). The esterification 
of pyridine-2,3-dicarboxylic anhydride 42b by methanol afforded a mixture of 43b (stable 
isomer) as a major product and 44b (unstable isomer) as a minor product (Scheme 11). 
Treatment of 2-(methoxycarbonyl)nicotinic acid 43b by ethyl chloroformate with 
triethylamine and sodium azide in the presence of a small amount of water gave the methyl 3-
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(azidocarbonyl)picolinate 45b which was transformed by Curtius rearrangement into methyl 
3-isocyanatopicolinate 46b. The subsequent reaction of isocyanate 46b with amino acids under 
mild conditions by gentle heating led to pyrido[3,2-d]pyrimidinediones 47b-49b. 




Scheme 12. Synthesis of 6-aryl-1,3-dimethyl-8-phenylpyrido[3,2-d]pyrimidine-2,4(1H,3H)-
dione from 5-amino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione 
 Majmudar et al.236 devised a mild and efficient method for the synthesis of pyrido[3,2-
d]pyrimidine derivatives 53b-56b (Scheme 12) via three-component domino reaction of 
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amines, aldehydes, and terminal inactivated alkynes. This method used BF3·OEt2 as a Lewis 




Figure 38. Disconnection strategy for pyrimido[4,5-b]indoles from indole precursors. 
 
Different methods used in the synthesis of pyrimido[4,5-b]indoles from indoles or 
tetrahydroindoles utilize a disconnection strategy, as shown in Fig. 38. 
 
Scheme 13. Synthesis of 2-amino-pyrimido[4,5-b]indoles from indoles 
 
Treatment of 1,2-dichloro-3-nitrobenzene 57b with ethyl cyanoacetate provided 
58b,123, which underwent reductive cyclization to the indole 59b (Scheme 13). 
Cyclocondensation of 59b with chlorformamidine hydrochloride afforded 2-amino-4-oxo-5-
chloro-pyrimido[4,5-b]indole 60b. 
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Alternatively, 2-amino-4-oxo-pyrimido[4,5-b]indoles can be synthesized by a two-step 
procedure as shown in Scheme 14 below.237 
 
Scheme 14. Sequential two-step synthesis of 2-amino-pyrimido[4,5-b]indoles 
 
 
Scheme 15. Synthesis of the 2-unsubstituted pyrimido[4,5-b]indole 67b. 
 
 
Analogous to 4-chloroindole derivative 59b in Scheme 13, the 5-chloroindole 66b 
(Scheme 15) was obtained from 1,3-dichloro-4-nitrobenzene 64b.238 Compound 66b was 
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cyclized using formamide to afford 2-unsubstituted 4-oxo-6-chloro-pyrimido[4,5-b]indole 
67b. 
Scheme 16. Versatile synthesis of 2-substituted pyrimido[4,5-b]indoles 
 
Showalter et al.239 reported a versatile procedure for the preparation of 2-substituted 4-
oxo-pyrimido[4,5-b]indoles 69b, 72b and 73b from ethyl 2-amino-1H-indole-3-carboxylate 
68b (Scheme 16). Compound 68b was cyclized using formamide under basic conditions to 2-
unsubstituted pyrimido[4,5-b]indole 69b. Treatment of 68b with cyanamide and acetonitrile 
under acidic conditions provided intermediates 70b and 71b, which were cyclized using 1N 
NaOH to 2-amino- and 2-methyl-pyrimido[4,5-b]indoles 72b and 73b, respectively. 
Venugopalan et al.237 reported the synthesis of 2-substituted pyrimido[4,5-b]indoles 
from ethyl 2-amino-4,5-dimethoxy-indole carboxylate 61b (Scheme 17). Treatment of 61b 
with ethyl carboxyisothiocyanate gave 74b, which cyclized to the 2-thio-4-oxopyrimido[4,5-
b]indole 75b under basic conditions. Methylation of 75b afforded the 2-methylthio-
pyrimido[4,5-b]indole 76b, which upon reduction gave the 2-unsubstituted pyrimidoindole 
77b. For the synthesis of 2-unsubstituted pyrimido[4,5-b]indoles, this strategy presents an 
alternative to the approach described in Schemes 15 and 16, in which 2- unsubstituted 
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pyrimidoindoles 67b (Scheme 15) and 69b (Scheme 16) were synthesized by a direct reaction 
of indoles with formamide. 
 
Scheme 17. Venugopalan strategy for the synthesis of 2-substituted pyrimido[4,5-b]indoles 
 
 
Kumar et al.240 synthesized pyrimido[4,5-b]indoles from 2-haloindoles via palladium-
catalyzed amidation and cyclization. Coupling of the 3-formyl- or 3-acetyl-2-haloindoles 78b 
and amides 79b provided 80b in 80‒94% yield (Scheme 18). Treatment of 80b with 
ammonium formate resulted in the formation of pyrimido[4,5-b]indoles 81b. According to the 
proposed mechanism for 80b→81b, ammonium formate thermally decomposes and releases 
ammonia which attacks 3-carbonyl of 80b and generates the “imine” intermediate, which then 
cyclizes to provide the desired pyrimido[4,5-b]indole 81b. 
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Scheme 18. Synthesis of pyrimido[4,5-b]indoles via Pd-catalyzed amidation and cyclization 
of 2-haloindoles 
 
In Schemes 13‒18 above, indoles were utilized to obtain pyrimido[4,5-b]indoles. 
Schemes 19 and 20 below present synthesis of pyrimido[4,5-b]indoles from tetrahydroindoles. 
Scheme 19. Synthesis of pyrimido[4,5-b]indoles from tetrahydroindoles 
 The tetrahydro-1H-indole 83b (Scheme 19) was obtained by the treatment of 2-
hydroxycyclohexanone 82b with benzylamine and malononitrile.241 Compound 83b was 
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cyclized using formic acid to the 4-oxo-tetrahydropyrimido[4,5-b]indole 84b. Chlorination of 
the 4-oxo of 84b followed by displacement with 3-chloroaniline afforded 85b. Oxidation of 
85b using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and subsequent removal of the 
benzyl group provided pyrimido[4,5-b]indole 86b. 
Müller et al.242 synthesized a series of chiral pyrimido[4,5-b]indole derivatives 91b and 
92b (Scheme 20). Reaction of chiral tetrahydroindoles 87b with benzonitrile and sodium 
methoxide yielded the 2-phenyl-4-amino-tetrahydropyrimido[4,5-b]indoles 88b. On the other 
hand, treatment of 87b with benzoyl chloride provided 90b, which was subsequently cyclized 
to the 2-phenyl-4-oxo-tetrahydropyrimido[4,5-b]indoles 91b. Dehydrogenation of the 
tetrahydroindoles 88b and 91b furnished the desired pyrimido[4,5-b]indoles 89b and 92b, 
respectively. 





Scheme 21. Synthesis of pyrrolo[2,3-d]pyrimidines from 6-aminopyrimidin-4(3H)-one 
 
6-amino-5-bromopyrimidin-2(1H)-one, 94b (Scheme 21) was synthesized by 
electrophilic substitution of 6-aminopyrimidin-2(1H)-one 93b with bromine. Palladium 
catalyzed Stille coupling of 94b with Z-1-ethoxy-2-(nbutylstanyl)ethane followed by 
deprotection of resulting enol ether 95b with concomitant cyclization gave 4-methyl-1,3,4,7-
tetrahydro-2H-pyrrolo[2,3-d]pyrimidin-2-one, 96b.243 
Scheme 22. Synthesis of pyrrolo[2,3-d]pyrimidines from ethyl 2-cyano-4,4-diethoxybutanoate 
 
Cyclocondensation of ethyl 2-cyano-4,4-diethoxybutanoate 97b (Scheme 22) with 
thiourea affords 6-amino-5-(2,2-diethoxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)- 
one, 98b. Acidic hydrolysis of acetal 98b and cyclization and final desulfurization with Raney 
nickel forms 1,2,3,7-tetrahydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, 100b.243  
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Scheme 23. Synthesis of pyrrolo[2,3-d]pyrimidines from 5-bromo-2,4-dichloropyrimidine 
 The synthetic route (Scheme 23), based on Besong’s method244 starts with the reaction 
of 5-bromo-2,4-dichloropyrimidine, 101b and cyclopentylamine in N,N-
diisopropylethylamine to yield compound 102b, followed by Pd catalyzed Sonogashira 
coupling with propargyl alcohol afforded 3-(2-chloro-4-(cyclopentylamino)pyrimidin-5-
yl)prop-2-yn-1-ol, 103b. Cyclization of 103b was carried out in THF using TBAF to afford (2-
chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol, 104b.245 
Scheme 24. Synthesis of pyrrolo[2,3-d]pyrimidines from 6-amino-2-
(dimethylamino)pyrimidin-4-(3H)-one 
 
Gangjee et al.246 reported the synthesis of 109b (Scheme 24) by the condensation of 
an aqueous solution of α-chloroacetone 105b in presence of NaOAc in 70% yield. Linz et al.247 
also reported the synthesis of a series of pyrrolo[2,3-d]pyrimidines from 6-amino-2-
(dimethylamino)pyrimidin-4(3H)-ones 106b (Scheme 24). Compound 106b on treatment with 
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α-chloroacetone 107b or α-chloroacetaldehyde 108b provided the corresponding pyrrolo[2,3-
d]pyrimidines 109b or 110b in 68% and 75% yields respectively. 
Taylor et al.248 synthesized methyl 4-(2-(2-amino-6-methyl-4-oxo-4,7-dihydro-
3Hpyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate 113b (Scheme 25) by a Fisher-Indole 
approach. Reaction of 2-amino-6-hydrazinylpyrimidin-4(3H)-one, 111b with one equivalent 
of methyl 4-(4-oxopentyl)benzoate in 2-methoxyethanol under reflux afforded the requisite 
intermediate 112b, methyl (Z)-4-(4-(2-(2-amino-6-oxo-1,6-dihydropyrimidin-4-
yl)hydrazineylidene)pentyl)benzoate. The cyclization was accomplished by thermolysis of 
112b in refluxing diphenyl ether to regioselectively afford the pyrrolo[2,3-d]pyrimidine 113b. 
Scheme 25. Synthesis of pyrrolo[2,3-d]pyrimidines using Fisher-Indole reaction 
 
Scheme 26. Synthesis of pyrrolo[2,3-d]pyrimidines from 1-benzyl-2-amino-3-cyanopyrroles 
 
Traxler et al.241 reported the synthesis of a series of pyrrolo[2,3-d]pyrimidines (Scheme 
26) starting from substituted α-hydroxy ketone 114b. Ketone 114b was converted to 2-amino-
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1-benzyl-4,5-dimethyl-1H-pyrrole-3-carbonitrile 115b by treatment with benzylamine at 
reflux in toluene and further condensation with malononitrile in toluene at reflux. 2-Amino-1-
benzyl-4,5-dimethyl-1H-pyrrole-3-carbonitrile, 115b underwent condensation with 85% 
formic acid at reflux to provide the target 7-benzyl-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-
ol, 116b. 
Scheme 27. Synthesis of 2-amino-pyrrolo[2,3-d]pyrimidines from 4-substituted 2,6-diamino 
pyrimidines 
 
Khalaf et al.249 synthesized pyrrolopyrimidines 124b-128b (Scheme 27) with 5- 
hydrophobic substituents via Michael addition-based synthesis to include a wide range of aryl 
and some alkyl substituents in both 4-oxo- and 4-aminopyrimidine series. Using 4- substituted 
2,6-diamino pyrimidines 117b with (E)-(2-nitrovinyl)aryl 118 to afford 5-(1-aryl-2-
nitroethyl)pyrimidine-4-substituted-2,6-triamines were obtained in varying yields. They note 
slower reaction rates and poorer yields for the preparation of the 2,4-diamino compounds than 
in the preparation of the 2- amino-4-oxo compounds could be that the mildly basic conditions 
used for the Michael addition step increased the reactivity of the 2-amino-4-oxo pyrimidine 
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through formation of the anion. Condensation of 119b-123b to 4-substituted-5-aryl-7H-
pyrrolo[2,3-d]pyrimidine-2-amines 124b-128b were accomplished using base. 
Scheme 28. Synthesis of pyrrolo[2,3-d]pyrimidines from 2-bromo-1,1-diethoxyethane 
 
El-Gamal and Oh250 synthesized the intermediate 2-(2,2-diethoxyethyl)malononitrile 
130b (Scheme 28) from 2-bromo-1,1-diethoxyethane 129b with malononitrile by heating in 
N,N-dimethylformamide (DMF) in the presence of base K2CO3. Synthesis of 4,6-diamino-5-
(2,2-diethoxyethyl)pyrimidine-2-thiolate 131b was carried out by refluxing the geminal 
dicyano 130b with thiourea in the presence of a stronger base potassium tert-butoxide. 
Cyclization to 131b could be achieved by neutralization of the thiol potassium salt 130b using 
5 N aqueous HCl followed by heating with 10 N aqueous NaOH. Reduction of the thiol 
compound 131b using Raney nickel afforded 7H-pyrrolo[2,3-d] pyrimidin-4-amine 132b. 
Gangjee et al.251 attempted synthesis of 2-amino-pyrrolo[2,3-d]pyrimidines by reacting 
3-acetyldihydrofuran-2(3H)-one 133b (Scheme 29) and guanidine carbonate in refluxing 
conditions with absolute ethanol in the presence of triethylamine to afford 136b. It was 
converted to 4-chloro-5-(2-chloroethyl)-6-methylpyrimidin-2-amine 135b by refluxing with 
phosphorus oxychloride. Condensation of benzylamine with 135b in the presence of 
triethylamine under reflux in n-BuOH afforded the bicyclic 7-benzyl-4-methyl-6,7-dihydro-
5H-pyrrolo[2,3-d]pyrimidin-2-amine 136b. Oxidation to 137b was carried out using the 
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manganese dioxide. Removal of benzyl protecting group was carried out using liquid ammonia 
to afford the target compound 4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-amine 138b. 




Scheme 30. Synthesis of pyrrolo[3,2-d]pyrimidines from (2-substituted-pyrimidin-5- 
yl)boronic acids 
 
Beveridge and Gerstenberger252 reported one-pot four-step cascade sequence to 
synthesize pyrrolo[3,2-d]pyrimidines via reaction of (2-substituted-pyrimidin-5-yl)boronic 
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acids 139b with di-tert-butyl-azodicarboxylate (DBAD) and 1,3-dicarbonyls 141b (Scheme 
30). The reaction proceeds via a with key steps involving a copper-catalyzed boronic acid 
coupling to DBAD and a Fischer indolization to provide 2-,6- and 7- substituted pyrrolo[3,2-
d]pyrimidines 142b-144b. 
Scheme 31. Synthesis of 2-amino 4-oxo pyrrolo[3,2-d]pyrimidines from 2-amino-6- 
methylpyrimidin-4(3H)-one 
 
Furneaux et al. 253 reported the synthesis of 2-amino-3H,5H-pyrrolo[3,2-d]pyrimidin- 
4-one 148b (Scheme 31). Nitration of 2-amino-6-methylpyrimidin-4(3H)-one 145b afforded 
compound 2-amino-6-methyl-5-nitropyrimidin-4(3H)-one, 146b. On treatment of nitro 
derivative 146b with 6 equivalent of DMF dimethyl acetal in DMF at 100 °C, compound (E)-
Nˊ-(4-((E)-2-(dimethylamino)vinyl)-5-nitro-6-oxo-1,6-dihydropyrimidin-2-yl)-N,N-
dimethylformimidamide, 147b is obtained which upon subsequent dithionite reduction and 
cyclization affords pyrrolo[3,2-d]pyrimidine 148b. 
Taylor et al.254 obtained (E)-N'-(4-((E)-2-(dimethylamino)vinyl)-1-methyl-5-nitro-6-
oxo-1,6-dihydropyrimidin-2-yl)-N,N-dimethylformimidamide, 150b (Scheme 32) upon 
reaction of 2-amino-6-methyl-5-nitropyrimidin-4(3H)-one, 149b with DMF dimethyl acetal. 
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Subsequent addition of sodium dithionite provided (E)-N,N-dimethyl-Nˊ-(3-methyl-4-oxo-4,5-
dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)formimidamide 151b, which hydrolysis provides 2-
amino-3-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 152b. 
Scheme 32. Synthesis of 2-amino 4-oxo pyrrolo[3,2-d]pyrimidines from 2-amino-6- 
methyl-5-nitropyrimidin-4(3H)-one 
 
Tian et al.234 condensed (Z)-4-(benzyloxy)-3-hydroxybut-2-enenitrile, 153b (Scheme 
33) with diethyl aminomalonate in the present of acetic acid to afford intermediate 154b, which 
was further cyclized under basic condition to produce ethyl 3-amino-5-((benzyloxy)methyl)-
1H-pyrrole-2-carboxylate, 155b using methodology published by Gangjee et al.255 The pyrrole 
155b was condensed with 1,3-bis(methoxycarbonyl)-2-methylthiopseudourea with acetic acid 
as catalyst in MeOH to afford 156b. The self-condensation reaction of 156b could be processed 
in the present of sodium methoxide in MeOH to obtain (6-((benzyloxy)methyl)-4-oxo-4,5-
dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)carbamate, 157b. Hydrolysis of the carbamate 





Scheme 33. Synthesis of 2-amino 4-oxo pyrrolo[3,2-d]pyrimidines from (Z)-4-(benzyloxy)-3-
hydroxybut-2-enenitrile 
 
Scheme 34. Synthesis of 2-alkyl-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl 3-amino-5- 
substituted-1H-pyrrole-2-carboxylate 
 
Pyrrolo[3,2-d]pyrimidines with 2-alkyl substituents are obtained by treatment of 5-
substituted pyrrole 159b (Scheme 34) with an alkyl nitriles in anhydrous hydrochloric acid 
followed by heating with sodium hydroxide.256 For R = methyl, the yield was 53%. 
Pyrrolo[3,2-d]pyrimidines with 2-H are obtained by cyclocondensation of substituted 




Scheme 35. Synthesis of 3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one from ethyl 3-amino-1H-
pyrrole-2-carboxylate 
 
Scheme 36. Synthesis of 2-sulfanyl-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl 3-amino-1H-
pyrrole-2-carboxylate 
 
Pyrrolo[3,2-d]pyrimidine 164b with 2-sulfanyl substituent can be obtained by 
treatment of 2-amino-6-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 163b (Scheme 
36) with an ethyl isothiocyanatoformate and hydrochloric acid in benzene at reflux followed 
by heating with aqueous sodium hydroxide.237 
Scheme 37. Synthesis of 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl 3-amino-5-
phenyl-1H-pyrrole-2-carboxylate 
 
Pyrrolo[3,2-d]pyrimidine 165b with 2-amino substituents are obtained by treatment of 
from ethyl 3-amino-5-phenyl-1H-pyrrole-2-carboxylate 163b (Scheme 37) with cyanamide 









Pyrrolo[3,2-d]pyrimidine 166b with 2,4-dioxo substituent is obtained by 
cyclocondensation of ethyl 3-amino-5-phenyl-1H-pyrrole-2-carboxylate 163b (Scheme 38) 
with potassium cyanate under acidic conditions at room temperature followed by heating with 
aqueous sodium hydroxide.258 
 




Treatment of substituted cyanoacetylenes 168b (Scheme 39) with 
diethylaminomalonate 167b followed by a base catalyzed intramolecular cyclization affords 
substituted ethyl 3-amino-1H-pyrrole-2-carboxylate 169b-171b.259 The pyrroles can be 
cyclized to afford 2-substituted 4-oxo pyrrolo[3,2-d]pyrimidines, as exemplified in Scheme 33 
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and 37 (2-amino), Scheme 34 (2-alkyls), Scheme 35 (2-H), Scheme 36 (2-sulfanyl) and 
Scheme 38 (2-oxo). 
Scheme 40. Synthesis of 5-substituted ethyl 3-amino-1H-pyrrole-2-carboxylate from 3- 
oxo-3-substituted propanenitrile 
 
Treatment of 3-oxo-3-phenylpropanenitrile 172b (Scheme 40) with p-toluenesulfonic 
anhydride provides the corresponding 2-cyano-1-phenylvinyl 4-methylbenzenesulfonate 
173b.260 The crude enol ester 173b is immediately condensed with diethyl aminomalonate 
using sodium ethoxide to provide ethyl 3-amino-5-phenyl-1H-pyrrole-2-carboxylate 165b. 














III. STATEMENT OF THE PROBLEM 
 
The present work deals with the design and molecular modeling studies in the following three 
major areas: 
A. Single agents with combination chemotherapy potential 
A.1. Inhibition of multiple tyrosine kinases and microtubule targeting agents: 
Quinazoline and Pyrido[3,2-d]pyrimidine analogs as multiple tyrosine kinase inhibitors and 
microtubule targeting agents 
A.2. Single agents with TS and multiple tyrosine kinase inhibitors:  
Pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors   
B. Folate Receptors (FR) and/or Proton-Coupled Folate Transporter (PCFT) targeted 
(cytosolic and/or mitochondrial) one-carbon (1C) metabolism inhibitors  
B.1 Inhibitors of de novo purine biosynthetic enzymes (cytosolic 1C metabolism) 
1. 5-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyridyl classical antifolates 
B.2 Dual inhibitors of cytosolic (de novo purine biosynthetic) and mitochondrial (serine 
hydroxymethyltransferase 2) 1C metabolism enzymes 
1. 5-Substituted, 2-amino-4-oxo pyrrolo[3,2-d]pyrimidine-pyridyl classical antifolates 
2. 5-Substituted, 2-amino-4-oxo pyrrolo[3,2-d]pyrimidine-3’-fluoropyridyl classical 
antifolates 
B.3 5-Substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]/[3,2-d]pyrimidine-pyridyl 
classical antifolates 
C. Selective inhibition of P. jirovecii dihydrofolate reductase 
1. 5-Substituted, 2,4-diamino pyrimidines (trimethoprim analogs) as selective pjDHFR 
inhibitors 
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A. Single agents with combination chemotherapy potential 
Angiogenesis – the process of formation of new blood vessels from existing 
vasculature – is essential for tumor growth and metastasis.58 When a tumor grows beyond 2 
mm3, it requires nutrients and oxygen for its growth and survival and thus initiates 
angiogenesis. Under hypoxic conditions, tumors secrete proangiogenic growth factors such as 
VEGF, PDGF, and EGF, key mediators of angiogenesis. These growth factors bind to their 
respective RTKs (VEGFR, PDGFR-β, and EGFR) and stimulate the process of angiogenesis, 
resulting in tumor growth, survival, and metastases. Agents that circumvent angiogenesis by 
inhibition of RTKs have established a new paradigm in cancer chemotherapy.57 RTK inhibitors 
that function by inhibition of a single RTK are prone to resistance by numerous mechanisms 
including redundant pathways, point mutations in the ATP-binding site, and upregulation of 
additional RTKs.261, 262 Consequently, multi-RTK inhibition in cancer chemotherapy has 
emerged as a promising approach, and its validity has been highlighted by the approval of 
several multi-RTK inhibitors including sorafenib (inhibits VEGFR-2, VEGFR-3, PDGFR-β, 
and Raf kinase) and sunitinib (inhibits VEGFRs, PDGFRs, and c-kit).263 However, the 
antiangiogenic treatment only prevents blood supply to the tumor but does not destroy cancer 
cells. Thus antiangiogenic agents need to be combined with radiotherapy or chemotherapy to 
form an effective therapy and achieve synergistic effects.264 
Inhibitors of TS and tubulin are widely used cytotoxic agents in cancer chemotherapy. 
While inhibition of the enzyme TS prevents the de novo synthesis of nucleotides crucial for 
DNA synthesis,41 tubulin inhibitors target microtubule dynamics involved in mitosis.5 
TS catalyzes the de novo synthesis of dTMP from dUMP utilizing 5,10-CH2THF as the 
cofactor.40 Because of its vital role in DNA synthesis and cell growth, TS is a viable target for 
several clinically used cancer chemotherapeutic agents.41 Nucleoside‒based inhibitors such as 
5-FU and capecitabine have found extensive utility in ovarian, breast, colon, and several other 
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cancers alone and in combinations and are a mainstay in cancer chemotherapy.44, 46 Antifolates, 
including raltitrexed and pemetrexed, are TS inhibitors clinically used, alone or in combination, 
in the treatment of mesotheliomas, non-small cell lung, and advanced colorectal cancers.49, 265 
Since microtubule dynamics plays a crucial role in mitosis and cell division,5 
microtubule targeting agents represent an important class of anticancer agents. Tubulin binding 
agents such as paclitaxel and vinca alkaloids are widely used to treat solid tumors and 
hematological malignancies.263, 266, 267 
Combination chemotherapy with antiangiogenic agents and cytotoxic agents is more 
effective in cancer treatment than either agent alone.264, 268 Single agents with dual 
antiangiogenic and cytotoxic activities significantly decreased tumor growth, tumor metastasis 
and angiogenesis superior to docetaxel and sunitinib in xenograft mice models, remarkably 
without any toxicity.122, 123 Such single agents with multiple mechanisms of action are 
commonly referred to as designed multiple ligands and have several pharmacokinetic and 
pharmacodynamic advantages over separately administered agents. These agents could 
potentially avoid drug-drug interactions and pharmacokinetic problems associated with two or 
more agents.269, 270 Also, they could prevent or delay the emergence of resistance and not cause 
overlapping toxicities.269, 271 Most significantly, single agents with dual cytotoxic and 
antiangiogenic activities simultaneously target rapidly proliferating tumor cells and the tumor 
vasculature. Also, such single agents could afford synergistic effects as they can exert their 
cytotoxic effect as soon as and during transient tumor vasculature normalization caused by the 
antiangiogenic component.272 As a result, structural design of such multitargeted single agents 
should allow the cytotoxicity to be manifested as soon as the antiangiogenic effects are 
operable. Thus, the cytotoxic component of these agents need not be as potent as conventional 
chemotherapeutic agents. Dosing of such an antiangiogenic agent with comparatively lower 
cytotoxic activity would mimic metronomic chemotherapy, which utilizes more frequent and 
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low-dose administrations of cytotoxic agents compared with conventional chemotherapy.273 
Several clinical trials attest to the safety and efficacy of using antiangiogenic agents such as 
sunitinib and sorafenib with metronomic doses of cytotoxic agents.274-277 The single agents 
offer other advantages such as decreased cost and increased patient compliance,270 which can 
play a major part in the clinical success of therapy. 
The antiangiogenic component of single agents targets RTK-overexpressing 
endothelial cells and as a result, is typically targeted to tumor cells under normal 
circumstances.58 In contrast, the cytotoxic component interferes with tumor cell division with 
less selectivity over rapidly dividing normal cells present in bone marrow, hair, and cells lining 
the mouth and gut.271 Therefore, a key challenge in the design of single agents with a cytotoxic 
component is that the cytotoxic component should only destroy tumor cells that are 
compromised via the antiangiogenic effect but should not cause toxicity to normal cells not 
affected by the antiangiogenic effect.123 As a result, the cytotoxic component of these single 
agents need not be as potent as conventional chemotherapeutic agents and hence should avoid 
dose-limiting toxicities278 associated with other cytotoxic agents. 
Single agents with dual antiangiogenic and cytotoxic activities significantly decreased 
tumor growth, tumor metastasis and angiogenesis in xenograft mice models, remarkably 
without any toxicity.118, 122, 123, 279 The antiangiogenic effects of these compounds were due to 
inhibition of RTKs and the cytotoxic effects were due to inhibition of thymidylate synthase123 
or tubulin118, 122 or dihydrofolate reductase.279 In these studies, VEGFR-2, PDGFR-β, and 
EGFR were the chosen targets for antiangiogenic effects because of their crucial role in 
angiogenesis. Additionally, the successful clinical and preclinical combinations of TS 
inhibitors (e.g., capecitabine, pemetrexed) or tubulin inhibitors like paclitaxel with 




A.1. Inhibition of multiple tyrosine kinases and microtubule targeting agents 
A.1.1. Design of quinazoline and pyrido[3,2-d]pyrimidine analogs as multiple tyrosine 
kinase inhibitors and microtubule targeting agents 
 
Figure 39. Structure of the lead compounds.  
Compound 33c (Fig. 39) was reported as a potent inducer of apoptosis, binding at the 
colchicine site and an inhibitor of tubulin polymerization (EC50 T47D = 2 ± 0.1 nM).
285 The 
compound was also shown to overcome resistance due to multidrug-resistant transporters such 
as P-glycoprotein (Pgp), breast cancer resistance protein (BCRP1) and was able to cross the 
BBB to attain 30-fold higher concentration in the brain compared to the plasma. These 
pharmacokinetic parameters led to the evaluation of 33c in glioblastoma multiforme (GBM) 
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and other cancers, and it is currently approved by FDA as an orphan drug in the treatment of 
GBM.286 Derivatives of 33c (34c-42c, Fig. 39) with different substitutions at the 2-position 
(CH3, Cl or H) and 4-position (anilines) were synthesized by Choudhary and Gangjee.
117 
Table 4. Inhibition of microtubule polymerization, antiproliferative activity and cellular 








Cellular RTK Inhibition 
MDA-MB-435 
IC50 (nM) ± SD 
VEGFR2 
IC50 (nM) ± 
SD 
EGFR 
IC50 (nM) ± 
SD 
33c 2.1 1.7 ± 0.1 8.4 ± 2.2  2.8 ± 1.1  
34c 3 1.1 ± 0.2 9.3 ± 3.9 5.0 ± 0.4 
35c 2 1.2 ± 0.2 14.7 ± 2.8 8.7 ± 1.6 
36c 2.4 2.0 ± 0.4 16.8 ± 4.1 10.6 ± 1.8 
37c 2 0.6 ± 0.1 97.5 ± 10.1 3.6 ± 0.6 
38c 2 0.7 ± 0.2 55.2 ± 11.1 5.4 ± 0.3 
39c 1.9 1.4 ± 0.1 ND ND 
40c 2.1 7.1 ± 0.8 ND ND 
41c 3 12.4 ± 1.7  111.1 ± 19.2 48.9 ± 6.0 
42c 2 7.8 ± 0.8 ND ND 
CA4 9.8  4.4 ± 0.46 ND ND 
Sunitinib ND ND 18.9 ± 2.7 172.1 ± 19.4 
Erlotinib ND ND 124.7 ± 18.2 1.2 ± 0.2 
ND- Not Determined 
In the antiproliferative assays and the microtubule depolymerization assays compounds 
33c-42c displayed potent inhibitory activities (Table 4). The 2-H substituted compounds (40c-
42c) were 7- to 10-fold less potent than the 2-Me (33c-36c) and 2-Cl (37c-39c) substituted 
compounds, suggesting bulk is important for antitubulin activity at the 2-position of the 
quinazoline scaffold. In the RTK inhibitory assays, the 2-Me and 2-Cl substituted compounds 
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were also more potent than 2-H substituted compounds. For the 2-substituted quinazolines 
(33c-36c), varying the aniline substitution at 4-position was well tolerated. The 2-Cl substituted 
compound 37c was a potent inhibitor of EGFR but resulted in the loss of 10-fold and 15-fold 
activity in VEGFR-2 and PDGFR-β, respectively when compared to corresponding 2-Me 
compound 33c. 
Table 5. IC50s in parent cell lines (HeLa and SKOV3), βIII- and Pgp-overexpressing resistant 
cancer cell lines (WTβ3 and M6/6, respectively)  
# IC50 ± SD in 
HeLa (nM) 








IC50 ± SD in 
SKOV3 
Cells (nM) 







33c 0.6 ± 0.2 0.6 ± 0.1 1.0 0.8 ± 0.1 1.1 ± 0.3 1.4 
34c 0.6 ± 0.2 0.7 ± 0.2 1.2 0.8 ± 0.2 1.0 ± 0.5 1.3 
35c 2.8 ± 0.5 1.6 ± 0.3 0.6 2.8 ± 0.4 2.6 ± 0.4 0.9 
36c 2.0 ± 0.2 1.5 ± 0.2 0.8 2.2 ± 0.1 2.6 ± 0.1 1.2 
37c 1.2 ± 0.5 1.2 ± 0.4 1.0 1.5 ± 0.3 2.2 ± 0.6 1.5 
38c 1.3 ± 0.6 1.1 ± 0.4 0.8 1.6 ± 0.2 2.1 ± 1.1 1.3 
39c 2.5 ± 0.3 1.7 ± 0.2 0.7 2.9 ± 0.3 3.5 ± 0.4 1.2 
40c 8.6 ± 0.3 7.4 ± 0.7 0.9 10.4 ± 1.1 14.3 ± 0.5 1.4 
41c 16.8 ± 2.2 13.1 ± 0.4 0.8 18.1 ± 1.8 23.4 ± 4.5 1.3 
42c 8.5 ± 0.8 7.3 ± 0.4 0.6 13.6 ± 0.9 15.6 ± 1.4 1.1 
CA-4 3 ± 0.4 3.3 ± 0.3 1 5.5 ± 0.5 7.2 ± 1.1  1.3 
Paclitaxel 2.8 ± 0.36 24 ± 3 8.6 5 ± 0.6 1200 ± 58 240 
 
The lead compounds were also tested against Pgp- and βIII-overexpressing cell lines 
to determine their efficacy against the most common type of resistance that renders current 
MTAs such as the vinca alkaloids and taxanes ineffective.117  The colchicine site agents like 
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CA-4 and the lead compounds 33c-42c circumvent these resistance mechanisms as evidenced 
by relative resistance (Rr) values close to 1 or lower than 1 (Table 5). However, paclitaxel is 
ineffective against these resistant cell line with Rr values ~9 and 240 for βIII- and Pgp-
overexpressing resistant cancer cell lines (WTβ3 and M6/6), respectively. These data suggest 
that these compounds overcome both Pgp and βIII-tubulin mediated resistance and in that 
regard, have advantages over paclitaxel. 
   
 
Figure 40. Few of the representative 6,6-bicyclic based RTK inhibitors. 
The quinazoline scaffold has also been widely explored for its RTK inhibitory activity 
as exemplified by gefitinib (EGFR), afatinib (EGFR), erlotinib (EGFR) and vandetanib 
(VEGFR-2, VEGFR-3, and EGFR) (Fig. 40). Structure-activity relationships of the 
quinazoline scaffold, to date, include only N4-desmethyl analogs as EGFR inhibitors (Fig. 40) 
which suggested that the quinazoline scaffold showed bulk tolerance at the 6- and 7-
positions.287, 288 However, the corresponding N4-Me analogs were not explored for their RTK 
inhibitory activities. The N4-Me analogs presented above (Fig. 39) not only showed potent 
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antitubulin activity but also inhibited one or more RTKs in the nanomolar range, suggesting 
that 2,4-disubstituted quinazoline analogs act as single agents with a combination of tubulin 
depolymerization and antiangiogenic activity. 
 
Figure 41. Structure of proposed compounds in Series I. 
 Compounds 1c and 2c (Series I) are designed to vary substitutions at 2- and 4-positions 
of the quinazoline scaffold. The 2-Cl substitution in the lead compounds showed the most 
potent microtubule depolymerization activity compared to the 2-CH3 and 2-H substitutions and 
also showed potent EGFR inhibition (IC50 = 3.6 to 10.6 nM) with moderate VEGFR-2 and 
PDGFR-β inhibition. The 4’-SCH3 substitution on the N
4-aryl group also produced potent 
antitubulin activity (Table 4). Therefore, compound 1c combining these two pharmacophores 
is predicted to be a single agent with potent microtubule depolymerization and RTK inhibitory 
activity. The 2-H substitution of compound 2c mimics the RTK inhibitors, which will allow 
hinge region binding and maintain interaction with the colchicine binding site in tubulin. 
 We performed molecular docking studies using Maestro 11.9289 on the proposed 
compounds 1c and 2c, and one of the most active leads compound 5 in tubulin (PDB: 4O2B),290 
VEGFR-2 (PDB: 4AG8)291 and EGFR (PDB: 1M17)292 to determine their binding poses and 
ligand-interactions. The molecular modeling protocol was validated by redocking the 
crystallized ligands colchicine, axitinib and erlotinib in tubulin, VEGFR-2, and EGFR, 
respectively with RMSD of 0.17 Å, 0.50 Å, and 1.19 Å, respectively.   
 87 
  
Figure 42. A) Superimposition of the docked poses of 37c (orange) and 1c (pink) and B) 
docked pose of 2c (cyan) in the colchicine binding site of tubulin (PDB ID: 4O2B).290 
 The docked poses of 1c (Fig. 42A) and 2c (Fig. 42B) are very similar to the docked 
pose of the lead compound 37c in the colchicine site of the tubulin. The N1 makes water-
mediated H-bond with the Cys241. The quinazoline scaffold sits deep in the β-tubulin pocket 
lined by hydrophobic residues such as Ile318, Ala354, Ile378, Ala316, Ala250, Leu252, 
Leu242, Val238, and Leu255. The 2-position substitution orients towards the pocket lined by 
Ala250, Leu242, and Leu252, the 2-Cl substitution makes favorable hydrophobic interaction 
with the pocket, whereas the 2-H group does not interact with the pocket. This results in a 
better docking score for the 2-Cl compound 1c compared to the 2-H compound 2c. Due to a 
similar reason, the lead compounds with the 2-Cl and 2-CH3 substitutions were more active 
than the 2-H lead compounds. These 2-position variations can allow for optimization of the 
antitubulin activity and hence the cytotoxic activity of these potential single agents. The N4-
Me group makes hydrophobic interaction with Ala250 whereas the N4-aryl ring orients toward 
the pocket lined by the β-tubulin residues, Ala316, Met259, Asn258, Lys352, Thr317 and the 
α-tubulin residues Ala180 and Val181 residues. The 4’-SMe group of compound 1c is more 
A B 
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hydrophobic in comparison to the 4’-OMe group of the lead 37c and can make better 
hydrophobic interaction with hydrophobic residues of α-tubulin. This results in a better 
docking score for 1c (-9.60 kcal/mol) than 37c (-9.08 kcal/mol). The 4’-OMe-phenyl and 4’-
SMe-phenyl rings of 37c and 1c do not fully occupy the pocket at the α- and β-tubulin interface, 
whereas the docked pose of 2c shows that the bulky 2-naphthyl ring at the N4-position goes 
deeper in the pocket. Such a bulkier group at the interface of the heterodimer should produce 
the more curved structure of the microtubule, thus further reducing polymerization.1 
Compounds 1c (-9.60 kcal/mol) and 2c (-9.88 kcal/mol) have better docking scores than 37c (-
9.08 kcal/mol), suggesting that these compounds should have similar or better activity than 37c 










Figure 43. A) Superimposition of the docked pose of 1c (pink) and crystallized ligand axitinib 
(green) and B) docked pose of 2c (cyan) in the axitinib binding site of VEGFR-2 (PDB ID: 
4AG8).291 
 The docked poses of 1c and 2c in the binding site of VEGFR-2 (Fig. 43) show that the 
quinazoline scaffold binds to the pocket where the thiobenzamide of axitinib binds and 
A B 
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interacts with residues Lys868 (cation-pi interaction), Val899 and Val914. The 4-position 
aniline substituents interact with Val848, Ala866, Leu1035 and Phe1047 (face-to-edge pi-pi 
stacking interaction) and bind in the pocket where the indazole scaffold of axitinib binds. The 
docking scores of 1c and 2c in VEGFR-2 were -10.86 and -12.00 kcal/mol, respectively, 
compared to axitinib which had a docking score of -12.44 kcal/mol. 
Figure 44. A) Superimposition of the crystallized ligand Erlotinib (orange) and 1c (pink) and 
B) docked pose of 2c (cyan) in the erlotinib binding site of EGFR (PDB: 1M17).292 
 Fig. 44A shows the superimposition of the docked pose of 1c with the crystallized 
ligand erlotinib in the EGFR binding site. The quinazoline scaffolds of both ligands overlap 
well with each other, N1 H-bonds with the Met769 backbone NH, N3 makes a water-mediated 
H-bond with Thr766 and a dipole-dipole interaction with the backbone CO of Met769. The 2-
Cl group of 1c makes a halogen bond with the backbone CO of Gln767 in addition to the NH 
with hinge region (pink colored dotted line shown in Fig. 44A). The N4-aryl groups of erlotinib 
and 1c occupy the hydrophobic pocket of EGFR near the DFG motif in the kinase binding site 
and the hydrophobic 4’-SMe group occupies the same region as the acetylene group of the 
erlotinib. In comparison, the 2-H compound 2c makes H-bond interactions with the hinge 
region like erlotinib, where 2-H makes dipole-dipole interaction with the backbone CO of the 
A B 
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Gln767. The 2-naphthyl group of 2c binds in the hydrophobic pocket and also interacts with 
the Asp831 of the DFG motif and the OMe group H-bonds with Thr830. Overall, the proposed 
compounds in Series I make unique interactions with the EGFR binding site while maintaining 
the interactions of erlotinib, the standard EGFR inhibitor. The docking scores of 1c and 2c 
were -8.21 and -9.09 kcal/mol, respectively compared to erlotinib, which had a docking score 
of -9.29 kcal/mol. Overall, based on our in-silico studies and good docking scores in the 
tubulin, EGFR and VEGFR-2 binding sites we predict that the compounds 1c and 2c  
(Series I) should have potent inhibitory activity at all three targets.         
Figure 45. Superimposition of the docked poses of 1c (left) and 2c (right) in the binding sites 
of EGFR, VEGFR-2, and tubulin. 
To determine the change in conformations these molecules undergo to bind to the three 
separate targets, the docked conformations of 1c and 2c in all three targets were superimposed 
(Fig. 45). The conformations of these molecules primarily differ in the N4-Me- and anilino 
orientations. The N4-aryl moieties of both 1c and 2c in the tubulin and VEGFR-2 binding sites 
orient toward the 5-position of the quinazoline scaffolds, whereas in the EGFR binding site the 
N4-Me group orients toward the 5-position. Therefore, rotation around the C4-N4 bond is 
necessary to adopt these opposite conformations to bind to multiple targets, which are restricted 
due to a steric clash between the 5-CH and the methyl or aryl groups depicted in Fig 45. 
 91 
Verubulin and its derivatives have been effective MTAs and VDAs but still suffer from narrow 
therapeutic indices causing cardiotoxicity, thus have not been successful in clinical trials so 
far.293 The benzene rings of the quinazoline scaffold of compounds 33c-42c, and 1c-2c were 
predicted, by Maestro, to be liable for metabolic oxidation by CYP450. 
Figure 46. Structure of proposed compounds in Series II. 
Introduction of a nitrogen atom is a high-impact design element for multiparameter 
optimization such as improvement of the therapeutic index and/or metabolic liability of small 
molecules.294 Therefore,  we propose compounds 3c-10c (Series II, Fig. 46) with a pyrido[3,2-
d]pyrimidine scaffold in place of the quinazoline.  
         
Figure 47. Rotational barrier around the C4-N4 bond (kcal/mol) for A) quinazoline analogs 
(37c-42c and 1c-2c), and B) pyrido[3,2-d]pyrimidine analogs (3c-10c), prediction with 
Maestro 11.9.289   
Introduction of the nitrogen atom in the scaffold can influence the conformation of 


















Energy Kcal/mol Energy Kcal/mol 
 92 
the C4-N4 bond to bind to multiple targets which is hindered due to the steric clash of either 
N4-aryl or N4-methyl moiety with the hydrogen of 5-CH, thus replacing the 5-CH group with 
a sp2 nitrogen atom is hypothesized to reduce the steric clash and thereby decrease the 
rotational barrier around C4-N4 bond. Using molecular modeling, the rotational barrier around 
the C4-N4 bond of both the quinazoline compounds and corresponding pyrido[3,2-
d]pyrimidine compounds were determined (Fig. 47). This was done by carrying out a 
coordinate (dihedral) scan around the bond and plotting the relative energies of the molecules 
versus the dihedral angle. The plot clearly shows that the quinazoline compounds (Fig. 47) 
have higher rotational barriers (-7.5 to -15 kcal/mol) compared to the pyrido[3,2-d]pyrimidines 
(Series II, -3 to -4 kcal/mol), indicating that compounds in Series II (Fig. 46) should afford 
greater conformational flexibility than the lead quinazoline compounds. This should allow 
these compounds to adopt different conformations necessary to bind the multiple targets 
(tubulin, EGFR, and VEGFR-2), more easily than the quinazoline analogs (37c-42c and 1c-2c) 
and thus increase potency.  
                                      
Figure 48. Cytochrome P450 metabolism prediction showing metabolically liable sites (green 
circles) on A) pyrido[3,2-d]pyrimidine analog (6c) and B) quinazoline analog (39c), Maestro 
11.9.289   
Maestro also predicted that replacement of 5-CH of the quinazoline with a N atom 
removes the metabolic liability of the benzene ring of the quinazoline (Fig. 48). Thus, such  
A B 
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small change can have several important effects on molecular and physicochemical properties 
and hence enhance clinical utility.  
 
Figure 49. A) Docked poses of 39c (cyan) and B) 6c (pink) in the colchicine binding site of 
tubulin (PDB ID: 4O2B), orange dashed line depicts steric clash within the ligand. 
Compounds in Series II were docked in the colchicine binding site of tubulin. Fig. 49 
shows the docked poses of the quinazoline analog 39c and the pyrido[3,2-d]pyrimidine analog 
6c in the binding site of tubulin. Both ligands show similar interactions with the tubulin binding 
site. However, the pyridine containing compound 6c (-10.21 kcal/mol) shows a better docking 
score than the lead 39c (-8.33 kcal/mol). This is, partially, attributed to the relief of intra-ligand 
strain caused by a steric clash (orange dashed line, Fig. 49A) between the naphthalene ring and 
the 5-CH hydrogen in the docked pose of 39c, which is absent in 6c. Similarly, due to a lock 
of the steric clash other compounds in the Series II (-8.66 to -10.46 kcal/mol) also showed 
better docking scores than the corresponding quinazoline analogs (-8.07 to -9.39 kcal/mol) 
because of the same reason. Compounds 3c-10c showed similar binding and good docking 
scores compared to the lead compounds in both EGFR and VEGFR-2. With potentially 
decreased metabolic liability and increased docking scores, conformational flexibility and 
A B 
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water solubility induced by the replacement of the aromatic CH with a nitrogen atom provide 
a strong rationale for the synthesis of compounds in Series II.        
A.2. Single agents with TS and multiple tyrosine kinase inhibitors: Pyrimido[4,5-
b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors   
  
Gangjee et al.123 reported tricyclic pyrimido[4,5-b]indoles 43c and 44c (Fig. 50) as 
dual inhibitors of thymidylate synthase and multiple RTKs (VEGFR-2 and PDGFRβ). In 
COLO-205 mice xenografts, compounds 43c and 44c significantly inhibited tumor growth, 
tumor vasculature and liver metastasis better than docetaxel and remarkably with no toxicity.  
Figure 50. Structure of lead and proposed compounds in Series III 
Table 6. Inhibition of TS, RTKs and angiogenesis by 43c and 44c.187 












43c 0.54 15.1 ± 2.5 22.6 ± 2.7 2.8 ± 0.3 28.2 ± 2.9 
44c 0.39 10.41 ± 1.9 56.3 ± 8.2 40.3 ± 6.7 20.3 ± 5.2 
Raltitrexed 0.38 ND ND ND ND 
Sunitinib ND 172.1 ± 19.4 18.9 ± 2.7 83.1 ± 10.1 1.3 ± 0.07 
Erlotinib ND 1.2 ± 0.2 124.7 ± 18.2 ND 29.1 ± 1.9 
ND- Not Determined 
Table 6 shows inhibitory data for 43c and 44c against human TS (hTS) and kinases 
EGFR, VEGFR-2, and PDGFR-β.289  
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Compounds 11c and 12c (Fig. 50) are analogs of 43c and 44c, respectively, with an 
oxygen atom at the 5-position in place of a sulfur atom. From molecular modeling of the lead 
compounds, it was observed that the 5-position phenyl ring of 43c and 44c is surrounded by 
hydrophobic amino acid residues in VEGFR-2, EGFR, PDGFR-β, and hTS binding sites (Fig. 
51). Thus, compounds with an oxygen atom linkers in place of the sulfur atom linker were 
designed. This modification results in changes in the dihedral angle and bond lengths of the 
linker region and could allow better interactions with hydrophobic residues in the binding site 
of the targeted kinases and hTS. 
 
 
Figure 51. Docked poses of A) 43c (cyan) and 44c (peach) in VEGFR-2 (PDB: 4AG8) and B) 
11c (green) and 12c (yellow) in VEGFR-2, C) 43c (cyan) in the hTS (PDB: 1JU6) and D) 11c 




Compounds 11c and 12c (Fig. 51B) show similar interactions at the VEGFR-2 binding 
site as the lead compounds 43c and 44c (Fig. 51A). The hinge region binding of the 4-NH2 
group of 11c and 12c with Glu917 (C = O); N3 with Cys919 (N-H); 2NH2 with Cys917 (C = 
O) are observed. The 5-phenoxy rings fit in the hydrophobic pocket with Val899, Leu889, 
Val899, and Ala866. Thus, the possible inhibition of VEGFR-2 by 11c and 12c is possible. In 
the hTS crystal structure the C- ring of compounds 43c and 44c (Fig. 51D) show hydrophobic 
interactions with Trp109, the 5-phenoxy rings make hydrophobic interactions with Ile108, 
Leu221, and Phe225 and stacking of 11c and 12c with dUMP (pink color) in the binding site 
is observed (Fig. 51D). Compounds 11c and 12c also showed similar interactions (not shown) 
with targeted kinases and hTS with docking scores comparable to the lead compounds 43c and 
44c (Compound 43c: hTS; -11.39 kcal/mol, VEGFR-2; -10.48 kcal/mol, EGFR; -5.47 kcal/mol 
and PDGFR-β; -8.47 kcal/mol, Compound 44c: hTS; -11.99 kcal/mol, VEGFR-2; -10.87 
kcal/mol, EGFR; -5.61 kcal/mol and PDGFR-β; -8.54 kcal/mol, Compound 11c: hTS; -11.48 
kcal/mol, VEGFR-2; -11.63 kcal/mol, EGFR; -6.63 kcal/mol and PDGFR-β; -8.78 kcal/mol, 
and Compound 12c: hTS; -12.07 kcal/mol, VEGFR-2; -10.38 kcal/mol, EGFR; -6.52 kcal/mol 
and PDGFR-β; -9.45 kcal/mol). Therefore, these compounds are predicted to be potential 
single agents with multiple RTKs and hTS inhibitory activities.  
B. Folate Receptors (FR) and/or Proton-Coupled Folate Transporter (PCFT) targeted 
one carbon (1C) metabolism (cytosolic and/or mitochondrial) inhibitors 
RFC and PCFT are facilitative folate transporters, whereas FRs (Folate receptors) 
mediate uptake of folates into cells by receptor-mediated endocytosis.295 FRα and FRβ, as well 
as PCFT,  are narrowly expressed in tissues132, 156 where they perform specialized functions 
such as in the proximal tubules of the kidney where FRα contributes to reabsorption of folate 
from the urine.156 Importantly, FRs in normal tissues are either inaccessible to circulating 
folates (e.g., FRα in renal tubules) or are nonfunctional (e.g., FRβ in the thymus). PCFT is 
 97 
expressed in the upper gastrointestinal tract where it functions as the major transporter for 
dietary folates at acidic pH.153, 296, 297 While PCFT is expressed in a number of other normal 
tissues (e.g., liver, kidney),132 it shows maximum activity at acidic pH (pH < 7, optimum at pH 
5−5.5),298 thus limiting PCFT mediated folate transport in most normal tissues at physiological 
pH (7 – 7.4). Several solid tumors (e.g., ovarian, non-small cell lung cancer) express PCFT, 
often together with FRα.175, 299, 300 In tumors FRα is accessible to the circulation. Thus, selective 
tumor targeting via PCFT of acidic solid tumors and/or FRs is an attractive approach for the 
development of antifolates.159, 301 PCFT is active at the acidic pH typically associated with the 
tumor microenvironment,132 which provides additional tumor selectivity. FRβ is expressed in 
hematologic malignancies such as acute myeloid leukemia156 and in white blood cells of 
myeloid lineage156 including tumor-associated macrophages (TAMs).302 Based on the pattern 
of expression and functions of FRs, RFC and PCFT in tumors and normal tissues, it is possible 
to design agents with tumor selective targeting. Folic acid-vindesine conjugate (vintafolide) 
was internalized by FRs, and its cleavage intracellularly releases the cytotoxic vinca 
alkaloid.303, 304 Another folic acid-tubulysin conjugate completed phase I clinical trials.305 In 
addition small molecule N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-
oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-L-γ-glutamyl-D-glutamic acid 
(ONX0801) has substrate selectivity for FRs over RFC and has TS as its intracellular target.306 
In comparison to the conjugates developed, it is of interest to design single agents with tumor 
transporter specificity and cytotoxic abilities within a single molecule, which should not 
require an intracellular cleavage mechanism to release the cytotoxic component. Premature 





B.1 Inhibitors of de novo purine biosynthetic enzymes (cytosolic 1C metabolism) 
B.1.1. Design of 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyridyl classical 
antifolates 
Gangjee and coworkers185 synthesized 5-substituted pyrrolo[2,3-d]pyrimidine agents  
(Fig. 52) as dual-acting inhibitors of glycinamide ribonucleotide formyl transferase 
(GARFTase) and 5-aminoimidazole-4-carboxamide ribonucleotide formyl transferase 
(AICARFTase) in de novo purine nucleotide biosynthesis (Table 7 and 8). These compounds 
were substrates for FRs, PCFT, and RFC. Thus, they did not provide tumor-specificity. Like 
PMX, these analogs (45c-47c) have significant uptake through RFC, which results in dose-
limiting toxicity (Table 7) and tumor resistance. 
Figure 52.  Structures of lead 5-substituted Pyrrolo[2,3-d]pyrimidine analogs 
Table 7. IC50 Values (nM) for 5-substituted Pyrrolo[2,3-d]pyrimidine classical antifolates in 
RFC-, PCFT-, and FR-expressing CHO cell lines.159, 185 
 hRFC hFRα hPCFT 
 PC43-10 R2 RT16 RT16(+FA) R2/hPCFT4 R2(VC) 
PMX 26.2 ± 5.5  138 ± 13   42 ± 9  >1000  8.3 ± 2.7  >1000  
45c 68.8 ± 21.2  >1000  72.0 ± 27.1  >1000  329 ± 61  >1000  
46c 56.6 ± 5.8  >1000  8.6 ± 2.1  >1000  840 ± 90  >1000  
47c 196.4 ± 55.0  >1000  33.5 ± 2.5  >1000  >1000  >1000  
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Table 8. Growth inhibition assays: IC50 Values (nM) for 5-Substituted Pyrrolo[2,3- 
d]pyrimidines in KB human tumor sublines (expressing RFC, FRα, and PCFT) and 




PMX 68 ± 12 TS 
45c 68.8 ± 21.2 AICARFTase/GARFTase 
46c 56.6 ± 5.8 AICARFTase/GARFTase 
47c 196.4 ± 55.0 GARFTase 
 
The 5-substituted pyrrolo[2,3-d]pyrimidines 45c and 46c, can circumvent the TS inhibition 
resistance, as these analogs were inhibitors of GARFTase and AICARFTase (Table 8). Dual 
inhibition in the purine synthesis pathway is beneficial as the tumor cell cannot survive with 
resistance to only one of the targets. Efforts have been focused on developing agents to achieve: 
(i) transporter specificity; (ii) dual inhibition of GARFTase and AICARFTase; and (iii) 
increased KB tumor cell inhibition. 
Figure 53. Structure of proposed compounds in Series IV 
  
The phenyl side-chain, in previously reported185 5-Substituted pyrrolo[2,3-
d]pyrimidine analogs (Fig. 52), is replaced by a pyridyl side-chain in designed compounds 
13c-16c (Series IV, Fig. 53) to induce conformational restriction by promoting an intra-
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molecular H-bond between the pyridine nitrogen and the amide NH. The conformational 
restriction has been successfully used in the drug discovery process to induce selectivity.294 
Thus, a high impact design element such as the pyridyl side-chain to induce conformational 
restriction is to be studied regarding its potential to induce FRα/PCFT selectivity over RFC by 
either increasing transport by FRα or PCFT or by decreasing the uptake by RFC. The length of 
the linker between the pyrrolo[2,3-d]pyrimidine scaffold and the pyridyl glutamate side-chain 
are varied in the compounds 13c-16c to vary the distance between the two and allow 
optimization of their activity at multiple targets.   
Figure 54. Molecular and physicochemical changes induced by pyridine ring (modified form 
ref. 295).294 
 
Along with the H-bond acceptor capability, changing the benzene ring to the pyridyl ring 
has multiple effects such as the introduction of a dipole moment, increased polar surface area, 
decreased lipophilicity, increased water solubility, uneven distribution of electron density, and 
stronger π-π stacking interactions. Thus, pyridine for benzene substitution can change 
molecular and physicochemical properties which can influence various intra- and 
intermolecular orbital, steric, electrostatic and hydrophobic interactions such as dipole-dipole, 
H-bonding, van der Waals and π-π stacking interactions which can change the pharmacological 
profile of these compounds.  
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To understand the binding of these compounds in transporters and intracellular targets, 
molecular modeling studies of PMX, 45c-47c and 13c-16c were carried out in the crystal 
structures of FRs, GARFTase and AICARFTase using Maestro 11.9. As a representative, 
docking studies of the four-carbon linker lead (46c) and corresponding target compound 15c 
are presented below.  
 
Fig. 55 depicts the binding mode of 46c and 15c in the active site of FRα. Compounds 
46c and 15c show similar binding interactions; the 2-NH2 group makes H-bond with the Asp81, 
the 7-NH makes H-bind with Thr82, the 3-NH makes H-bond with the Ser174, and the 4-oxo 
makes ion-dipole interaction with the Arg103. The pyrrolo[2,3-d]pyrimidine scaffold π-π 
stacks with Tyr85 and Trp171. The phenyl and pyridyl rings of compounds 46c and 15c can 
make π-π stacking interactions with Trp102, and the electron-deficient pyridyl ring can make 
a stronger π-π stacking interaction than the phenyl ring with the electron-rich Trp102. The 
pyridyl nitrogen in 15c (docking score: -15.49 kcal/mol) is oriented on the same side as the 
amide NH in the binding site due to the intramolecular H-bond, which resembles the minimum 
energy pose of compound 15c. This intramolecular H-bond can provide entropic benefit for 
the pyridyl analogs (13c-16c) in comparison to the lead compounds. The α-COOH group 
makes an ionic salt bridge with Lys136 and an ion-dipole interaction with Trp138, whereas the 
γ-COOH group makes ion-dipole interactions with Gln100 and Ser101. The compounds in the 
Series IV showed similar or better docking scores (-14.75 to -15.49 kcal/mol) than the lead 
compounds PMX and 45c-47c (-14.74 to -15.11 kcal/mol) suggesting these compounds would 
be transported by FRα. 
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Figure 55. A) Docked pose of 46c (cyan) and B) 15c (orange) in the FRα binding site (PDB 
ID: 5IZQ).  
Figure 56. A) Docked pose of 46c (cyan) and B) 15c (orange) in the FRβ binding site (PDB 
ID: 4KN2). 
Fig. 56 shows the docked poses of 46c (-16.03 kcal/mol) and 15c (-16.23 kcal/mol) in 
the binding site of FRβ. The 2-NH2 and N1 for both compounds make ion-dipole interactions 
with the Asp97 side-chain and the 4-oxo groups provide water-mediated H-bonds with Ser190, 
Arg122 and Arg119 and also H-bonds with His151. The pyridyl ring CH group of 15c makes 




docking scores of the compounds 13c-16c suggest that they would display transport through 
FRβ.  
 
Figure 57. A) Docked poses of 46c (cyan) and B) 15c (pink) in the GARFTase binding site 
(PDB ID: 4ZZ1), substrate GAR showed in orange. 
 
The molecular modeling studies of 46c and 15c in the GARFTase binding site are 
shown in Fig. 57. The pyrrolo[2,3-d]pyrimidine scaffold of these compounds make H-bond 
interactions with the backbone of Leu899, Asp949, and Ala947. The aromatic side-chains 
phenyl (46c) and pyridyl (15c) occupy the solvent-exposed binding pocket. Therefore, 
heteroaromatic side-chains such as the pyridyl ring can make polar interactions with the water 
molecules in contrast to the hydrophobic phenyl ring of 46c. This should afford better binding 
of the pyridyl analogs (13c-16c) to GARFTase than the corresponding phenyl analogs (45c-
47c). The α-COOH group makes salt bridges with Arg871 and Arg897, whereas the γ-COOH 
group makes a salt bridge with Lys844 and is solvated by water molecules (Fig. 57). The 






 Figure 58. A) Docked poses of 46c (grey) and B) 15c (cyan) in the AICARFTase binding site 
(PDB ID: 1P4R), substrate AICAR shown in orange. 
Compound 46c is a bona fide AICARFTase inhibitor; thus, to compare the binding pose of 
the compounds in Series IV, we performed molecular modeling studies were carried out in the 
AICARFTase binding site. Similar to 46c, 15c also showed H-bonding with Asp546, Asn547, 
and the backbone of Met312. The α-COOH and γ-COOH groups make dipole-dipole 
interactions with water molecules. Compounds 13c-16c showed similar or better docking 
scores (-12.38 to -12.83 kcal/mol) compared to compound 46c (-12.38 kcal/mol), suggesting 
these compounds would display more potent inhibition of AICARFTase (Fig. 58).     
The docking studies of 15c in the targets (Figures 55-58) displayed different 
conformational preferences of the side chain linker about the pyrrolo[2,3-d]pyrimidine 
scaffold. Superimposition of the docked poses of 15c was carried out in the crystal structures 
of FRs, GARFTase, and AICARFTase and enabled visualization of these conformations (Fig. 
59). In reference to the scaffold, the side chains extend at different angles to bind to a 
particularly active site. It emphasizes the importance of the necessity of a flexible linker, with 
A B 
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a specific length to obtain optimal activity at all four targets for possible transport (FRs) and 
inhibition (GARFTase and/or AICARFTase). 
 
Figure 59. Superposition of docked poses of 15c in crystal structures for FRα (grey), FRβ 
(pink), GARFTase (green) and AICARFTase (cyan). 
Figure 60. Structure of proposed compounds in Series V 
The Series IV (Fig. 53) was designed to investigate the influence of an intramolecular H-
bond between the pyridyl nitrogen and the amide NH, whereas Series V (17c-19c, Fig. 60) 
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with the other regioisomer of the pyridyl ring was designed to evaluate influence of the pyridyl 
ring in the absence of the intramolecular H-bond on the antitumor activity and FRs/PCFT 
selectivity over RFC. Along with a lack of the intramolecular H-bond, varying the pyridyl 
regioisomer in 17c-19c versus the compounds 13c-16c alters the direction of the dipole 
moment of the pyridyl ring in the molecules which could result in different conformations and 
thereby different interaction with the binding sites. Compounds 17c-19c showed good docked 
scores in the binding sites of  FRα (-14.68 to -15.17 kcal/mol), FRβ (-15.06 to -15.90 kcal/mol), 
GARFTase (-14.25 to -14.96 kcal/mol) and AICARFTase (-9.91 to -12.58 kcal/mol), 
suggesting these compounds would have potent antitumor activity.    
 
B.2 Dual inhibitors of cytosolic (de novo purine biosynthetic) and mitochondrial (serine 
hydroxymethyltransferase 2) 1C metabolism enzymes 
B.2.1. Design of 5-substituted, 2-amino-4-oxo pyrrolo[3,2-d]pyrimidine-pyridyl classical 
antifolates  
Metabolic reprogramming is one of the hallmarks of cancer.307 1C metabolism is 
dependent on an adequate supply of tetrahydrofolate (THF) metabolites to generate critical 
purine, thymidylate, and glycine metabolites for cell proliferation and tumor progression126, 141, 
308  and it is a major pathway associated with the malignant phenotype. It is compartmentalized 
into the cytosol (de novo synthesis of thymidylate and purine nucleotides) and mitochondria 
(serine catabolism). Cytosolic and mitochondrial 1C metabolic pathways are interconnected 
by the exchange of serine, glycine, and formate.  In cancer cells, serine is the major source of 
1C units, and in mitochondria, serine catabolic enzymes including SHMT2, 5,10-methylene-
THF dehydrogenase 2 (MTHFD2) and 10-formyl-THF synthetase (reverse) (MTHFD1L) 
generate glycine and 1C units (i.e., formate) to sustain 1C-dependent nucleotide and amino 
acid biosynthesis in the cytosol.  10-Formyl-THF is resynthesized from formate in the cytosol 
 107 
by the trifunctional enzyme MTHFD1.  10-Formyl-THF is utilized for purine nucleotide 
biosynthesis and can be further converted by MTHFD1 to 5,10-methylene-THF for TS and 
SHMT1. 
A study188 of messenger RNA profiles for over one thousand enzymes within nearly 
two thousand tumors across nineteen different cancer types identified SHMT2 and MTHFD2 
among the top most upregulated genes. Thus, highlighting the key role of mitochondrial 1C 
metabolism across a wide spectrum of cancers.  Metabolomic analyses of 219 extracellular 
metabolites from the NCI-60 cancer cell lines showed that glycine metabolism strongly 
correlated with cancer cell proliferation.309 Thus, mitochondrial 1C metabolism has been 
implicated as critical to the malignant phenotype.188, 309-311   These findings, combined with 
evidence of functional shortages of amino acids (e.g., glycine) in tumors,312 suggested a 
therapeutic opportunity for SHMT2 targeting in cancer.  
 
Khushbu and Gangjee313 have reported the synthesis of a series of novel 5-substituted 
pyrrolo[3,2-d]pyrimidine compounds (48c-53c, Fig. 61), which showed primarily transport via 
FRα and FRβ with limited or no transport via RFC and PCFT (Table 6).  
 




Table 9. IC50 Values (nM) for 5-Substituted Pyrrolo[3,2-d]pyrimidine Classical Antifolates in 
RFC-, PCFT-, and FR-Expressing Cell Lines. 
 hRFC hFRα hFRβ hPCFT 
 PC43-10 R2 RT16 D4 R2/hPCFT4 
48c 43 >1000 50 1.59 25.2 
49c 516 >1000 2.13 1.29 309 
50c >1000 >1000 26.6 6.3 327 
51c >1000 >1000 33 1.94 497 
52c >1000 >1000 2.82 1.13 >1000 
53c >1000 >1000 14.62 7.89 >1000 
 
Table 10. Growth inhibition assays: IC50 Values (nM) for 5-Substituted Pyrrolo[3,2- 
d]pyrimidines in KB human tumor sublines (expressing RFC, FRα, and PCFT) and protection 




48c 6.7 AICARFTase/SHMT2 
49c 6.8 GARFTase/AICARFTase/SHMT2 
50c 6.3 GARFTase/AICARFTase 
51c 24 ND 
52c 2.58 ND 
53c 7.47 GARFTase/AICARFTase/SHMT2 
 
Compounds 48c-53c showed potent inhibition of KB tumor cell lines with inhibition 
of 1C metabolism cytosolic de novo purine biosynthesis (GARFTase and/or AICARFTase) 
and/or mitochondrial SHMT2 (Table 10). Inhibition of SHMT2 by classical antifolates has not 
been previously reported, and importantly this was achieved via scaffold hopping, as the 
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classical antifolates with the pyrrolo[2,3-d]pyrimidine scaffold, reported so far, have not been 
potent mitochondrial 1C enzyme inhibitors. 
To determine the structural requirements for binding to the SHMT2 folate binding site, 
we docked 5-formyl THF (5-CHO-THF, resembles a natural substrate THF), 45c (pyrrolo[2,3-
d]pyrimidine analog) and 48c (pyrrolo[3,2-d]pyrimidine analog) in the recently published314 
SHMT2 crystal structure.  
Figure 62. Docked pose of 5-CHO-THF (white) in the SHMT2 folate binding site (PDB ID: 
5V7I). 
 As there is no reported crystal structure of SHMT2 with classical folates, we docked 
5-CHO-THF, which resembles the natural cofactor THF, to determine the binding 
requirements of SHMT2 binding site. Fig. 62 shows the docked pose of 5-CHO-THF in the 
SHMT2 binding site. The active site is located at the interface of chain A (green) and chain B 
(blue) and consists of a cavity at the bottom with a narrow channel opening into the solvent 











cavity with the para-amino benzoyl (PABA) ring binding in the narrow channel lined by 
Tyr176 and Tyr105, and the α-COOH makes a salt bridge with Lys181 whereas the γ-COOH 
makes ion-dipole interaction with the Ser178. The docked pose reveals an interesting 
conformation with the pteridine lying flat in the pocket with the PABA ring orthogonal to the 
pteridine scaffold. Based on the docked pose of 5-CHO-THF, it is hypothesized that for 
compounds to bind to SHMT2, they need to mimic this orthogonal conformation in the SHMT2 
folate binding site. 
Figure 63. Superposition of docked poses of 5-CHO-THF (white) and 45c (orange) in the 
SHMT2 folate binding site (PDB ID: 5V7I). 
 The docked pose of 5-substituted pyrrolo[2,3-d]pyrimidine analog 45c in the SHMT2 
cavity does not go as deep as the 5-CHO-THF (Fig. 63). Thus, the phenyl side-chain loses the 
π-π stacking interactions with Tyr105 and Tyr176. Therefore, the compound 45c shows a poor 





docking score in the SHMT2 binding site (-7.42 kcal/mol) compared to 5-CHO-THF (-10.04 
kcal/mol). 
Figure 64. Superposition of docked poses of 5-CHO-THF (white) and 48c (cyan) in the 
SHMT2 folate binding site (PDB ID: 5V7I). 
 Fig. 64 shows the superposition of 48c and 5-CHO-THF in the SHMT2 binding site, 
the pyrrolo[3,2-d]pyrimidine scaffold moves deeper in the pocket similar to 5-CHO-THF. This 
allows the phenyl side-chain to make the π-π stacking interactions with Tyr176 and the α- and 
γ-COOH groups to make salt bridges with Lys181 and Lys103, respectively. Compound 48c 
(-7.90 kcal/mol) showed a somewhat better docking score than the compound 45c (-7.42 
kcal/mol) and similar interactions to the 5-CHO-THF. 
Chain B  
(blue) 
Chain A  
(green) 
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 Figure 65. Superposition of docked poses of 5-CHO-THF (white), 45c (orange) and 48c 
(cyan) in the SHMT2 folate binding site (PDB ID: 5V7I). 
 Superimposing the docked poses of 5-CHO-THF (white), 45c (orange) and 48c (cyan) 
clearly show the difference among the docked poses of 5-CHO-THF, 48c, and 45c (Fig. 65). 
The compound 48c with the side-chain phenyl ring attached to the pyrrole nitrogen of the 
pyrrolo[3,2-d]pyrimidine scaffold can mimic the orthogonal conformation of 5-CHO-THF, 
whereas 45c with the side-chain phenyl ring at the 5-position of the pyrrolo[2,3-d]pyrimidine 
scaffold is unable to adopt the same conformation. This unique feature of the pyrrolo[3,2-
d]pyrimidine scaffold could be the reason that 48c can bind into the cavity of the SHMT2 
binding site. Therefore, the pyrrolo[3,2-d]pyrimidine scaffold offers a unique opportunity to 
develop dual 1C metabolism inhibitors with inhibition of cytosolic de novo purine biosynthesis 
enzymes and the mitochondrial SHMT2 enzyme. Such compounds with selective transport via 
FRs and/or PCFT over RFC can achieve targeted tumor therapy with multiple enzyme 
inhibition that would eliminate or decrease dose-limiting toxicity and would circumvent or 
delay the development of tumor resistance. 
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Figure 66. Series VI 
 Metabolite protection studies of 48c-53c (Table 10) implicate that not only the 
pyrrolo[3,2-d]pyrimidine  scaffold but also the length of the linker and aromatic side-chain 
dictate the binding to various cellular targets. On the basis of this, compounds 20c-22c are 
proposed in Series VI (Fig. 66) with 3- (20c), 4- (21c), and 5-carbon (22c) linker analogs of 
48c-50c with the pyridyl side-chain to evaluate the influence of the pyridyl ring, which can 
make intra- and intermolecular H-bonds in contrast to the phenyl ring along with other 
additional changes in molecule’s properties (Fig. 54), FRs/PCFT transport selectivity over 
RFC, multi-target engagement (GARFTase/AICAFTase/SHMT2) and on tumor cell inhibition.   
Figure 67. Docked pose of 21c (magenta) in SHMT2 folate binding site (PDB: 5V7I). 
Chain B  
(blue) Chain B  
(green) 
 114 
  The docked pose of compound 21c in the SHMT2 binding site is shown in Fig. 67. 
The pyrrolo[3,2-d]pyrimidine scaffold sits deep into the cavity similar to the 5-CHO-THF, the 
pyridyl ring makes π-π stacking interactions with Tyr105. The electron deficient pyridyl ring 
of 21c can make stronger π-π stacking interaction with Tyr105 than the phenyl side-chain in 
48c. The α- and γ-COOH groups make salt bridges with Lys181 and Lys103, respectively. 
Compound 21c (-10.27 kcal/mol) showed higher docked score than the lead compound 48c (-
7.90 kcal/mol), suggesting that it would be a more potent inhibitor of SHMT2 than the lead 
48c. Three carbon (20c, -8.82 kcal/mol) and five carbon (22c, -9.56 kcal/mol) linker analogs 
also showed good docked scores in the SHMT2 binding site. Compounds 20c-22c also showed 
good docked scores in the transporters; FRα (-15.67 to -15.79 kcal/mol) and FRβ (-14.06 to -
15.13 kcal/mol) and de novo purine biosynthesis enzymes; GARFTase (-13.98 to -15.01 
kcal/mol), and AICARFTase (-11.27 to -12.39 kcal/mol). Thus, compounds 20c-22c are 
proposed as potent inhibitors of both cytosolic and mitochondrial 1C metabolism enzymes.     
  
 
B.2.2. Design of 5-substituted, 2-amino-4-oxo pyrrolo[3,2-d]pyrimidine-3’-fluoropyridyl 
classical antifolates 
 Bioisosteric replacement of the hydrogen atom with the fluorine atom in bioactive 
molecules has been successfully used for modifying the biological properties of drugs. FDA-
approved fluorinated drugs increased in past decade (from 20% in 2010 to about 30% 
currently).315, 316 Fluorine is ~20% larger than hydrogen (van der Waals radii), the C−F bond is 
longer and larger compared to a C−H bond, has a larger dipole moment in the opposite direction 
of a C−H, is modestly more lipophilic and can form strong electrostatic interactions including 
fluorine-hydrogen bonds (Table 11).317-325 Fluorine is also a high impact design element, 
owing to its multitude of effects, can be used for multi-parameter optimization. 
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Table 11. Properties and application of the C-F bond compared to the C-H bond.324 
Properties C-H C-F Applications 
Bond Length (Å) 1.09 1.35 Hydrophobic interactions, lipophilicity, 
conformational effects Total size (Å3) 2.29 2.82 
Electronegativity of 
H/F 
2.2 3.98 Non-covalent interactions, 
steric/electronic effects, conformational 
effects Dipole moment (µ) -0.4 1.4 
 
 
Figure 68. Previously synthesized pyrrolo[2,3-d]/[3,2-d]pyrimidine classical antifolates. 
Ravindra et al.326 recently reported the influence of 2’-fluorine (ortho to L-glutamate 
group) substitution in the phenyl side-chain ring on the transporter selectivity (FRs/PCFT over 
RFC) and tumor cell inhibition of 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine 
antifolates (54c-57c, Fig. 68). Junayed and Gangjee327 also evaluated the influence of 
replacement of the hydrogen with a fluorine atom on the phenyl side-chain of 2-amino-4-oxo-
5-substituted pyrrolo[3,2-d]pyrimidine antifolates (58c-61c, Fig. 68) with dual cytosolic and 
mitochondrial 1C metabolism enzyme inhibition.  
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Table 12. IC50 Values (nM) for classical antifolates with the phenyl and fluorinated-phenyl 
side-chain in RFC-, PCFT-, and FR-expressing cell lines and KB tumor cell line. 
 hRFC hFRα hFRβ hPCFT KB 
(IC50s) nM  PC43-10 R2 RT16 D4 R2/hPCFT4 
54c 304 448 4.1 5.6 23 1.8 
56c 62 140 1.12 3.87 3.82 2.6 
55c >1000 >1000 6.3 6.3 213 1.6 
57c >1000 >1000 0.58 1.6 23 0.59 
58c 43 >1000 50 1.59 25.2 6.7 
60c >1000 >1000 22.89 0.52 155 9.07 
59c 516 >1000 2.13 1.29 309 6.8 
61c >1000 >1000 0.8 1.03 >1000 1.05 
Note: The fluoro analogs highlighted with blue color fonts. 
Interestingly, the fluorine atom had a variable influence on the biological activities of 
antifolates depending on the scaffold and linker length (Table 12). Fluorine increased 
inhibition of CHO cells with transport by FRα and FRβ compared to the des-fluoro analogs. 
The pyrrolo[2,3-d]pyrimidine analogs (56c and 57c) showed an increase in inhibition of PCFT-
expressing CHO cell lines compared to 54c and 55c, whereas the pyrrolo[3,2-d]pyrimidine 
analogs (60c and 61c) showed the reverse trend upon fluorine substitution. The fluoro analogs 
showed similar or better potency towards the KB tumor cell lines and completely lost RFC 
transport, except for compound 56c, compared to their corresponding des-fluoro analogs. 
These results indicated that the fluorine was conducive to selective transport via FR and PCFT 
over RFC.   
We designed compounds 23c and 24c (Fig. 69) to evaluate the effects of the fluorine 
atom on transporter selectivity and tumor cell inhibition of the compounds 21c and 22c. The 
pyridyl side-chain in 21c and 22c can intramolecularly H-bond with the amide NH, resulting 
in conformational restriction, whereas in compounds 23c and 24c the conformational 
 117 
restriction can occur either due to the pyridyl nitrogen or the fluorine atom making 
intramolecular H-bonds with the amide NH or an unfavorable electronic repulsion with the 
lone pairs of the carbonyl oxygen. Also, the fluorine atom can make H-bond or other dipole-
dipole interactions in the binding pockets of the various targets. 
 
Figure 69. Series VII. 
 Figure 70. A) Superimposition of the conformations of 23c produced by a coordinate scan 
and B) Plot of the relative energy of the conformations (kcal/mol) versus the N1-C2-C3-O4 







 A coordinate scan around the N1-C2-C3-O4 dihedral angle (Fig. 70A) was performed 
to determine the rotational barrier and water as a solvent to perform the calculations to mimic 
physiological conditions using Maestro. Fig. 70A shows the superimposition of all the 
conformations of 23c, with the minimum energy conformation shown in cyan (dihedral angle: 
50 °) and the second lowest energy conformation in pink (dihedral angle: -50.1 °) both adopt 
gauche conformation around the N1-C2-C3-O4 which suggests that electronic repulsion effect 
dominates over intra-molecular H-bond interaction, which requires a dihedral angle of 0 ° or 
180 °. The plot indicates the energy barrier of ~4 kcal/mol between the two minima, 
represented by a dihedral angle of 180 °, the conformation in which fluorine and carbonyl 
oxygen are in the same plane and on the same side affords the most unfavorable electronic 
repulsion. The energy barrier predicted by the calculations in Fig. 70A further corroborates our 
hypothesis that introduction of fluorine can have several effects, one of which is a 
conformational restriction. Thus, compounds with a 3’-fluoropyridyl side-chain (23c and 24c) 
are predicted to adopt different conformations than the compounds with just the pyridyl side-
chain (20c-22c) or phenyl side-chains (60c and 61c).   
 The docked poses of compounds 23c and 24c in the SHMT2 binding site are shown in 
Figure 71. The pyrrolo[3,2-d]pyrimidine scaffold sits deep into the cavity similar to 5-CHO-
THF, the 3’-fluoropyridyl ring occupies the narrow channel lined by Tyr105 and Tyr176, the 
amide group makes H-bonds with Tyr105 and Tyr176. The relative conformations of the 
pyridyl ring and the amide group in the docked conformations of 23c and 24c in the SHMT2 
binding site are gauche (N1-C2-C3-O4 dihedral angle: -71° and 90°) which are closer to the 
minimum energy conformations of these molecules. Thus, it can provide entropic benefit to 
these compounds when bound in the SHMT2 folate binding site. The compounds 23c and 24c 
also showed good docked scores in the folate transporters; FRα (-15.55 and -15.12 kcal/mol, 
respectively) and FRβ (-15.89 and -15.80 kcal/mol, respectively) and de novo purine 
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biosynthesis enzymes; GARFTase (-14.08 and -13.79 kcal/mol, respectively), and 
AICARFTase (-10.89 to -11.99 kcal/mol). Thus, 23c and 24c are proposed to be potent 
inhibitors of both cytosolic and mitochondrial 1C metabolism enzymes. 
Figure 71. Docked poses of 23c (cyan) and 24c (orange) in SHMT2 folate binding site (PDB: 
5V7I). 
 
B.3 Design of 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]/[3,2-d]pyrimidine-
pyridyl classical antifolates 
 
Although the methyl group, often considered as chemically inert, only participates in 
London dispersion interactions, it plays a very important role in the molecular recognition of 
endogenous and exogenous ligands by bioreceptors.328 The stereoelectronic effects of a methyl 
leads to selective binding and increased potency, among various other pharmacological 
effects.329-331 As such, it is a useful tool employed in medicinal chemistry design to modify 
 120 
aspects related to conformation, electronic factors, pharmacokinetics, among other factors.330, 
331  
Studies of 5- and 6-substituted pyrrolo[2,3-d]pyrimidines established that while the 6-
substituted analogs are selective (>100 fold for FR and/or PCFT expressing CHO cells over 
those that express RFC) and potent GARFTase inhibitors, the related 5-substituted pyrrolo[2,3-
d]pyrimidines are non-selective (<10 fold for FR and/or PCFT expressing CHO cells over those 
that express RFC) dual GARFTase and AICARFTase inhibitors.175, 181, 185, 332, 333 A superior 
inhibitor to the above two series of analogs would be a compound that is FR- and PCFT-
selective (over RFC) and dual GARFTase and AICARFTase inhibitor. Thus, it was of interest 
to synthesize and evaluate 6-methylated, 2-amino-4-oxo-pyrrolo[2,3-d]pyrimidines 64c, 65c, 
and 66c as the hybrids of 5- and 6-substituted analogs, to evaluate for improved selectivity and 
dual enzyme inhibitory activity (Fig. 72). 
 
  
Figure 72. Lead compounds 62c, 63c, PMX, 45c, 46c, 64c, 65c and 66c.   
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Table 13. IC50 Values (nM) and FR-and PCFT-expressing CHO cell selectivity ratios over 
RFC-expressing CHO cells. For KB cells, data are shown for the protective effects of 





















PMX 0.62 0.44 3.15 Thd/Ade 9.94±3.11 
45c 0.95 - 0.2 Ade 49.5±13.2 
65c >15 >385 >17 Ade/AICA/Thd 49.9 
Gangjee et al334 performed a study of a 5-substituted, 2-amino-4-oxo-6-methyl 
pyrrolo[2,3-d]pyrimidine 57 with a 3C-linker length and found that the hypothesis for 
selectivity due to a 6-methyl substitution was supported by the biological activity. Compound 
65c is a multi-enzyme inhibitor of purine and pyrimidine biosynthesis (Table 13); in vitro 
growth inhibition of KB tumor cells was completely protected only in the presence of both Ade 
(adenine) and Thd (thymidine) (Table 13). The potency of compound 65c towards KB cells 
(49.9 nM) was identical to its parent desmethyl analog 45c (Table 13). Unlike 45c (equally 
potent for RFC- and FRα-expressing CHO cells, and ~5- fold selective for RFC- over PCFT-
expressing CHO cells), 65c is selective for FRα, FRβ and PCFT over RFC- expressing CHO 
cells (>15-, >385- and >17-fold, respectively) primarily due to loss of uptake by RFC (Table 
13). This study led to the discovery of a compound that was ~5-fold less potent against KB cell 
proliferation and ~5-(PCFT) to 900-(FRβ) fold more selective than PMX. The pharmacological 
influences of a methyl substitution for the observed loss of RFC binding is perhaps due to steric 
repulsion. The crystal structure of hRFC is not known, and hence, the arrangement of the amino 
acids that line the folate binding pocket and the binding interactions remain unidentified. 
However, based on the general trend of reduced RFC binding by the 6-substituted pyrrolo[2,3-
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d]pyrimidine series of analogs, a possible steric repulsion in the scaffold binding subsite caused 
by the alkyl group at 6-position is proposed.  
To investigate the contribution of 6-methyl substitution in the pyridyl series of 5- 
substituted pyrrolo[2,3-d] and [3,2-d]pyrimidine analogs for improved potency as well as 
selectivity, compounds 25c and 26c with 3C- (6-methyl analog of 14c) and 4C-linkers (6-
methyl analog of 21c), respectively were designed (Fig. 73). 
 
Figure 73. Target compounds 25c and 26c, Series VIII. 
Molecular modeling studies of the 6-methylated analogs 25c-26c were carried out 
using X-ray crystal structures of human FRα (5IZQ), and GARFTase (4ZZ1) to explore the 
binding interactions and to validate their drug targets. The compounds display similar 
interactions as the native crystal structure ligands (not shown here for clarity)  
The docked poses of the 25c (-15.23 kcal/mol) and 26c (-16.18 kcal/mol) in FRα (Fig. 
74) display similar interactions as the native crystal structure ligands (not shown here for 
clarity) by maintaining key interactions involving the bicyclic scaffolds and the pyridyl L-
glutamate tail. The 6-methyl substitution neither sterically clashes with the binding site of FRα, 
nor does it alter the conformation of the scaffold when compared to the desmethyl analogs. 
Additionally, the 6-methyl group orients towards hydrophobic amino acid residues such as Leu 





          
 
Figure 74. A) Docked pose of 25c (orange) and B) 26c (cyan) in the FRα binding site (PDB 
ID: 5IZQ). 
 
Unlike the extended pocket of the FRs, the binding pocket in GARFTase is curved and 
forces a conformation such that the linker projects the sidechain aryl ring almost at a 90° angle. 
As such, the binding pocket accommodates and maintains key interactions with classical folate 
analogs that have linkers ranging from 2-atoms to 5-atoms. The 6-methyl analog 25c can 
accommodate the bent conformation similar to other classical antifolates with the 6-Me 
oriented toward hydrophobic residue Leu 892 whereas, the 6-Me in 26c forces the scaffold to 
bind in a flipped orientation (Fig. 75). Although 25c (-14.53 kcal/mol) shows a better docking 
score than 26c (-13.70 kcal/mol), the docking scores are within the range to predict good 
GARFTase inhibition. 





Figure 75. A) Docked pose of 25c (orange) and B) 26c (cyan) in the GARFTase binding site 
(PDB ID: 4ZZ1). 
  
C. Selective inhibition of pjDHFR 
One of the most efficient strategies to treat PCP infection is to target Pneumocystis 
jirovecii DHFR (pjDHFR).220 DHFR catalyzes the reduction of 7,8-dihydrofolate to the 
5,6,7,8-tetrahydrofolate. Inhibition of DHFR interferes with thymidylate biosynthesis and 




causing inhibition of purine synthesis as well.203 This inhibition disrupts DNA, RNA, and 
protein synthesis of the organism and eventually leads to the death of the organism. 
 
Figure 76. Superimposition of active sites of pcDHFR (pink color) and pjDHFR (green color), 
co-crystallized with the ligand N6-methyl-N6-(naphthalen-2-yl)pyrido[2,3-d]pyrimidine-2,4,6-
triamine (cyan) represent the active site of pcDHFR (PDB: 4QJZ, 1.61 Å). 
Pneumocystis infection is host-species specific. Most of the drugs synthesized and 
evaluated thus far for PCP infections were tested against Pneumocystis carinii DHFR 
(pcDHFR), which was presumed to be the causative species of PCP infection in humans.203, 335 
P. carinii, however, is a distinct species that infects rats, different from P. jirovecii, responsible 
for human infections. The amino acid sequence of the DHFR of P. carinii (pcDHFR) differs 
by 38% when compared to the DHFR of P. jirovecii (pjDHFR).221 Isolation of pjDHFR along 
with the development of a homology model for pjDHFR provided the amino-acid sequence 
differences between pjDHFR and pcDHFR, as well as hDHFR. The superimposition of the 
active site of pcDHFR and pjDHFR (Fig. 76) displays the amino acid differences present in 
the active sites of the two enzymes and underscores the futility of designing and evaluating 
activity against the surrogate pcDHFR as inhibitors of pjDHFR. Hence, drugs evaluated against 
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the surrogate pcDHFR in vitro may not translate into activity in the treatment of PCP infection 
in humans. 
Table 14. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity Ratios. 
 pjDHFR (nM) hDHFR (nM)  Selectivity Ratios 
[hDHFR/pjDHFR] 
TMP (27c) 92 245000 266 
PTX 41 2 0.05 
The recently isolated pjDHFR221 has been used to evaluate clinically used agents such 
as TMP (trimethoprim), PTX (piritrexim), and novel DHFR inhibitors.222 These studies 
demonstrated that the inhibition of human(h)DHFR compared with pjDHFR allows a 
selectivity ratio (IC50 hDHFR/ IC50 pjDHFR) that provides a measure of the selectivity of the 
agent for pjDHFR over hDHFR. Compounds, such as PTX and TMQ (trimetrexate) due to low 
selectivity for pjDHFR over hDHFR and are much too toxic, and this explains the reason for 
their discontinuation for the treatment of opportunistic infections. The selectivity of TMP for 
pjDHFR over hDHFR is 266-fold and is an aspect that contributes to its clinical success in PCP 
treatment (Table 14). However, besides the selectivity for pjDHFR, another aspect that is 
highly desirable is for selective agents potency for pjDHFR. TMP is a poor inhibitor of 
pjDHFR and lacks single agent in vivo efficacy against parasitic infections and must be used 
with SMX. The long-term goal is to provide analogs with excellent potency along with high 
selectivity for pjDHFR. Such agents could be used alone as well as with sulfonamides and 
other drugs for PCP infections in humans. 
Rational design of pjDHFR inhibitors is hampered due to a lack of X-ray crystal 
structure of pjDHFR. However, homology models can be used with refinement to model 
pjDHFR in the absence of crystal structures.222 Thus, along with known hDHFR X-ray crystal 
structures,223 pjDHFR homology models can be used to design potent and selective pjDHFR 
inhibitors. Another significant impediment in the drug discovery of inhibitors of pjDHFR is 
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the inability to grow the organism outside the human lung, and hence it is difficult to develop 
a tissue culture for in vitro studies or an animal model for in vivo evaluation of the synthesized 
compounds. Due to this drawback, isolation and use of the pjDHFR enzyme is currently the 
only direct indicator that a compound could be tested for the treatment of PCP infection in 
humans. 
 
Figure 77. Superimposition of active sites of hDHFR (pink color) and pjDHFR (green color), 
co-crystallized with the ligand N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine-
2,4,6-triamine (magenta) (cyan) represents the active site of hDHFR (PDB: 4QJC, 1.62 Å). 
To study the differences in the active site of pjDHFR and hDHFR, the pjDHFR 
homology model sequence was superimposed on the hDHFR X-ray crystal published with 
pyrido[2,3-d]pyrimidines (Fig. 77).222, 223 The amino acid differences are displayed. The active 
site of hDHFR is composed of Phe31, Ile60, Asn64, and Val115. The corresponding residues 
in the active site of pjDHFR are composed of Met33, Leu65, Ser69, and Ile123. These amino 
acids possess varied shapes, sizes, and electrostatic properties, which display different bindings 
to a potential ligand and can be exploited for selectivity and potency over hDHFR. 
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Figure 78. Lead compound trimethoprim (TMP) and target compounds 28c-32c, Series IX. 
 
Figure 79. Docked pose 29c (orange) in (A) homology model of pjDHFR (-10.27 kcal/mol) 
and (B) crystal structure of hDHFR (-8.56 kcal/mol) (PDB: 4QJC, 1.62 Å) 
The pocket where the side chain aryl group binds is partially composed of Met33, 
Pro66, Leu65, Ser64, and Ile123 in pjDHFR and Phe31, Pro61, Ile60, Ser59, and Val115 in 
hDHFR. Thus, the two active sites have different properties of electrostatics, shape, and size. 
To achieve potency and selectivity by targeting these differing residues, the side-chain aryl 
substituents with electron withdrawing, and electron donating groups in place of the 3ˊ,4’,5’-
trimethoxyphenyl group in TMP were chosen for Series IX (compounds 28c-32c, Fig. 79). 
Gangjee and coworkers194, 222 have previously showed that changes in the side-chain aryl 





Figure 80. Docked pose of 32c (cyan) in (A) homology model of pjDHFR (-10.34 kcal/mol) 
and (B) crystal structure of hDHFR (-8.91 kcal/mol) (PDB: 4QJC, 1.62 Å) 
All the proposed compounds displayed favorable docking scores for pjDHFR (-10.09 
to -10.37 kcal/mol) over hDHFR (-8.39 to -8.91 kcal/mol), similar or better than the lead 















IV. CHEMICAL DISCUSSION 
The present work deals with the development of synthesis in the following three major areas: 
 
D. Synthesis of single agents with combination chemotherapy potential 
A.1. Synthesis of multiple receptor tyrosine kinases inhibitors and microtubule targeting 
agents: 
Quinazoline and Pyrido[3,2-d]pyrimidine analogs as multiple receptor tyrosine kinase 
inhibitors and microtubule targeting agents 
A.2. Synthesis of single agents with TS and multiple tyrosine kinase inhibitors:  
Pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors   
B. Synthesis of folate Receptors (FR) and/or proton-coupled folate transporter (PCFT) 
targeted (cytosolic and/or mitochondrial) one-carbon (1C) metabolism inhibitors  
B.1. Synthesis of inhibitors of de novo purine biosynthetic enzymes (cytosolic 1C metabolism) 
1. 5-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyridyl classical antifolates 
B.2. Synthesis of dual inhibitors of cytosolic (de novo purine biosynthetic) and mitochondrial 
(serine hydroxymethyltransferase 2) 1C metabolism enzymes 
1. 5-Substituted, 2-amino-4-oxo pyrrolo[3,2-d]pyrimidine-pyridyl classical antifolates 
2. 5-Substituted, 2-amino-4-oxo pyrrolo[3,2-d]pyrimidine-3’-fluoropyridyl classical 
antifolates 
B.3. Synthesis of 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]/[3,2-d]pyrimidine-
pyridyl classical antifolates 
C. Synthesis of selective inhibition of P. jirovecii dihydrofolate reductase 
2. 5-substituted, 2,4-diamino pyrimidines (trimethoprim analogs) as selective pjDHFR 
inhibitors 
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A. Synthesis of single agents with combination chemotherapy potential 
A.1. Synthesis of multiple tyrosine kinases inhibitors and microtubule targeting agents: 
Quinazoline and Pyrido[3,2-d]pyrimidine analogs as multiple tyrosine kinase inhibitors and 
microtubule targeting agents 
Scheme 41: Synthesis of target compound 1c (Series I) 
 
4-(methylthio)aniline (1d) (Scheme 41) was reacted with paraformaldehyde and 
sodium methoxide in methanol at rt for 5 h, then sodium borohydride was added, and the 
solution was heated to reflux for 2 h to provide N-methyl-4-(methylthio)aniline (2d) in 89% 
yield.336 Displacement of the 4-chloro of 2,4-dichloroquinazoline (3d) with 2d in acetonitrile 
provided final compound 2-chloro-N-methyl-N-(4-(methylthio)phenyl)quinazolin-4-amine 
(1c) in 22% yield.   
Monomethylated aniline, 5-methoxy-N-methylnaphthalen-2-amine (7d, Scheme 42), 
was synthesized over three steps from 6-aminonaphthalen-1-ol (4d).337   Boc protection of 4d 
in THF at rt yielded tert-butyl (5-hydroxynaphthalen-2-yl)carbamate (5d) in 86% yield over 4 
hours. Compound 5d was methylated using 2.1 eq of methyl iodide to give tert-butyl (5-
methoxynaphthalen-2-yl)(methyl)carbamate (6d) in 90% yield. Finally, Boc deprotection 
using trifluoroacetic acid (TFA) provided 5-methoxy-N-methylnaphthalen-2-amine (7d) in 
93% yield. Commercially available quinazolin-4(3H)-one (8d) (Scheme 42) was reacted with 
stoichiometric amounts of phosphorous oxychloride (POCl3) and triethylamine in toluene to 
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produce 4-chloroquinazoline (9d) in 67% yield.338 To reduce side-products care was taken 
during work-up that ice-cold solutions of ethyl acetate, water, sat. NaHCO3, 1N HCl and brine 
were used. SNAR displacement of the 4-chloro of 9d with aniline 7d in acetonitrile using a 
drop of conc. HCl as catalyst provided the final compound N-(5-methoxynaphthalen-2-yl)-N-
methylquinazolin-4-amine (2c) in 85% yield as a yellow solid.   
Scheme 42: Synthesis of target compound 2c (Series I) 
  
 3-Aminopicolinic acid (10d) (Scheme 43) was cyclized with urea at 160 °C overnight 
to afford pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione (11d) in 60% yield.339 Dichlorination of 
11d using stoichiometric amounts of POCl3 (2.2 eq) gave 2,4-dichloropyrido[3,2-d]pyrimidine 
(12d) in 68% yield.338 Displacement of the 4-chloro of 12d with the corresponding anilines in 
acetonitrile using catalytic amount of conc. HCl gave final compounds 3c – 6c as yellow solids 
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in 44-69% yields (Compound 3c = 55%, compound 4c = 44%, compound 5c = 48% and 
compound 6c = 69%).    
Scheme 43: Synthesis of target compounds 3c - 6c. 
 
The carbon (13C) NMR spectra of the final compounds (3c-6c) were used to confirm 
the regioselectivity of the SNAr reaction at 4-position vs 2-position of 12d. To establish the 
structures of the final compounds, compound 6c (synthesis and X-ray crystal structure of it was 
recently published340) was used as a template by comparing the 13C spectrum of 6c reported in 
literature with our experimental spectrum. Literature340 13C NMR (DMSO-d6) δ 161.36, 
156.39, 155.56, 148.63, 147.74, 134.99, 133.57, 132.68, 132.61, 128.45, 124.98, 112.48, 
111.65, 55.15, 48.48, 25.97, 23.58. Experimental 13C NMR (500 MHz, DMSO-d6) δ 161.86, 
156.90, 156.07, 149.13, 148.24, 135.49, 134.07, 133.18, 133.12, 128.95, 125.48, 112.98, 




Scheme 44: Synthesis of target compounds 7c – 10c 
 
3-Aminopicolinic acid (10d) (Scheme 44) was cyclized with formamide (13d) at 170 
°C in the microwave reactor for 1 h to afford pyrido[3,2-d]pyrimidin-4(3H)-one (14d) in 56% 
yield.341 Chlorination of 14d using stoichiometric amount of POCl3 gave 4-chloropyrido[3,2-
d]pyrimidine (15d) in 70% yield.338 Displacement of 4-chloro of 15d with the corresponding 
anilines in acetonitrile using catalytic amounts of conc. HCl gave the final compounds 7c – 10c 






A.2. Synthesis of single agents with TS and multiple tyrosine kinase inhibitors:  
Pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors   
Scheme 45: Retrosynthetic scheme of lead compounds. 
 
 The lead compounds were synthesized previously123 using the retrosynthetic scheme 
presented above (Scheme 45). Nucleophilic aromatic substitution of ethyl cyanoacetate with 
commercially available 1,2-dichloro-3-nitrobenzene (H), and reductive cyclization to afford 
ethyl 2-amino-4-chloro-1H-indole-3-carboxylate (F). Cyclization of F with chlorformamidine 
to give tricyclic 2-amino-5-chloro-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-one (E). The 2-
amino group was protected with the pivaloyl group to afford N-(5-chloro-4-oxo-4,9-dihydro-
3H-pyrimido[4,5-b]indol-2-yl)pivalamide (D). Chlorination and amination provided 5-chloro-
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9H-pyrimido[4,5-b]indole-2,4-diamine (B) and final SNAR displacement of the 5-chloro of B 
at 250 °C with respective aryl thiols provided the lead compounds (A1-A2).  
Scheme 46: Synthesis of target compounds (11c and 12c) 
 
 The synthesis of target compounds (11c and 12c) (Scheme 46) was envisioned via a 
nucleophilic aromatic substitution reaction in the first step of the lead compounds (Scheme 45) 
but with different starting materials, malononitrile and 1-bromo-2-fluoro-3-nitrobenzene 
(16d), instead of 1,2-dichloro-3-nitrobenzene (H) and ethyl cyanoacetate. This change was 
proposed to increase the reactivity of the 2-position at the aromatic ring with fluorine instead 
of chlorine. Switching to malononitrile from ethyl cyanoacetate removed the need for multiple 
steps to convert the 4-oxo to 4-amino group, reducing the number of steps. The reaction of 16d 
with malononitrile gave 2-(2-bromo-6-nitrophenyl)malononitrile (17d) in 78% yield. 
Reductive cyclization of 17d with zinc in acetic acid at 55 °C afforded 2-amino-4-bromo-1H-
indole-3-carbonitrile (18d) in 60% yield and cyclization with chlorformamidine HCl in methyl 
sulfone at 120 °C overnight yielded 5-bromo-9H-pyrimido[4,5-b]indole-2,4-diamine (19d) in 
45% yield. Another crucial change in the synthesis of the target compounds was the C-O bond 
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formation at the 5-position of 19d. Direct nucleophilic displacement was initially attempted 
but it resulted in mainly the dehalogenated product and degradation side-products. This was 
due to the poor nucleophilic nature of the phenoxide compared to the aryl thiols. Ullmann-type 
copper-catalyzed couplings have been successfully used for C-O bond formation.342 Ullmann 
coupling of 19d with corresponding sodium phenoxides with copper iodide and potassium 
carbonate were tried at different temperatures (130-180 °C) but only trace amounts of the 
products  were observed with the dehalogenated product as the major product on TLC.  
Table 15: Optimization of Ullmann Coupling conditions. 
# Ligand Base Reaction Progress  
(% conversion) 
1 
  L1  
K2CO3 Yes (50%) 
2 
  L2        
K2CO3 No 
3 
  L3        
K2CO3 No 
4 
  L4       
K2CO3 No 
5 
   L5      
K2CO3 Yes (20%) 
6 
   L6    
K2CO3 No 
7 
   L1  
Cs2CO3 Yes (50%) 
8 
   L4       
Cs2CO3 Yes (10%) 
9 
   L5      
Cs2CO3 Yes (90%) 
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Addition of ligands have been reported to improve yield and decrease dehalogenated 
products in these types of coupling reactions.342 Several roles have been assigned to ligands 
such as increasing solubility of copper reagents, and facilitating various stages of the coupling 
i.e. oxidative-addition or reductive-elimination. The most successful ligands are of two types: 
neutral (neocuproine L1, N,N-dimethylethane-1,2-diamine L4, and 2-aminopyridine L5) or 
anionic (dimethylglycine L2, quinolin-8-ol L3 and 2-isobutyrylcyclohexan-1-one L6) (Table 
15). Thus these ligands were implemented in the Ullmann coupling to synthesize the final 
compound 11c. First, these ligands were used with potassium carbonate (base) under 
previously reported conditions (180 °C, Scheme 46). The reaction progress was observed with 
only two ligands L1 (50% conversion) and L5 (20% conversion). The rest of the ligands 
showed no trace of product after 1 h of reaction. Neutral ligands have been especially 
successful in formation of C-O bond with Ullmann coupling.343 Copper catalysts ligated with 
neutral ligands need to coordinate with nucleophiles to facilitate oxidative addition to the aryl-
halide bond (rate-determining step) and coordination of copper metal with the oxygen 
nucleophile is highly favored. As the nucleophile is already coordinated to the catalyst while 
it undergoes oxidative-addition into the aryl-halide bond this further accelerates reductive-
elimination. The presence of neutral ligands also reduces the formation of dehalogenated side-
product. For further optimization potassium carbonate was substituted with cesium carbonate 
as cesium ions can improve solubility of various copper species (Cu(I) and Cu(III)) involved 
in the catalytic cycle. Indeed, cesium carbonate showed significant improvement in the reaction 






Scheme 47: Optimized Ullmann coupling for synthesis of 11c and 12c 
 
   The optimized coupling condition with ligand 24d (Scheme 47) and cesium carbonate 
as base was used to synthesize the final compounds 11c and 12c in 70% and 68% yield, 
respectively.  
B. Synthesis of folate Receptors (FR) and/or proton-coupled folate transporter (PCFT) 
targeted (cytosolic and/or mitochondrial) one-carbon (1C) metabolism inhibitors  
B.1. Synthesis of inhibitors of de novo purine biosynthetic enzymes (cytosolic 1C metabolism) 
1. 5-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyridyl classical antifolates 
Scheme 48: Synthesis of intermediate aldehyde 22d.  
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 Esterification of 5-bromopicolinic acid (20d) (Scheme 48) using the reported 
procedure344 produced ethyl 5-bromopicolinate (21d) as a white solid in 80% yield. To 
synthesize the key intermediate ethyl 5-(5-oxopentyl)picolinate (22d) for the synthesis of the 
final compound 14c, initially a Heck coupling345 (condition A, Scheme 48) between 21d and 
pent-4-en-1-ol was attempted which produced too many impurities and afforded 22d in only 
10% yield as a clear oil. Alternatively, Sonogashira coupling346 of 21d and pent-4-yn-1-ol 
using palladium chloride, triphenyl phosphine, triethyl amine and copper iodide at 100 °C in a 
microwave reactor yielded ethyl 5-(5-hydroxypent-1-yn-1-yl)picolinate (23d) in 70% yield. 
Palladium-catalyzed reduction of the alkyne and oxidation of the alcohol using Dess-Martin 
periodinane yielded intermediate aldehyde 22d as a clear oil,347 in better yield (~42%) over 
three steps from 21d to 22d compared to the Heck coupling (~10%). Therefore, to synthesize 
the intermediate aldehydes this three step route (condition B) was utilized.            
Scheme 49: Synthesis of compound 14c.  
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 First, α-bromination of the aldehyde 22d (Scheme 49) with bromine (Br2) in 1,4-
dioxane at room temperature was attempted. This afforded a more non-polar spot on TLC thus 
it was advanced further without purification or characterization. The crude product was reacted 
with 2,6-diaminopyrimidin-4(3H)-one (26d) and sodium acetate at 45 °C for 4 h. No cyclized 
product, ethyl 5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)picolinate (27d), was formed. Alternatively, reaction of 22d with 5,5-dibromo-2,2-
dimethyl-1,3-dioxane-4,6-dione (24d) in 1N HCl in diethyl ether (condition B)348 resulted in 
a more polar spot (not observed with Br2/dioxane, condition A) on TLC and was taken 
advanced to the next step without purification. The reaction of the crude product from 
condition B with 26d resulted in a pink spot on TLC,345 which upon chromatography 
purification was confirmed as the cyclized product 27d. Hydrolysis of the pteroic ester resulted 
in acid 28d. Glutamate coupling (65%) and saponification afforded (5-(3-(2-amino-4-oxo-4,7-
dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)picolinoyl)-L-glutamic acid (14c) in 78% 
yield as a white solid.     
Scheme 50: Synthesis of intermediate 30d.  
 
  To synthesize other compounds in the series (13c, 15c and 16c), 5-
bromopicolinic acid (20d) (Scheme 50) was first reacted with diethyl L-glutamate  to 
synthesize the key intermediate diethyl (5-bromopicolinoyl)-L-glutamate (30d).345 Using 30d 
and the alternative synthetic scheme (using Sonogashira coupling and 5,5-dibromo-2,2-
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dimethyl-1,3-dioxane-4,6-dione (24d) for bromination) was utilized to synthesize target 
compounds (Scheme 51).  
Scheme 51: Synthesis of target compounds 13c, 15c and 16c. 
 
 The key intermediate aldehydes (37d-39d) (Scheme 51) were synthesized using the 
optimized procedure from Scheme 48 through the Sonogashira coupling, hydrogenation and 
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oxidation. The α-bromination of the aldehydes and the cyclization reaction of the 
corresponding α-bromo aldehydes (40d-42d) with 2,6-diaminopyrimidin-4(3H)-one (26d) 
afforded the pteroic esters (43d-45d) in 25-40% yield over two steps. Saponification of the 
pteroid esters (43d-45d) gave the target compounds (13c, 15c and 16c) in 63-75%.   
Scheme 52: Synthesis of target compounds 17c, 18c and 19c. 
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 The target compounds 17c-19c were synthesized using the synthetic procedure 
presented in Scheme 52. Glutamate coupling was performed on the 6-bromonicotinic acid 
(46d) to afford diethyl (6-bromonicotinoyl)-L-glutamate (47d) in 83% yield as a clear oil. 
Sonogashira coupling, catalytic reduction and oxidation of the corresponding alcohols (51d-
53d) afforded the aldehydes (54d-56d) in 47-60% yield. The α-bromination, cyclization and 
hydrolysis resulted in the final acids 17c-19c in 64-75% yield. The longer time (upto 2 h) taken 
for complete D2O exchange of the amide-NH of 13c -16c in comparison to the regioisomers 
17c-19c (D2O exchange time about 10 min) provided partial proof for possible intra-molecular 
H-bonding in 13c-16c.349, 350  
B.2. Synthesis of dual inhibitors of cytosolic (de novo purine biosynthetic) and mitochondrial 
(serine hydroxymethyltransferase 2) 1C metabolism enzymes 
1. 5-Substituted, 2-amino-4-oxo pyrrolo[3,2-d]pyrimidine-pyridyl classical antifolates 




 The proposed synthetic scheme for the target compounds 20c-22c involved synthesis 
of pteroic acids (63d-65d) (Scheme 53). The key step for the pteroic acids synthesis was 
alkylation of the pyrrole nitrogen of 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 
(66d) using methyl 5-(3-iodoalkyl)picolinate (67d-69d). 
Scheme 54: Synthesis of the key intermediates methyl 5-(3-iodoalkyl)picolinates (67d-69d). 
 
 Sonogashira coupling of corresponding alkyn-1-ol with methyl 5-bromopicolinate 
(70d) (Scheme 54) using previously reported conditions afforded methyl 5-(3-hydroxyalk-1-
yn-1-yl)picolinates (71d-73d) as clear oils in 63-70% yield. Subsequently, catalytic 
hydrogenation afforded methyl 5-(3-hydroxyalkyl)picolinates (74d-76d) in 75-88% yield. To 
make the hydroxyl groups of 74d-76d better leaving groups it was functionalized into a mesyl 
group using mesyl chloride to afford 77d-79d in 62-69% yield. Subsequently, a Finkelstein 
reaction was carried out to obtain the methyl 5-(3-iodoalkyl)picolinate (67d-69d) in 64-70% 
yield. This two-step synthetic scheme afforded iodides (67d-69d) in 37-50% yield over two 
steps from alcohols 74d-76d. Alternatively, a one pot reaction from alkyl alcohols (74d-76d) 
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using triphenylphosphine, imidazole and iodine afforded iodides (67d-69d) in 80-85% yield. 
This method was a significant improvement over the previous two-step method for conversion 
of the alcohol to mesylate and to the iodide (Scheme 54). This procedure requires one step, 
one workup and one column chromatographic separation and is more efficient, compared to 
the previous method (Scheme 54), which needs two steps, two workups and a column 
chromatographic separation. It is also less time consuming.   
Scheme 55: Synthesis of the key intermediate 2-amino-3,5-dihydro-4H-pyrrolo[3,2-
d]pyrimidin-4-one (66d).    
  To increase the solubility of the pyrrolo[3,2-d]pyrimidine (66d) (Scheme 55) for N-
alkylation, the pivaloyl protected derivative of 66d (84d) was synthesized using the procedure 
in Scheme 55. Nitration at the 5-position of 2-amino-6-methylpyrimidin-4(3H)-one (80d) 
afforded 2-amino-6-methyl-5-nitropyrimidin-4(3H)-one (81d) in 97% yield as a yellow solid. 
Treatment of 81d with N,N-dimethylformamide dimethyl acetal in DMF afforded N'-(4-(2-
(dimethylamino)vinyl)-5-nitro-6-oxo-1,6-dihydropyrimidin-2-yl)-N,N-
dimethylformimidamide (82d) in 90% yield. Reductive cyclization of 82d with sodium 
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dithionite in water/THF under reflux yielded N,N-dimethyl-N'-(4-oxo-4,5-dihydro-3H-
pyrrolo[3,2-d]pyrimidin-2-yl)formimidamide (83d) in 89% yield. Hydrolysis and 
pivaloylation of 83d afforded the protected derivative of 66d (84d) as a white solid.351   
Scheme 56: Attempted N-alkylation of 84d. 
  
 The crucial N-alkylation step was first attempted with sodium hydride (Scheme 56) 
as a base. Instead of mono-alkylation product (85d) (Scheme 56) the reaction condition 
caused alkylation at both the 3-NH (lactam) and the 5-NH (pyrrole) positions of 84d to 
give methyl 5-(3-(5-(3-(4-(methoxycarbonyl)phenyl)propyl)-4-oxo-2-pivalamido-4,5-
dihydro-3H-pyrrolo[3,2-d]pyrimidin-3-yl)propyl)picolinate (86d). Alternatively, using a 
weaker base such as cesium carbonate resulted in only 10% yield with most of the starting 
material, 84d, recovered unreacted. Therefore, an alternative procedure254 was adopted 
which involved protecting both the 2-NH2 and 3-NH group of the pyrrolo[3,2-d]pyrimidine 
to make the N-alkylation cleaner and increase the yield (Scheme 57).  
Treatment of DMF dimethylacetal with 81d (Scheme 57) in dichloromethane gave 
protection at the 2-NH2 position to give N,N-dimethyl-N'-(4-methyl-5-nitro-6-oxo-1,6-
dihydropyrimidin-2-yl)formimidamide (87d) in 60% yield over 4 h. The resulting brown oil 
(88d) was reacted with excess of chloromethyl pivalate and 1.1 eq. of sodium hydride to give 
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a mixture of N3- alkylated (89d, 65%) and O4-alkylated products (90d, 15%) which were 
separated by column chromatography and characterized by 13C NMR (see Experimental 
section). Next step involved reacting 89d or 90d with DMF dimethylacetal. Reaction of O-
alkylated 90d with DMF dimethylacetal resulted in incomplete conversion and a mixture of 
products. N-alkylated 89d however gave full conversion and a clean reaction to afford (2-
((dimethylamino)methylene)amino)-4-(-2-(dimethylamino)vinyl)-5-nitro-6-oxopyrimidin-
1(6H)-yl)methyl pivalate (91d) in 90% yield as a yellow powder. Subsequent reduction of the 
nitro group of 91d with sodium hydrosulfite and simultaneous intramolecular cyclization 
resulted in (2-(((dimethylamino)methylene)amino)-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-
d]pyrimidin-3-yl)methyl pivalate (92d) in 89% yield. 





Scheme 58: Synthesis of target compounds (20c-22c).  
 
 The N-alkylation at the pyrrole nitrogen (5-position) of 92d (Scheme 58) with the 
corresponding alkyl iodides (67d-69d) gave the 5-substituted pyrrolo[3,2-d]pyrimidines 
(93d-95d) in moderate yields (40-50%). This method improved yields and gave cleaner 
reactions compared to the previous N-alkylation procedure (Scheme 56). Simultaneous 
deprotection and hydrolysis of the esters, subsequent glutamate coupling and 
saponification afforded target compounds 20c-22c in 74-90% yield. D2O study indicated 
that possible intramolecular H-bonding of amide NH with pyridyl N may be responsible 
for increased time (> 2 h vs ~ 10 min) taken for complete D2O exchange of amide NH.
350  
2. 5-Substituted, 2-amino-4-oxo pyrrolo[3,2-d]pyrimidine-3’-fluoropyridyl classical 
antifolates 
The standard amide coupling reagent, 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), 
used for the synthesis of previous series of target compounds gave ~20% yield for the reaction 
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of 5-bromo-3-fluoropicolinic acid (102d) (Scheme 59) and diethyl L-glutamate. Alternatively, 
using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU)350 improved the amide coupling reaction yield to 90% to afford 
the diethyl (3-fluoro-5-bromopicolinoyl)-L-glutamate (103d) as a clear oil (Scheme 59). The 
glutamate 103d was Sonogashira coupled with the alkyn-1-ols to afford diethyl (3-fluoro-5-
(hydroxyalk-1-yn-1-yl)picolinoyl)-L-glutamates (104d-105d) in 65-69% yield as yellow oils. 
Subsequent catalytic hydrogenation, mesylation and Finkelstein reaction afforded diethyl (3-
fluoro-5-(iodoalkyl)picolinoyl)-L-glutamates (110d-111d) in excellent yields. 
 






Scheme 60: Synthesis of target compounds 23c-24c. 
 
 N-alkylation, deprotection and hydrolysis afforded target compounds 23c-24c 
(Scheme 60) as white solids.  
B.3. Synthesis of 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]/[3,2-d]pyrimidine-
pyridyl classical antifolates 
Scheme 61: Retrosynthesis of target compound 25c. 
 
The synthesis of the 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine 
pyridyl target compound 25c (Scheme 61) was envisioned via a Fischer indole cyclization of 
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the hydrazine 115d and ketone 116d. The ketone, methyl 5-(5-oxohexyl)picolinate (116d), was 
to be synthesized via a Heck coupling of the 5-bromopicolinate (118d) and 5-hexene-2-one 
(117d).     
Scheme 62: Heck coupling for the synthesis of intermediate 116d. 
 
 Treatment of 118d (Scheme 62) with 117d using the previously reported Heck 
coupling conditions185 gave a mixture of regioisomers of alkene 119d, indicative of palladium 
assisted migration of unsaturation along the hydrocarbon chain towards the tethered carbonyl 
group of the ketone (Scheme 62).352 The presence of these different alkene regioisomers were 
confirmed via 1H NMR spectrum. The spectrum clearly shows three different sets of peaks for 
three different types of pyridyl protons of the regioisomers of 119d (Fig. 81). The sets of the 
protons Ha (δ = 8.67-8.81, d, ortho to the pyridyl N), Hb (δ = 8.07-8.17, d, para to the pyridyl 
N) and Hc (δ = 7.78-7.96, d, meta to the pyridyl N) in the 
1H NMR indicated the presence of 
three regioisomers of 119d formed via the Heck coupling reaction. The regioisomers of 119d 
were taken further without purification for hydrogenation to afford a single product 116d in 





Figure 81: NMR spectrum showing mixture of alkene isomers of 119d afforded by the Heck 
coupling reaction, three sets of proton peaks seen for each pyridine hydrogens (Ha, Hb and Hc) 












































































































































Scheme 63: Attempted synthesis of intermediate 114d using Fischer-indole synthesis.  
 Condensation of ketone 116d with the hydrazine 115d under reflux in 2-
methoxyethanol afforded the key intermediate hydrazonopyrimidine 121d in 83% yield as a 
brown solid (Scheme 63).353 However, the Fischer indole condensation of 121d in diphenyl 
ether at 250 °C led to charred material without yielding the desired cyclized product 114d. The 
failure of this condensation was attributed to the low melting point (~183 °C) of 114d which 
decomposed at the high temperature conditions of the Fischer indole condensation.     
Scheme 64: Synthesis of intermediate ethyl 3-amino-5-methyl-1H-pyrrole-2-carboxylate 
(125d) 
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 Using a literature method,354 the synthesis of ethyl 3-amino-5-methyl-1H-pyrrole-2-
carboxylate, 125d was accomplished (Scheme 64). The crucial intermediate 124d (E/Z 
mixture) was readily obtained from 3-aminobut-2-enenitrile 122d (E/Z-mixture) and diethyl 
aminomalonate hydrochloride, 123d, in methanol at room temperature overnight. The TLC 
shows multiple spots and the reaction required extensive chromatographic separation. The 
formation of a light pink spot on TLC is an indication of the desired intermediate 124d, and it 
was advanced to the cyclization along with impurities. The intermediate diethyl 2-((1-
cyanoprop-1-en-2-yl)amino)malonate 124d under reflux conditions with sodium ethoxide in 
ethanol afforded intermediate 125d in 60% yield over two steps. 
 The N-alkylation of ethyl 5-methyl-3-amino-1H-pyrrole-2-carboxylate 125d using 
iodide 68d (Scheme 65) and sodium hydride under anhydrous conditions afforded the N-5-
substituted pyrrole 126d.354 The crude N-substituted pyrrole 126d was directly subjected to 
condensation with 1,3-bis(methoxycarbonyl)-2-methylthiopseudourea with 5 equivalent of 
acetic acid as catalyst and MeOH. Hydrolysis of the carbamate group with aqueous sodium 
hydroxide at 55 °C afforded the 2-amino-4-oxo-6-methyl-pyrrolo[3,2-d]pyrimidine 128d in 
25% yield (over three steps). Conversion of the free acid 128d to the corresponding L-glutamic 
acid diethyl ester 129d involved conventional peptide coupling with L-glutamic acid diethyl 
ester hydrochloride using 2-chloro-4,6-dimethoxy-l,3,5-triazine followed by chromatographic 
purification to afford the coupled products in 64% yields. Hydrolysis of 129d with aqueous 
NaOH at room temperature, followed by acidification with 1 N HCl, afforded target compound 
26c in 73% yield. 
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C. Synthesis of selective inhibition of P. jirovecii dihydrofolate reductase 
1. 5-substituted, 2,4-diamino pyrimidines (trimethoprim analogs) as selective pjDHFR 
inhibitors 
Scheme 66: Synthesis of the target compounds 28c-31c. 
Protection of 2,4-dichloropyrimidine (130d) (Scheme 66) with the tert-butoxy group 
provided 5-bromo-2,4-di-tert-butoxypyrimidine (131d) in 87% yield.355, 356 Treatment of 5-
bromo-2,4-di-tert-butoxypyrimidine (131d) with iPrMgClLiCl (0 °C, 4 h) provided the 
intermediate magnesium reagent in >95% yield.357 Its cross-coupling with the corresponding 
diethyl benzyl phosphates (132d-136d) (60 °C, 1 h) led to 2,4-di-tert-butoxy-5-substituted-
pyrimidines (137d-141d) in 40-60% yield. The pyrimidine derivatives 137d-141d were 
deprotected using concentrated HCl in methanol to give the corresponding uracil derivatives, 
which were converted to the 2,4-dichloro-5-substituted pyrimidines (142d-146d) with 
POCl3.
358 The nucleophilic substitution of the chlorines by two amino functions was performed 
by heating the  2,4-dichloro pyrimidine derivatives 142d-146d with a 7 M solution of ammonia 
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in methanol at 150 °C in a microwave reactor, providing the desired trimethoprim analogs 

























All evaporations were carried out in vacuum with a rotary evaporator. Analytical 
samples were dried in vacuo in a CHEM-DRY drying apparatus over P2O5 at 50 °C. Melting 
points were determined either using a MEL-TEMP II melting point apparatus with FLUKE 51 
K/J electronic thermometer or using an MPA100 OptiMelt automated melting point system 
and are uncorrected. Thin-layer chromatography (TLC) was performed on Whatman® PE SIL 
G/UV254 flexible silica gel plates or Sorbetch silica g TLC plates w/UV254 and the spots were 
visualized under 254 and 365 nm ultraviolet illumination. Proportions of solvents used for TLC 
are by volume. All analytical samples were homogeneous on TLC in at least two different 
solvent systems. Flash chromatography was carried out on the CombiFlash® Rf 200 (Teledyne 
ISCO) automated flash chromatography system with prepacked RediSep® Rf normal-phase 
flash columns (230 to 400 meshes) of various sizes were used. The amount (weight) of silica 
gel for column chromatography was in the range of 50-100 times the amount (weight) of the 
crude compounds being separated. Nuclear magnetic resonance spectra for proton (1H NMR) 
were recorded on the Bruker Avance II 400 (400 MHz) or Bruker Avance II 500 (500 MHz) 
NMR systems and were analyzed using MestReC NMR data processing software. The 
chemical shift values (δ ) are expressed in ppm (parts per million) relative to tetramethylsilane 
as an internal standard: s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, 
multiplet; br, broad singlet; td, triplet of doublet; dt, doublet of triplet; quin, quintet. Elemental 
analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Element compositions are 
within ± 0.4% of the calculated values. Fractional moles of water or organic solvents frequently 
found in some analytical samples could not be prevented despite 24 to 48 hours of drying 
in vacuo and were confirmed where possible by their presence in the 1H NMR spectra. Mass 
spectrum data were acquired on an Advion expressionS CMS system using the ESI probe. All 
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solvents and chemicals were purchased from Sigma-Aldrich or Fisher Scientific and were used 
as received. 
N-Methyl-4-(methylthio)aniline (2d). 
To a solution of sodium methoxide (1.94 g, 36 mmol) in 25 mL of MeOH in a 100 mL round 
bottom flask was added 4-(methylthio)aniline 1d (0.89 ml, 7.18 mmol). The resultant solution 
was then added to a 100 mL round-bottomed flask containing paraformaldehyde (0.3 g, 10.06 
mmol) in 25 mL of MeOH. The reaction mixture was stirred at rt under argon atmosphere. 
After 5 h, sodium borohydride (0.27 g, 7.18 mmol) was added, and the reaction mixture was 
heated to reflux for 2 h. After cooling to rt, silica gel (3 g) was added, and the solvent was 
removed in vacuo. The resultant plug was chromatographed and eluted with 5% 
EtOAc/hexane. Fractions containing the product (TLC) were pooled and evaporated to afford 
2d as a light brown liquid (0.98 g, 89%). TLC Rf = 0.76 (hexane/EtOAc, 1:1); 
1H NMR (400 
MHz, DMSO-d6): δ = 2.33 (s, 3H, SCH3), 2.64–2.66 (s, 3H, NCH3), 5.72–5.73 (d, J = 7.0 Hz, 
1H, NH), 6.50–6.52 (d, J = 6.8 Hz, 1H, Ar), 7.11–7.13 (d, 2H, Ar). 1H NMR agreed well with 
the literature reported359 values. Mass calculated for C8H11NS [M + H]
+, 154.06; Found 154.06.  
Tert-butyl (5-hydroxynaphthalen-2-yl)carbamate (5d). 
To a 100 mL round-bottomed flask was added 6-aminonaphthalen-1-ol 4d (2 g, 12.56 mmol), 
DMAP (0.15 g, 1.26 mmol), triethylamine (1.75 mL, 12.56 mmol) and 1M solution of di-tert-
butyl dicarbonate in THF (41.46 mL) and stirred overnight at rt. TLC showed completion of 
the reaction. The crude mixture was chromatographed using 10% EtOAc/Hexanes and 
fractions containing the product were pooled to give 2.8 g of 5d (86%) as a black liquid. TLC 
Rf = 0.63 (Hexanes/EtOAc, 3:1). 
1H NMR (400 MHz, Chloroform-d) δ 7.80 (dt, J = 8.5, 1.0 
Hz, 1H, Ar), 7.49 (dt, J = 8.3, 1.1 Hz, 1H, Ar), 7.36 (dd, J = 8.2, 7.5 Hz, 1H, Ar), 7.07 (dd, J = 




Tert-butyl (5-methoxynaphthalen-2-yl)(methyl)carbamate (6d). 
A 250 mL round-bottomed flask was equipped with a stir bar and charged with 5d (2.8 g, 10.80 
mmol) and an anhydrous DMF (100 mL) and cooled in ice bath. To this was added 60% 
dispersion of NaH in oil (1.3 g, 32.39 mmol) under argon and kept at 0 °C for 15 min. After 
15 min, methyl iodide (1.48 mL, 23.76 mmol) was added dropwise to the solution and reaction 
was warmed to rt. After 2 h, silica gel was added and DMF was evaporated in vacuo to make 
plug. The plug was purified using column chromatography, eluting with 10% EtOAc/Hexanes 
to afford 2.79 g of 6d (90%) as a brown liquid. TLC Rf = 0.90 (Hexanes/EtOAc, 1:1) 
1H NMR 
(400 MHz, Chloroform-d) δ 8.19 (d, J = 9.0 Hz, 1H), 7.58 (d, J = 2.2 Hz, 1H, Ar), 7.42 – 7.33 
(m, 3H, Ar), 6.78 (dd, J = 6.1, 2.5 Hz, 1H, Ar), 4.00 (s, 3H, OCH3), 3.36 (s, 3H, NCH3), 1.46 
(s, 9H, CH3). Mass calculated for C17H21NO3 [M + H]
+, 288.16; Found 288.15. 
5-Methoxy-N-methylnaphthalen-2-amine (7d). 
In a 100 mL round-bottomed flask was added 6d (2.79 g, 9.71 mmol) and trifluoroacetic acid 
(30 mL) and stirred for 2 h at rt. The reaction mixture was chromatographed, eluting with 10% 
EtOAc/Hexanes to afford 1.70 g of 7d (93%) as a black semisolid. TLC Rf = 0.78 
(Hexanes/EtOAc, 1:1). 1H NMR (400 MHz, Chloroform-d) δ 8.06 (d, J = 9.1 Hz, 1H, Ar), 7.35 
– 7.22 (m, 2H, Ar), 6.88 (ddd, J = 9.0, 2.4, 0.9 Hz, 1H, Ar), 6.79 (d, J = 2.3 Hz, 1H, Ar), 6.60 
(dd, J = 7.3, 1.2 Hz, 1H, Ar), 3.99 (s, 3H, OCH3), 2.96 (s, 3H, NCH3). Mass calculated for 
C12H23NO [M + H]
+, 188.10; Found 188.10. 
4-Chloroquinazoline (9d). 
To a 250 mL round-bottomed flask were added quinazolin-4(3H)-one 8d (1.11 g, 7.59 mmol), 
trimethylamine (1.36 mL, 9.87 mmol), and toluene (20 mL). The mixture was cooled to 0 °C 
to which phosphorus oxychloride (0.85 mL, 9.11 mmol) was added and stirred at room 
temperature for 1 h. The reaction was heated to 95 °C for 3 h. After monitoring the reaction on 
TLC, the reaction was cooled to room temperature and diluted with 30 mL of ethyl acetate. 
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The solution was then washed with 10 mL of ice-cold water, 10 mL of saturated NaHCO3, 10 
mL of water, 1N HCl (5 mL), 10 mL of water, 10 mL of saturated NaHCO3 and 10 mL of 
saturated NaCl. The organic layer was dried over Na2SO4, filtered and concentrated to obtain 
9d as white solid (1.08 g, 80%). TLC Rf = 0.85 (MeOH:CHCl3; 1:5); mp, 96.5 – 97.5 °C (lit.
360 
97 - 98 °C); 1H NMR, DMSO-d6 (400 MHz): 7.59-7.63 (dt, 1 H, J1 = 1.09, J2 = 7.23, J3 = 8.01, 
Ar), 7.76-7.78 (d, 1 H, J = 8.24, Ar), 7.89-7.92 (dt, 1 H, J1 = 1.47, J2 = 7.24, J3 = 8.29, Ar), 
8.15-8.17 (d, 1 H, J = 7.03, Ar), 8.58 (s, 1 H, Ar). 
Pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione (11d). 
In a 100 mL round-bottomed flask, 3-aminopicolinic acid 10d (4 g, 28.96 mmol) and urea 
(17.39 g, 289.59 mmol) were mixed ad kept in a preheated oil bath at 160 °C overnight, then 
50 mL of water was added and mixture was cooled down to rt and filtered. The crude was 
dissolved in 0.2 M NaOH stirred again at 100 °C for 20 min and cooled down to rt. The solution 
was filtered and washed with water/MeOH (1/1 v/v) and dried to afford 3.78 g (80%) of 11d 
as a white solid. mp, >300 °C (lit.361 320 °C); 1H NMR (400 MHz, DMSO-d6) δ 11.50 (s, 1H, 
NH), 11.23 (s, 1H, NH), 8.46 (d, J = 4.1 Hz, 1H, Ar), 7.62 (d, J = 4.3 Hz, 1H, Ar), 7.57 (d, J = 
8.1 Hz, 1H, Ar). Mass calculated for C7H5N3O2 [M + H]
+, 164.04; Found 164.05. 
2,4-Dichloropyrido[3,2-d]pyrimidine (12d). 
To a 250 mL round-bottomed flask were added pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione 
(11d) (2 g, 12.26 mmol), trimethylamine (2.22 mL, 15.94 mmol), and toluene (40 mL). The 
mixture was cooled to 0 °C to which phosphorus oxychloride (2.51 mL, 26.97 mmol) was 
added and stirred at room temperature for 1 h. The reaction was heated to 95 °C for 3 h. After 
monitoring the reaction on TLC, the reaction was cooled to room temperature and diluted with 
30 mL of ethyl acetate. The solution was then washed with 10 mL of ice-cold water, 10 mL of 
saturated NaHCO3, 10 mL of water, 1N HCl (5 mL), 10 mL of water, 10 mL of saturated 
NaHCO3 and 10 mL of saturated NaCl. The organic layer was dried over Na2SO4, filtered and 
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concentrated to obtain 12d as white solid (1.68 g, 68%). TLC Rf = 0.65 (MeOH:CHCl3; 1:5); 
mp, 165.5 °C (lit.360 165-167 °C) 1H NMR (400 MHz, DMSO-d6) δ 9.22 (dd, J = 4.1, 1.5 Hz, 
1H, Ar), 8.50 (dd, J = 8.6, 1.5 Hz, 1H, Ar), 8.16 (dd, J = 8.6, 4.1 Hz, 1H, Ar). 
Pyrido[3,2-d]pyrimidin-4(3H)-one (14d) 
To a 2-5 mL Biotage® microwave vial were added 3-aminopicolinic acid 10d (1 g, 7.24 mmol) 
and formamide 13d (2 mL, 50.68 mmol) which were set up for microwave irradiation at 170 
°C for 60 min. To this was added 10 mL water and the resulting suspension was filtered and 
washed with water (10 mL x 2), dried over P2O5 to yield 14d as buff colored solid (0.38 g, 
36%). TLC Rf = 0.38 (MeOH:CHCl3; 1:5); mp, >300 °C (lit.
362 346-347 °C); 1H NMR (400 
MHz, DMSO-d6) δ 12.56 (s, 1H, NH), 8.79 (dd, J = 4.3, 1.6 Hz, 1H, Ar), 8.16 (s, 1H, Ar), 8.09 
(dd, J = 8.4, 1.6 Hz, 1H, Ar), 7.82 (dd, J = 8.3, 4.3 Hz, 1H, Ar). 
4-Chloropyrido[3,2-d]pyrimidine (15d). 
To a 250 mL round-bottomed flask was added pyrido[3,2-d]pyrimidin-4(3H)-one (14d) (1.3 g, 
8.84 mmol), triethylamine (1.6 mL, 11.49 mmol), and toluene (20 mL). The mixture was 
cooled to 0 °C to which phosphorus oxychloride (0.99 mL, 10.60 mmol) was added and stirred 
at room temperature for 1 h. The reaction was heated to 95 °C for 3 h. After monitoring the 
reaction on TLC, the reaction was cooled to room temperature and diluted with 30 mL of ethyl 
acetate. The solution was then washed with 10 mL of ice-cold water, 10 mL of saturated 
NaHCO3, 10 mL of water, 1N HCl (5 mL), 10 mL of water, 10 mL of saturated NaHCO3 and 
10 mL of saturated NaCl. The organic layer was dried over Na2SO4, filtered and concentrated 
to obtain 15d as yellow colored solid (1.03 g, 70%). TLC Rf = 0.78 (MeOH:CHCl3; 1:5); mp, 
140.3 °C decomposed (lit.363 136-139 °C decomposed); 1H NMR (400 MHz, Chloroform-d) δ 
9.24 – 9.18 (m, 1H, Ar), 9.17 (s, 1H, Ar), 8.48 – 8.42 (m, 1H, Ar), 7.95 (d, J = 8.8 Hz, 1H, Ar). 
General procedure for the synthesis of quinazoline (1c and 2c) and pyrido[3,2-
d]pyrimidine analogs (3c - 10c).  
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To a 50 mL round-bottomed flask were added 1 equivalent of 4-chloro compounds (6d, 9d, 
13d, and 15d) and 1 or 1.1 equivalent of appropriate anilines, acetonitrile (1c and 2c) or 
isopropanol (3c-10c) and a drop of conc. HCl and stirred at room temperature for 12 h. The 
compounds precipitated as a HCl salt, which were filtered and dried in vacuo over P2O5. If 
further purification was required, then the compounds were purified using column 
chromatography to give yellow solids. 
N-(5-Methoxynaphthalen-2-yl)-N-methylquinazolin-4-amine (1c).  
Using the general procedure described above, the reaction of 6d (0.2 g, 1.22 mmol) and 4d 
(0.23 g, 1.22 mmol) resulted in 1c (0.33 g, 85%) as yellow solid. TLC Rf = 0.85 (MeOH:CHCl3; 
1:5); mp: 123.6 °C, 1H NMR (400 MHz, Chloroform-d) δ 7.95 (s, 1H, Ar), 7.64 (s, 1H, Ar), 
7.32 (d, J = 8.6 Hz, 2H, Ar), 7.17 (d, J = 8.6 Hz, 2H, Ar), 7.10 (s, 1H, Ar), 7.02 – 6.97 (m, 1H, 
Ar), 3.68 (s, 3H, NCH3), 2.55 (s, 3H, SCH3). Anal. Calcd. for C16H14ClN3S: C, 60.85; H, 4.47; 
N, 13.31; S, 10.15; Cl, 11.22. Found: C, 60.97; H, 4.55; N, 13.19; S, 10.12; Cl, 11.07. 
2-Chloro-N-methyl-N-(4-(methylthio)phenyl)quinazolin-4-amine (2c). 
Using the general procedure described above, the reaction of 9d (0.3 g, 1.51 mmol) and 7d 
(0.23 g, 1.51 mmol) resulted in 2c (0.1 g, 22%) as dark yellow solid. TLC Rf = 0.76 
(MeOH:CHCl3; 1:5); mp, 243 °C, 
1H NMR (400 MHz, Chloroform-d) δ 1H NMR (400 MHz, 
Chloroform-d) δ 7.95 (d, J = 8.3 Hz, 1H, Ar), 7.64 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H, Ar), 7.37 – 
7.30 (m, 2H, Ar), 7.20 – 7.14 (m, 2H, Ar), 7.10 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H, Ar), 6.99 (dd, J 
= 8.7, 1.4 Hz, 1H, Ar), 3.68 (s, 3H, SCH3), 2.55 (s, 3H, NCH3). Anal. Calcd. for C20H17N3O 
1.09 HCl: C, 67.61; H, 5.13; N, 11.82; Cl, 9.41. Found: C, 67.61; H, 5.26; N, 11.85; Cl, 9.89. 
2-Chloro-N-(4-methoxyphenyl)-N-methylpyrido[3,2-d]pyrimidin-4-amine (3c). 
Using the general procedure described above, the reaction of 12d (0.06 g, 0.36 mmol) and 4-
methoxy-N-methylaniline (0.06 g, 0.4 mmol) resulted in 3c (0.09 g, 93%) as yellow solid. TLC 
Rf = 0.83 (MeOH:CHCl3; 1:5); mp: 245.1-248.3 °C, 
1H NMR (400 MHz, Chloroform-d) δ 9.16 
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(dd, J = 4.4, 1.8 Hz, 1H, Ar), 8.39 (dd, J = 8.4, 1.7 Hz, 1H, Ar), 7.90 (dd, J = 8.7, 4.1 Hz, 1H, 
Ar), 7.33 (d, J = 8.3 Hz, 2H, Ar), 7.15 (d, J = 8.4 Hz, 2H, Ar), 3.83 (s, 3H, OCH3), 2.56 (s, 3H, 
NCH3). Anal. Calcd. for C15H13ClN4O 0.18 CH3OH 0.24 HCl: C, 57.79; H, 4.46; N, 17.75; Cl, 
13.96. Found: C, 58.06; H, 4.65; N, 17.43; Cl, 14.08.  
4-(6-Methoxy-3,4-dihydroquinolin-1(2H)-yl)pyrido[3,2-d]pyrimidine (4c). 
Using the general procedure described above, the reaction of 12d (0.18 g, 1.09 mmol) and 6-
methoxy-1,2,3,4-tetrahydroquinoline (0.18 g, 1.09 mmol) resulted in 4c (0.25 g, 79%) as 
yellow solid. TLC Rf = 0.89 (MeOH:CHCl3; 1:5); mp: 139.8 °C (lit.
364 137-138 °C), 1H NMR 
(400 MHz, DMSO-d6) δ 8.69 (dd, J = 4.1, 1.6 Hz, 1H, Ar), 8.11 (dd, J = 8.5, 1.7 Hz, 1H, Ar), 
7.81 (dd, J = 8.6, 4.2 Hz, 1H, Ar), 7.09 (d, J = 8.9 Hz, 1H, Ar), 6.80 (d, J = 3.0 Hz, 1H, Ar), 
6.65 (dd, J = 8.9, 3.0 Hz, 1H, Ar), 4.33 (t, J = 6.3 Hz, 2H, CH2), 3.76 (d, J = 1.7 Hz, 3H, OCH3), 
2.81 (dt, J = 6.7 Hz, 2H, CH2), 1.98 (p, J = 6.6 Hz, 2H, CH2). Anal. Calcd. for C17H15ClN4O 
0.218 CH3COCH3: C, 62.46; H, 4.84; N, 16.50; Cl, 10.44. Found: C, 62.67; H, 4.85; N, 16.73; 
Cl, 10.06. 
2-Chloro-N-methyl-N-(4-(methylthio)phenyl)pyrido[3,2-d]pyrimidin-4-amine (5c). 
Using the general procedure described above, the reaction of 12d (0.15 g, 0.9 mmol) and N-
methyl-4-(methylthio)aniline (0.15 g, 0.99 mmol) resulted in 5c (0.1 g, 39%) as yellow solid. 
TLC Rf = 0.84 (MeOH:CHCl3; 1:5); mp: 251.4 °C, 
1H NMR (400 MHz, Chloroform-d) δ 9.18 
(dd, J = 4.2, 1.6 Hz, 1H, Ar), 8.37 (dd, J = 8.5, 1.6 Hz, 1H, Ar), 7.95 (dd, J = 8.7, 4.2 Hz, 1H, 
Ar), 7.31 (d, J = 8.3 Hz, 2H, Ar), 7.14 (d, J = 8.4 Hz, 2H, Ar), 3.86 (s, 3H, OCH3), 2.58 (s, 3H, 
NCH3). Anal. Calcd. for C15H13ClN4S: C, 56.87; H, 4.14; N, 17.69; Cl, 11.19; S,.10.12 Found: 
C, 56.80; H, 4.48; N, 17.44; Cl, 11.40; S, 9.78. 
2-Chloro-N-(5-methoxynaphthalen-2-yl)-N-methylpyrido[3,2-d]pyrimidin-4-amine (6c). 
Using the general procedure described above, the reaction of 12d (0.2 g, 1.21 mmol) and 5-
methoxy-N-methylnaphthalen-2-amine (0.23 g, 1.21 mmol) resulted in 6c (0.25 g, 65%) as 
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yellow solid. TLC Rf = 0.82 (MeOH:CHCl3; 1:5); mp: 187.2 °C, 
1H NMR (400 MHz, DMSO-
d6) δ 8.31 (dd, J = 4.1, 1.6 Hz, 1H, Ar), 8.11 (d, J = 8.9 Hz, 1H, Ar), 8.06 (dt, J = 8.5, 4.2 Hz, 
1H, Ar), 7.83 (d, J = 2.2 Hz, 1H, Ar), 7.71 – 7.63 (m, 1H, Ar), 7.48 – 7.37 (m, 3H, Ar), 7.01 – 
6.96 (m, 1H, Ar), 4.01 (s, 3H, OCH3), 3.78 (s, 3H, NCH3). Anal. Calcd. for C19H15ClN4O: C, 
65.05; H, 4.31; Cl, 10.11; N, 15.87. Found: C, 65.13; H, 4.15; Cl, 10.01; N, 15.64. 
 N-(4-Methoxyphenyl)-N-methylpyrido[3,2-d]pyrimidin-4-amine (7c). 
Using the general procedure described above, the reaction of 15d (0.11 g, 0.53 mmol) and 4-
methoxy-N-methylaniline (0.08 g, 0.58 mmol) resulted in 7c (0.12 g, 75.3%) as yellow solid. 
TLC Rf = 0.86 (MeOH:CHCl3; 1:5); mp: 250.4 °C, 
1H NMR (400 MHz, Chloroform-d) δ 9.02 
(s, 1H, Ar), 8.66 (s, 1H, Ar), 8.23 (dd, J = 8.5, 4.1 Hz, 1H, Ar), 7.88 (dd, J = 8.5, 4.2 Hz, 1H, 
Ar), 7.16 (s, 2H, Ar), 6.98 (s, 2H, Ar), 3.90 (s, 3H, OCH3), 3.86 (s, 3H, NCH3). Anal. Calcd. 
for C15H14N4O · 1.01 HCl: C, 59.44; H, 4.99; N, 18.48; Cl, 11.83. Found: C, 59.08; H, 5.14; 
N, 18.25; Cl, 11.57.  
4-(6-Methoxy-3,4-dihydroquinolin-1(2H)-yl)pyrido[3,2-d]pyrimidine (8c). 
Using the general procedure described above, the reaction of 15d (0.2 g, 1 mmol) and 6-
methoxy-1,2,3,4-tetrahydroquinoline (0.16 g, 1 mmol) resulted in 8c (0.28 g, 85%) as yellow 
solid. TLC Rf = 0.86 (MeOH:CHCl3; 1:5); mp: 237.7 °C, 
1H NMR (400 MHz, DMSO-d6) δ 
8.83 (s, 1H, Ar), 8.80 (s, 1H, Ar), 8.24 (dd, J = 8.6, 4.3 Hz, 1H, Ar), 7.94 (dd, J = 8.6, 4.2 Hz, 
1H, Ar), 7.17 (d, J = 9.0 Hz, 1H, Ar), 6.85 (d, J = 2.9 Hz, 1H, Ar), 6.68 (dd, J = 8.9, 2.9 Hz, 
1H, Ar), 4.48 (s, 2H, CH2), 3.77 (s, 3H, OCH3), 2.82 (t, J = 6.8 Hz, 2H, CH2), 2.02 (q, J = 6.6 
Hz, 2H, CH2). Anal. Calcd. for C17H16N4O · 1.0739 HCl: C, 61.59; H, 5.19; N, 16.91; Cl, 11.49. 
Found: C, 61.63; H, 5.46; N, 16.73; Cl, 11.05. 
N-Methyl-N-(4-(methylthio)phenyl)pyrido[3,2-d]pyrimidin-4-amine (9c). 
Using the general procedure described above, the reaction of 15d (0.09 g, 0.45 mmol) and N-
methyl-4-(methylthio)aniline (0.076 g, 0.5 mmol) resulted in 9c (0.1 g, 70%) as yellow solid. 
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TLC Rf = 0.88 (MeOH:CHCl3; 1:5); mp: 228.1 °C, 
1H NMR (400 MHz, DMSO-d6) δ 8.90 (s, 
1H, Ar), 8.66 (s, 1H, Ar), 8.23 (dd, J = 8.5, 4.6 Hz, 1H, Ar), 7.88 (dd, J = 8.5, 4.2 Hz, 1H, Ar), 
7.33 (s, 4H, Ar), 3.89 (s, 3H, NCH3), 2.53 (s, 3H, SCH3). Anal. Calcd. for C15H14N4S · 0.9951 
HCl: C, 56.54; H, 4.74; N, 17.58; S, 10.06; Cl, 11.08. Found: C, 56.55; H, 4.74; N, 17.55; S, 
10.06; Cl, 11.17. 
N-(5-Methoxynaphthalen-2-yl)-N-methylpyrido[3,2-d]pyrimidin-4-amine (10c). 
Using the general procedure described above, the reaction of 15d (0.4 g, 2 mmol) and 5-
methoxy-N-methylnaphthalen-2-amine (0.37 g, 2 mmol) resulted in 10c (0.49 g, 71 %) as 
yellow solid. TLC Rf = 0.9 (MeOH:CHCl3; 1:5); mp: 122.8 °C, 
1H NMR (400 MHz, DMSO-
d6) δ 8.99 (d, J = 0.6 Hz, 1H, Ar), 8.60 – 8.46 (m, 1H, Ar), 8.31 – 8.25 (m, 1H, Ar), 8.22 – 8.16 
(m, 1H, Ar), 7.93 (d, J = 1.9 Hz, 1H, Ar), 7.87 (d, J = 3.7 Hz, 1H, Ar), 7.53 – 7.41 (m, 3H, Ar), 
7.04 (dd, J = 7.1, 0.5 Hz, 1H, Ar), 4.01 (s, 6H, NCH3 and OCH3). Anal. Calcd. for C19H16N4O: 
C, 72.13; H, 5.10; N, 17.71. Found: C, 71.93; H, 5.19; N, 17.54. 
2-Amino-4-bromo-1H-indole-3-carbonitrile (18d). 
To an ice-cold solution of malononitrile (4.76 g, 72 mmol) in anhydrous DMF (500 mL) under 
argon atmosphere was added sodium hydride (2.6 g, 104 mmol). Thus formed white suspension 
was stirred for 15 min and then 1-bromo-2-fluoro-3-nitrobenzene 16d365 (10 g, 36 mmol) was 
added. Orange color was observed within 2-3 minutes after adding 16d. The mixture was 
stirred at 110 °C for overnight. After cooling the reaction mixture, 200 mL H2O was added, 
and the resulting aqueous mixture was acidified to pH 2.0 with conc. HCl. The mixture was 
extracted with diethyl ether (500 mL × 3) and then the combined organic phases were dried 
using anhydrous sodium sulfate and concentrated to give (2-Bromo-6-nitrophenyl)-
malononitrile 17d as dark-brown oil. TLC Rf = 0.42 (CHCl3/MeOH, 10:1); 
1H NMR (400 MHz, 
DMSO-d6) δ  = 8.19‒8.21 (m, 1H, Ar), 8.07‒8.09 (m, 1H, Ar), 7.62‒7.66 (m, 1H, Ar), 6.18 (s, 
1H, CH). The material was used directly for the next step. 
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A solution of 17d (3.92 g, 14.6 mmol) in glacial acetic acid (500 mL) was treated with a single 
charge of zinc dust (6.84 g, 104.62 mmol). The mixture was stirred at 55 °C for 45 min, then 
recharged with zinc dust (3.92 g, 59.96 mmol). After heating for another 105 min, the mixture 
was filtered through a pad of Celite®. The pad was washed with glacial acetic acid, the filtrate 
was concentrated and then washed with saturated Na2CO3 solution. The precipitate was 
collected and then dissolved in methanol. Silica gel (5 g) was added to make the plug and was 
then purified by column chromatography, eluting sequentially with 0% and 1% MeOH in 
CHCl3. The fractions containing the pure product (TLC) were pooled and evaporated to give 
2.52 g of 18d as a pink solid. The overall yield from 16d to 18d was 60%. TLC Rf = 0.25 
(CHCl3/MeOH, 10:1 with 2 drops of conc. NH4OH); mp 231.5 °C (lit
366: 231.1‒231.9 °C). 1H 
NMR (400 MHz, DMSO-d6) δ = 10.98 (s, 1H, NH), 7.10‒7.12 (m, 1H, Ar), 7.07‒7.08 (m, 1H, 
Ar), 6.89 (bs, 2H, NH2), 6.78‒6.82 (m, 1H, Ar).  
5-Bromo-9H-pyrimido[4,5-b]indole-2,4-diamine (19d). 
A mixture of 2-amino-4-bromo-1H-indole-3-carbonitrile 18d (3 g, 12.7 mmol), carbamimidic 
chloride hydrochloride367 (1.6 g, 13.9 mmol) and methyl sulfone (30 g) was premixed and 
charged to 100 mL round-bottomed flask. It was transferred to preheated oil bath at 120 °C and 
reacted for 8 h. The reaction mixture was cooled and 50 mL of 7N ammonia in methanol was 
added to neutralize the reaction mixture. Solvents were evaporated and the crude mixture was 
purified by column chromatography, eluting sequentially with 1% and 5% methanol in 
chloroform. Fractions containing the desired product (TLC) were pooled and evaporated to 
afford 2.16 g (61%) of 19d as an buff colored solid. TLC Rf = 0.27 (CHCl3/MeOH, 10:1 with 
2 drops of conc. NH4OH); mp 242 °C (lit
366: 240 °C). 1H NMR (400 MHz, DMSO-d6) δ = 
11.49 (br, 1H, 9-NH), 7.24‒7.26 (m, 2H, Ar), 7.01‒7.05 (m, 1H, Ar), 6.95 (br, 2H, 4-NH2), 
6.05 (bs, 2H, 2-NH2).  
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General procedure for the synthesis of 5-(substituted aryloxy)-9H-pyrimido[4,5-b]indole-
2,4-diamines 11c-12c. 
Compound 19d (1 equivalent), appropriate sodium phenoxides (1 equivalent), copper iodide 
(2 equivalents), cesium carbonate (2 equivalents) and ligands (1 equivalent) were added to a 
Biotage® microwave vial. DMF (10 mL) was added as the solvent and the vial was sealed. 
The reaction was run in a Biotage® Initiator at 180 °C for 1 h. After cooling to room 
temperature, the reaction mixture was filtered over Celite® pad and washed the pad with 20 
mL of DMF. The DMF filtrate was evaporated to concentration (2 mL) and transferred on top 
of the silica column and purified by column chromatography, sequentially eluting with 1%, 
2% and 3% methanol in chloroform. Fractions containing the product (TLC) were pooled and 
evaporated to afford the product. 
5-Phenoxy-9H-pyrimido[4,5-b]indole-2,4-diamine (11c). 
Using the general procedure described above, the reaction of 19d (0.2 g, 0.72 mmol) with 
sodium phenoxide (0.08 g, 0.72 mmol), copper iodide (0.27 g, 1.44 mmol), cesium carbonate 
(0.2 g, 1.44 mmol) and 2-aminopyridine 24d (0.068 g, 0.72 mmol) for 1 h afforded 0.15 g 
(70%) of 11c as a brown solid. TLC Rf = 0.65 (CHCl3/MeOH, 5:1 with 2 drops of conc. 
NH4OH); mp >250 °C (decomp), 
1H NMR (400 MHz, DMSO-d6) δ 11.33 (s, 1H, NH), 7.43 
(t, J = 7.7 Hz, 2H, Ar), 7.20 (t, J = 7.5 Hz, 1H, Ar), 7.15 – 7.10 (m, 2H, Ar), 7.10 – 7.03 (m, 
2H, Ar), 6.61 (s, 2H, 4NH2), 6.48 (dd, J = 6.6, 2.5 Hz, 1H, Ar), 5.99 (s, 2H, 2NH2). Anal. 






Using the general procedure described above, the reaction of 19d (0.2 g, 0.72 mmol) with 
sodium phenoxide (0.08 g, 0.72 mmol), copper iodide (0.27 g, 1.44 mmol), cesium carbonate 
(0.2 g, 1.44 mmol) and 2-aminopyridine 24d (0.068 g, 0.72 mmol) for 1 h afforded 0.14 g 
(68%) of 12c as a dark brown solid. TLC Rf = 0.65 (CHCl3/MeOH, 5:1 with 2 drops of conc. 
NH4OH); mp >250 °C (decomp). 
1H NMR (400 MHz, DMSO-d6) δ 11.15 (s, 1H, NH), 7.41 
(t, J = 7.7 Hz, 2H, Ar), 7.20 (t, J = 7.5 Hz, 1H, Ar), 7.15 – 7.11 (m, 2H, Ar), 7.10 – 7.01 (m, 
2H, Ar), 6.65 (s, 2H, 4-NH2), 6.38 (dd, J = 6.6, 2.5 Hz, 1H, , Ar), 5.73 (s, 2H, 2-NH2), 2.13 (s, 
3H, CH3).  Anal. Calcd. for C17H15N5O: C, 66.87; H, 4.95; N, 22.94. Found: C, 66.58; H, 4.70; 
N, 22.65. 
Ethyl 5-bromopiolinate (21d).  
Thionyl chloride (8.01 g, 67.32 mmol) was added dropwise to a solution of 5-bromopiconicate 
(3.4 g, 16.83 mmol) in MeOH (50 mL) and the mixture was stirred overnight at rt.344 After that 
the mixture was heated to 60 °C for 5 h. The mixture was concentrated, and ethyl acetate was 
added to the white solid. Saturated NaHCO3 was added and extracted twice more with ethyl 
acetate. The combined organic layer was washed with brine, dried over sodium sulfate and 
evaporated to afford 21d (3.1 g, 80%) as a white solid. TLC Rf = 0.70 (Hexane/EtOAc, 3:1); 
Mass calculated for C8H8BrNO2 [M + H]
+, 299.97; Found 299.9; 1H NMR368 (400 MHz, 
Chloroform-d) δ 8.82 (dd, J = 2.2, 0.8 Hz, 1H, Ar), 8.04 (dd, J = 8.4, 0.8 Hz, 1H, Ar), 8.00 (dd, 
J = 8.4, 2.2 Hz, 1H, Ar), 4.49 (q, J = 7.2 Hz, 2H, CH2), 1.46 (t, J = 7.1 Hz, 3H, CH3).    
Ethyl 5-(5-oxopentyl)picolinate (22d). 
Condition A: To a solution of Ethyl 5-bromopiolinate (21d, 1 g, 4.35 mmol) in 20 mL of 
anhydrous DMF were added pent-4-en-1-ol (1.12 g, 13.04 mmol), LiCl (0.18 g 4.35 mmol),  
LiOAc (0.72 g, 4.35 mmol), Bu4NCl (1.21 g, 4.35 mmol), and Pd(OAc)2 (0.2 g, 0.87 mmol), 
and the mixture was stirred at 70 °C for 4 h. TLC (hexane/EtOAc, 3:1) showed the 
disappearance of the starting material (Rf = 0.70) and formation of one major spot at Rf = 
 171 
0.50. To the reaction mixture cooled to room temperature was added ethyl acetate (30 mL). 
The resulting solution was extracted with H2O (10 mL × 3) and dried over Na2SO4. After 
evaporation of solvent, the residue was loaded on a silica gel column (4 × 20 cm) and flash 
chromatographed with hexane/EtOAc (2:1), and the desired fractions were pooled. After 
evaporation of the solvent, the residue was dried in vacuo using P2O5 to afford 22d (95 mg, 
10%) as a colorless liquid. Rf  = 0.48 (hexane/EtOAc, 3:1). 
1H NMR (400 MHz, Chloroform-
d) δ 9.79 (t, J = 4.1 Hz, 1H, CHO), 8.60 (d, J = 2.3 Hz, 1H, Ar), 8.29 (dd, J = 7.6, 1.7 Hz, 1H, 
Ar), 7.95 (ddd, J = 8.4, 7.1, 1.6 Hz, 1H, Ar), 7.66 (dd, J = 8.0, 2.3 Hz, 1H, Ar), 4.49 (q, J = 7.1 
Hz, 2H, CH2), 2.74 (t, J = 4.2 Hz, 2H, CH2), 2.55 – 2.47 (m, 2H, CH2), 1.75 – 1.67 (m, 4H, 
CH2), 1.46 (t, J = 7.1 Hz, 3H, CH3). Mass calculated for C8H8BrNO2 [M + K]
+, 274.08; Found 
274.2; The intermediate 22d was used for the next reaction without further characterization. 
Condition B: To a solution of ethyl 5-bromopiolinate, 21d (1 g, 4.63 mmol) in anhydrous 
acetonitrile was added palladium chloride (33 mg, 0.18 mmol), triphenylphosphine (49 mg, 
0.18 mmol), copper iodide (141 mg, 0.74 mmol), triethylamine (6.45 mL, 46.3 mmol), and 
pent-4-yn-1-ol (0.5 mL, 5.6 mmol). The reaction mixture was heated to 100 °C and run for 1 h 
under microwave heating. A silica plug was prepared by adding silica gel and methanol 
followed by evaporation of the solvent in vacuo, which was then loaded on to a silica gel 
column and eluted with hexane followed by 30% EtOAc in hexane. The desired fractions 
(TLC) were pooled and evaporated to afford the methyl 5-(5-hydroxypent-1-yn-1-yl)picolinate 
23d (0.71 g, 70 %) as oil. Rf = 0.40 (hexane/EtOAc, 3:1). 
1H NMR (400 MHz, Chloroform-d) 
δ 8.73 (dd, J = 2.1, 0.8 Hz, 1H, Ar), 8.06 (dd, J = 8.2, 0.9 Hz, 1H, Ar), 7.81 (dd, J = 8.1, 2.0 
Hz, 1H, Ar), 4.48 (q, J = 7.2 Hz, 2H, CH2), 3.82 (t, J = 6.1 Hz, 2H, CH2), 2.61 (t, J = 7.0 Hz, 
2H, CH2), 1.89 (tt, J = 7.1, 6.2 Hz, 2H, CH2), 1.44 (t, J = 7.1 Hz, 3H, CH3). Mass calculated 
for C13H15NO3 [M + H]
+, 234.11 Found 234.2; The intermediate 23d was used for the next 
reaction without further characterization. 
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To 10% palladium on activated carbon (1:1 wt equiv) in a Parr flask, ethanol was added to 
quench. Methanolic solutions of 23d (2 g, 9.12 mmol) were added, and hydrogenation was 
carried out at 55 psi of H2 for 5 h. The reaction mixture was filtered through Celite®, washed 
with MeOH, passed through a short silica gel column (3 cm × 5 cm), and concentrated under 
reduced pressure to give methyl 5-(5-hydroxypentyl)picolinate 23d’ (2 g, quant. yield) as oil. 
Rf = 0.38 (hexane/EtOAc, 3:1). 
1H NMR (400 MHz, DMSO-d6) δ 8.57 (d, J = 2.2 Hz, 1H, Ar), 
7.98 (d, J = 8.0 Hz, 1H, Ar), 7.82 (dd, J = 8.0, 2.3 Hz, 1H, Ar), 4.40 – 4.29 (m, 2H, CH2), 3.38 
(td, J = 6.4, 5.1 Hz, 2H, CH2), 2.68 (t, J = 7.6 Hz, 2H, CH2), 1.60 (p, J = 7.6 Hz, 2H, CH2), 1.50 
– 1.39 (m, 2H, CH2), 1.33 (t, J = 7.1 Hz, 3H, CH3), 1.31 – 1.22 (m, 2H, CH2). Mass calculated 
for C13H15NO3 [M + H]
+, 238.14 Found 238.3; The intermediate 23d’ was used for the next 
reaction without further characterization. 
To a solution of DMP (4.65 g, 10.96 mmol) in CH2Cl2 (20 mL) was added a solution 
of alcohol, methyl 5-(5-hydroxypentyl)picolinate (1.3 g, 5.5 mmol) in CH2Cl2 (40 mL) at 0 ° 
C, and the mixture was stirred for 4 hours at room temperature. The aldehyde product was 
extracted with organic solvent CH2Cl2, and the combined extracts were washed with brine, 
dried over anhydrous Na2SO4, and concentrated under reduced pressure. Silica gel was added, 
and the solvent evaporated to obtain a plug. Purification by column chromatography using 
10%, 30% and 50% EtOAc in hexanes afforded aldehyde 22d (1.35 g) in 60% yield as a 
transparent oil. Rf = 0.51 (10% EtOAc/hexanes). The intermediate 22d was used for the next 
reaction without further characterization. 
 Ethyl 5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)picolinate  
(27d). 
To a solution of aldehyde 22d (1.54 g, 6.2 mmol) in anhydrous Et2O was added 5,5-
dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 24d (932 mg, 3.09 mmol), 2 N HCl in Et2O 
solution (0.3 mL, 0.62 mmol) and the mixture was stirred at room temperature for 24 hours. 
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TLC showed the disappearance of the starting material and formation of one major non-polar 
spot (hexane/EtOAc). The reaction solution was washed with 5% NaHCO3 solution and 
extracted with H2O and dried over Na2SO4. After evaporation of solvent, the residue 25d was 
used directly in the next step without further characterization. TLC Rf = 0.9 (hexane/EtOAc 
1:1) 
To a solution of 2,6-diaminopyrimidin-4(3H)-one 26d (384 mg, 3.04 mmol) and 
sodium acetate (454 mg, 5.53 mmol) in water (5 mL) and methanol (5 mL) was added 
α-bromo aldehyde 25d (830 mg, 2.8 mmol). The reaction mixture was stirred at 45 °C 
for 4 hours. TLC showed the disappearance of starting materials and the formation of one 
major pink spot (CHCl3/MeOH). After evaporation of solvent, CH3OH was added followed by 
silica gel and solvent was evaporated to afford a plug. The plug was loaded onto a silica 
gel column and eluted initially with CHCl3 followed by gradual increase of 10% MeOH in 
CHCl3. Fractions with the required Rf were pooled and evaporated to afford 27d (740 mg, 
20% over two steps) as a light pink sticky solid. TLC Rf = 0.3 (CHCl3/MeOH, 10:1); 
1H NMR 
(400 MHz, DMSO-d6) δ 10.67 (s, 1H, NH), 10.12 (s, 1H, NH), 8.55 (s, 1H, Ar), 7.97 (d, J = 
8.1 Hz, 1H, Ar), 7.82 (d, J = 8.2 Hz, 1H, Ar), 6.39 (s, 1H, , Ar), 6.00 (s, 2H, 2-NH2), 4.48 (q, J 
= 7.2 Hz, 2H, CH2), 2.69 (t, J = 7.7 Hz, 2H, CH2), 2.58 (t, J = 7.4 Hz, 2H, CH2), 1.94 (d, J = 
7.5 Hz, 2H, CH2), 1.36 (t, J = 7.1 Hz, 3H, CH3). The intermediate 27d was used for the next 





To 27d (740 mg, 2.26 mmol), was added 1 N NaOH (2 mL) and the resulting mixture was 
stirred at rt for 1 h. TLC indicated the disappearance of starting material and the formation of 
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one major spot at the origin. The solution was cooled in an ice bath, and the pH was adjusted 
5 using 1 N HCl. The resulting suspension was chilled in a dry ice/acetone bath and thawed to 
4 °C overnight in a refrigerator. The precipitate was filtered, washed with cold water, and dried 
in a desiccator under reduced pressure using P2O5 to yield 28d (670 mg, 94%) as a brown 
semisolid. TLC Rf = 0.3 (CHCl3/MeOH, 10:1 in a drop of CH3COOH); 
1H NMR (400 MHz, 
DMSO-d6) δ 10.67 (s, 1H, NH), 10.13 (s, 1H, NH), 8.56 (d, J = 2.2 Hz, 1H, Ar), 7.97 (d, J = 
8.0 Hz, 1H, Ar), 7.84 (dd, J = 8.1, 2.1 Hz, 1H, Ar), 6.37 (d, J = 2.1 Hz, 1H, Ar), 6.02 (s, 2H, 
2NH2), 2.70 (t, J = 7.6 Hz, 2H, CH2), 2.59 (t, J = 7.5 Hz, 2H, CH2), 1.96 (p, J = 7.6 Hz, 2H, 
CH2). Anal. Calcd for C15H15N5O3 · 0.89 H2O: C, 54.68; H, 5.13; N, 21.25. Found: C, 54.80; 
H, 5.27; N, 20.98.   
Diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)picolinoyl)-L-glutamate (29d). 
A mixture of 28d (0.67 g, 2.14 mmol), N-methylmorpholine (0.28 mL, 2.57 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (0.45 g, 2.57 mmol) in anhydrous DMF in a round bottomed 
flask, was stirred for 1.5 h, at room temperature. Subsequently, N-methylmorpholine (0.28 mL, 
2.57 mmol) and L-glutamic acid diethylester hydrochloride (0.65 g, 3.21 mmol) was added to 
the mixture and stirred at room temperature overnight until disappearance of the starting 
material and a new major non-polar spot was observed on TLC (hexane/EtOAc). After 
evaporation of the solvent in vacuo, MeOH was added followed by silica gel and the solvent 
was evaporated by further drying. The resulting plug was loaded on to a silica gel column and 
eluted with hexanes followed by gradual increase of EtOAc to 50% EtOAc in hexanes. 
Fractions with the desired Rf (TLC) were pooled and evaporated to afford 29d (0.7 g, 65%) as 
a yellow syrup. TLC Rf = 0.45 (CHCl3/MeOH, 10:1); 
1H NMR (400 MHz, DMSO-d6) δ 10.67 
(s, 1H, NH), 10.14 (s, 1H, NH), 8.93 (d, J = 8.2 Hz, 1H, NH), 8.53 (d, J = 2.0 Hz, 1H, Ar), 7.94 
(d, J = 8.0 Hz, 1H, Ar), 7.84 (dd, J = 8.0, 2.2 Hz, 1H, Ar), 6.39 (d, J = 2.0 Hz, 1H, Ar), 6.01 (s, 
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2H, 2NH2), 4.53 (ddd, J = 9.5, 8.0, 5.0 Hz, 1H, CH), 4.12 (qd, J = 7.1, 1.8 Hz, 2H, CH2), 4.01 
(q, J = 7.1 Hz, 2H, CH2), 2.71 (t, J = 7.6 Hz, 2H, CH2), 2.60 (t, J = 7.4 Hz, 2H, CH2), 2.43 – 
2.32 (m, 2H, CH2), 2.23 – 2.03 (m, 2H, CH2), 1.97 (q, J = 7.6 Hz, 2H, CH2), 1.17 (t, 6H, CH3). 
The intermediate 29d was used for the next reaction without further characterization. 
(5-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)picolinoyl)-
L-glutamic acid (14c). 
Compound 14c was prepared using the similar procedure to 28d, from 29d (0.7 g, 1.4 mmol) 
to give 14c (485 mg, 78%) as a brown powder. mp: 241.5 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 10.65 (s, 1H, NH), 10.11 (s, 1H, NH), 8.97 (d, J = 7.8 Hz, 1H, NH), 8.54 (d, J = 2.0 Hz, 1H, 
Ar), 7.91 (d, J = 8.1 Hz, 1H, Ar), 7.74 (dd, J = 8.3, 2.1 Hz, 1H, Ar), 6.42 (d, J = 2.2 Hz, 1H, 
Ar), 6.01 (s, 2H, 2-NH2), 4.54 (m, 1H, CH), 2.78 (t, J = 7.6 Hz, 2H, CH2), 2.57 (t, J = 7.1 Hz, 
2H, CH2), 2.45 – 2.37 (m, 2H, CH2), 2.28 – 2.13 (m, 2H, CH2), 2.05 (q, J = 7.6 Hz, 2H, CH2). 
Anal. Calcd for C20H22N6O6 · 1.7177 H2O: C, 50.75; H, 5.42; N, 17.54. Found: C, 50.79; H, 
5.37; N, 17.61.   
 Diethyl (5-bromopicolinoyl)-L-glutamate (30d). 
To a solution of 5-bromopicolinic acid 20d (4 g, 19.8 mmol) in anhydrous DMF (20 mL) was 
added N-methylmopholine (2.61 mL, 23.76 mmol) and 2-chloro-4,6- dimethoxy-1,3,5-triazine 
(4.17 g, 23.76 mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture was added N-methylmopholine (2.61 mL, 23.76 mmol) and L-glutamic acid diethyl 
ester hydrochloride (6.04 g, 29.7 mmol). The reaction mixture was stirred for an additional 4 
h at room temperature. After evaporation of the solvent in vacuo, MeOH was added followed 
by silica gel and the solvent was evaporated by further drying. The resulting plug was loaded 
on to a silica gel column and eluted with hexanes followed by gradual increase of EtOAc to 
30% EtOAc in hexanes. Fractions with the desired Rf (TLC) were pooled and evaporated to 
afford glutamate ester 30d (6.2 g, 80%) as a colorless syrup. TLC Rf = 0.56 (Hexane: EtOAc, 
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3:1) 1H NMR (400 MHz, Chloroform-d) δ 8.67 (d, J = 4.4 Hz, 1H, Ar), 8.42 (d, J = 8.3 Hz, 
1H, NH), 8.08 (d, J = 8.4 Hz, 1H, Ar), 8.04 – 7.97 (m, 1H, Ar), 4.82 (td, J = 8.1, 4.5 Hz, 1H, 
CH), 4.33 – 4.20 (m, 2H, CH2), 4.14 (p, J = 7.1 Hz, 2H, CH2), 2.52 – 2.33 (m, 2H, CH2), 2.20 
(m, 2H, CH2), 1.33 (t, J = 8.7, 5.5 Hz, 3H, CH3), 1.26 (t, J = 7.1, 6.4 Hz, 3H, CH3). Mass 
calculated for C15H19BrN2O5 [M + Na]
+, 409.04 Found 409.3.  The intermediate 30d was used 
for the next reaction without further characterization. 
Diethyl (6-bromonicotinoyl)-L-glutamate (47d). 
Compound 47d was prepared using the similar procedure to 30d, from 6-bromonicotinic acid 
46d (3 g, 14.85 mmol), N-methylmopholine (1.96 mL, 17.82 mmol), 2-chloro-4,6- dimethoxy-
1,3,5-triazine (3.13 g, 17.82 mmol) and L-glutamic acid diethyl ester hydrochloride (4.53 g, 
22.28 mmol) to give 47d (4.79 g, 83%) as a clear oil. TLC Rf = 0.52 (Hexane: EtOAc, 3:1) 
1H 
NMR (400 MHz, Chloroform-d) δ 9.01 – 8.96 (d, J = 9.3 Hz, 1H, NH), 8.10 (dd, J = 8.1, 2.3 
Hz, 1H, Ar), 7.47 – 7.44 (d, J = 2.1 Hz, 1H, Ar), 7.43 (d, J = 8.1 Hz, 1H, Ar), 4.77 (td, J = 7.7, 
4.7 Hz, 1H, CH), 4.26 (qd, J = 7.2, 1.9 Hz, 2H, CH2), 4.14 (dtt, J = 9.3, 2.3 Hz, 2H, CH2), 3.73 
(s, 2H, CH2), 2.37 – 2.12 (m, 2H, CH2), 1.32 (t, J = 7.1 Hz, 3H, CH3), 1.25 (t, J = 7.2 Hz, 3H, 
CH3). Mass calculated for C15H19BrN2O5 [M + Na]
+, 409.04 Found 409.2. The intermediate 
47d was used for the next reaction without further characterization. 
Diethyl (5-(4-hydroxybut-1-yn-1-yl)picolinoyl)-L-glutamate (31d). 
Compound 31d (2.35 g, 60%) was prepared using similar procedure to 23d, from diethyl (5-
bromopicolinoyl)-L-glutamate, 30d (4 g, 10.33 mmol) in anhydrous acetonitrile was added 
palladium chloride (73.27 mg, 0.41 mmol), triphenylphosphine (108 mg, 0.41 mmol), copper 
iodide (315 mg, 1.65 mmol), triethylamine (14.4 mL, 103.3 mmol), and but-3-yn-1-ol (0.94 
mL, 12.4 mmol). TLC Rf = 0.48 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 
8.68 (s, 1H, Ar), 8.55 (d, J = 8.5 Hz, 1H, NH), 8.12 (d, J = 8.0 Hz, 1H, Ar), 7.86 – 7.78 (m, 
1H, Ar), 4.83 (dt, J = 8.2, 4.2 Hz, 1H, CH), 4.28 (q, J = 7.4, 2H, CH2), 4.12 (q, J = 7.0 Hz, 2H, 
 177 
CH2), 3.65 (dd, J = 6.4, 5.5 Hz, 2H, CH2), 2.55 – 2.53 (m, 2H, CH2), 2.52 – 2.32 (m, 4H, CH2), 
1.33 (t, J = 7.2 Hz, 3H, CH3), 1.26 (t, J = 7.1 Hz, 3H, CH3). The intermediate 31d was used for 
the next reaction without further characterization. 
Diethyl (5-(6-hydroxyhex-1-yn-1-yl)picolinoyl)-L-glutamate (32d). 
Compound 32d (2.82 g, 70%) was prepared using similar procedure to 23d, from diethyl (5-
bromopicolinoyl)-L-glutamate, 30d (4 g, 10.33 mmol) in anhydrous acetonitrile was added 
palladium chloride (73.27 mg, 0.41 mmol), triphenylphosphine (108 mg, 0.41 mmol), copper 
iodide (315 mg, 1.65 mmol), triethylamine (14.4 mL, 103.3 mmol), and hex-5-yn-1-ol (1.37 
mL, 12.4 mmol). TLC Rf = 0.49 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 
8.58 (s, 1H, Ar), 8.51 (d, J = 8.5 Hz, 1H, NH), 8.11 (d, J = 8.0 Hz, 1H, Ar), 7.86 – 7.81 (m, 
1H, Ar), 4.84 (dt, J = 8.2, 4.2 Hz, 1H, CH), 4.26 (q, J = 7.2 Hz, 2H, CH2), 4.12 (q, J = 7.0 Hz, 
2H, CH2), 3.75 (m, 2H, CH2), 2.57 – 2.52 (m, 2H, CH2), 2.52 – 2.32 (m, 4H, CH2), 1.77 (t, J = 
3.2 Hz, 4H, CH2), 1.33 (t, J = 7.1 Hz, 3H, CH3), 1.27 (t, J = 7.1 Hz, 3H, CH3). The intermediate 
32d was used for the next reaction without further characterization. 
Diethyl (5-(7-hydroxyhept-1-yn-1-yl)picolinoyl)-L-glutamate (33d). 
Compound 33d (2.9 g, 67%) was prepared using similar procedure to 23d, from diethyl (5-
bromopicolinoyl)-L-glutamate, 30d (4 g, 10.33 mmol) in anhydrous acetonitrile was added 
palladium chloride (73.27 mg, 0.41 mmol), triphenylphosphine (108 mg, 0.41 mmol), copper 
iodide (315 mg, 1.65 mmol), triethylamine (14.4 mL, 103.3 mmol), and hept-6-yn-1-ol (1.56 
mL, 12.4 mmol). TLC Rf = 0.53 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 
8.61 (s, 1H, Ar), 8.53 (d, J = 8.3 Hz, 1H, NH), 8.13 (d, J = 7.8 Hz, 1H, Ar), 7.85 (m, 1H, Ar), 
4.81 (m, 1H, CH), 4.21 (q, J = 6.9 Hz, 2H, CH2), 4.14 (q, J = 7.1 Hz, 2H, CH2), 3.69 (dd, J = 
6.4, 5.5 Hz, 2H, CH2), 2.55 (m, 2H, CH2), 2.51 – 2.35 (m, 4H, CH2), 1.74 (m, 4H, CH2), 1.52 
(m, 2H, CH2), 1.35 (t, J = 7.1 Hz, 3H, CH3), 1.21 (t, J = 7.1 Hz, 3H, CH3).  The intermediate 
33d was used for the next reaction without further characterization. 
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Diethyl (6-(5-hydroxypent-1-yn-1-yl)nicotinoyl)-L-glutamate (48d). 
Compound 48d (2.23 g, 55%) was prepared using similar procedure to 23d, from diethyl (6-
bromonicotinoyl)-L-glutamate, 47d (4 g, 10.33 mmol) in anhydrous acetonitrile was added 
palladium chloride (73.27 mg, 0.41 mmol), triphenylphosphine (108 mg, 0.41 mmol), copper 
iodide (315 mg, 1.65 mmol), triethylamine (14.4 mL, 103.3 mmol), and hex-5-yn-1-ol (1.17 
mL, 12.4 mmol). TLC Rf = 0.44 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 
8.99 (d, J = 8.6 Hz, 1H, NH), 8.12 (dd, J = 8.0, 1.8 Hz, 1H, Ar), 7.49 – 7.43 (d, J = 2.1 Hz, 1H, 
Ar), 7.39 (d, J = 8.3 Hz, 1H, Ar), 4.75 (m, 1H, CH), 4.25 (q, J = 7.2 Hz, 2H, CH2), 4.11 (q, J = 
9.3 Hz, 2H, CH2), 3.75 (t, 2H, CH2), 2.57 – 2.43 (m, 4H, CH2), 2.36 – 2.14 (m, 2H, CH2), 1.81 
– 1.74 (m, 2H, CH2), 1.32 (t, J = 7.1 Hz, 3H, CH3), 1.28 – 1.22 (m, 3H, CH3). The intermediate 
48d was used for the next reaction without further characterization. 
Diethyl (6-(6-hydroxyhex-1-yn-1-yl)nicotinoyl)-L-glutamate (49d). 
Compound 49d (2.65 g, 63%) was prepared using similar procedure to 23d, from diethyl (6-
bromonicotinoyl)-L-glutamate, 47d (4 g, 10.33 mmol) in anhydrous acetonitrile was added 
palladium chloride (73.27 mg, 0.41 mmol), triphenylphosphine (108 mg, 0.41 mmol), copper 
iodide (315 mg, 1.65 mmol), triethylamine (14.4 mL, 103.3 mmol), and hex-5-yn-1-ol (1.37 
mL, 12.4 mmol). TLC Rf = 0.47 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 
9.01 (d, J = 9.1 Hz, 1H, NH), 8.10 (dd, J = 8.2, 2.1 Hz, 1H, Ar), 7.45 (d, J = 2.4 Hz, 1H, Ar), 
7.41 (d, J = 7.9 Hz, 1H, Ar), 4.73 (m, J = 7.9 Hz, 1H, CH), 4.23 (q, J = 7.7 Hz, 2H, CH2), 4.13 
(q, J = 8.8 Hz, 2H, CH2), 3.69 (t, 2H, CH2), 2.59 – 2.47 (m, 4H, CH2), 2.28 (m, 2H, CH2), 1.84 
– 1.77 (m, 2H, CH2), 1.56 – 1.47 (m, 2H, CH2), 1.33 (t, J = 7.1 Hz, 3H, CH3), 1.25 (t, 3H, CH3). 
Mass calculated for C21H28N2O6 [M + H]
+, 405.2 Found 405.4. The intermediate 49d was used 
for the next reaction without further characterization. 
Diethyl (6-(7-hydroxyhept-1-yn-1-yl)nicotinoyl)-L-glutamate (50d). 
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Compound 50d (2.53 g, 58%) was prepared using similar procedure to 23d, from diethyl (6-
bromonicotinoyl)-L-glutamate, 47d (4 g, 10.33 mmol) in anhydrous acetonitrile was added 
palladium chloride (73.27 mg, 0.41 mmol), triphenylphosphine (108 mg, 0.41 mmol), copper 
iodide (315 mg, 1.65 mmol), triethylamine (14.4 mL, 103.3 mmol), and hept-6-yn-1-ol (1.56 
mL, 12.4 mmol). TLC Rf = 0.51 (Hexane: EtOAc, 3:1); 
1H NMR (400 MHz, Chloroform-d) δ 
9.00 – 8.95 (d, J = 9.0 Hz, 1H, NH), 8.11 (dd, J = 8.1, 2.4 Hz, 1H, Ar), 7.46 – 7.43 (d, J = 2.1 
Hz, 1H, Ar), 7.40 (d, J = 8.2 Hz, 1H, Ar), 4.75 (td, J = 8.1, 4.4 Hz, 1H, CH), 4.26 (q, J = 7.9, 
Hz, 2H, CH2), 4.14 (q, J = 8.8 Hz, 2H, CH2), 3.74 (t, 2H, CH2), 2.57 – 2.43 (m, 4H, CH2), 2.29 
(m, 2H, CH2), 1.81 – 1.74 (m, 2H, CH2), 1.59 – 1.45 (m, 4H, CH2), 1.32 (t, J = 7.1 Hz, 3H, 
CH3), 1.28 – 1.22 (m, 3H, CH3). The intermediate 50d was used for the next reaction without 
further characterization. 
Methyl 5-(3-hydroxyprop-1-yn-1-yl)picolinate (71d). 
Compound 71d (1.18 g, 66%) was prepared using similar procedure to 23d, from methyl 5-
bromopicolinate, 70d (2 g, 9.26 mmol) in anhydrous acetonitrile was added palladium chloride 
(65.66 mg, 0.37 mmol), triphenylphosphine (97.13 mg, 0.37 mmol), copper iodide (282 mg, 
1.48 mmol), triethylamine (12.9 mL, 92.58 mmol), and but-3-yn-1-ol (0.64 mL, 11.11 mmol). 
TLC Rf = 0.51 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.73 (dd, J = 2.2, 
0.8 Hz, 1H, Ar), 8.09 (dd, J = 8.1, 0.9 Hz, 1H, Ar), 7.83 (dd, J = 8.1, 2.1 Hz, 1H, Ar), 4.03 (s, 
3H, OCH3), 3.97 (t, J = 7.1 Hz, 1H, OH), 3.77(t, J = 5.9 Hz, 2H, CH2). The intermediate 71d 
was used for the next reaction without further characterization. 
Methyl 5-(4-hydroxybut-1-yn-1-yl)picolinate (72d). 
Compound 72d (1.34 g, 70%) was prepared using similar procedure to 23d, from methyl 5-
bromopicolinate, 70d (2 g, 9.26 mmol) in anhydrous acetonitrile was added palladium chloride 
(65.66 mg, 0.37 mmol), triphenylphosphine (97.13 mg, 0.37 mmol), copper iodide (282 mg, 
1.48 mmol), triethylamine (12.9 mL, 92.58 mmol), and propargyl alcohol (0.84 mL, 11.11 
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mmol). TLC Rf = 0.49 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.79 (dd, 
J = 2.1, 0.9 Hz, 1H, Ar), 8.13 (dd, J = 8.3, 0.8 Hz, 1H, Ar), 7.89 (dd, J = 8.2, 2.4 Hz, 1H, Ar), 
4.11 (q, J = 7.0 Hz, 1H, OH), 4.01 (s, 3H, OCH3), 3.85 (q, J = 6.9 Hz, 2H, CH2), 2.68 (t, J = 
7.0 Hz, 2H, CH2). The intermediate 72d was used for the next reaction without further 
characterization. 
Methyl 5-(5-hydroxypent-1-yn-1-yl)picolinate (73d). 
Compound 73d (1.28 g, 63%) was prepared using similar procedure to 23d, from methyl 5-
bromopicolinate, 70d (2 g, 9.26 mmol) in anhydrous acetonitrile was added palladium chloride 
(65.66 mg, 0.37 mmol), triphenylphosphine (97.13 mg, 0.37 mmol), copper iodide (282 mg, 
1.48 mmol), triethylamine (12.9 mL, 92.58 mmol), and pent-4-yn-1-ol (1.03 mL, 11.11 mmol). 
TLC Rf = 0.54 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.76 (dd, J = 2.4, 
0.7 Hz, 1H, Ar), 8.13 (dd, J = 8.2, 0.8 Hz, 1H, Ar), 7.81 (dd, J = 8.2, 1.8 Hz, 1H, Ar), 4.14 (q, 
J = 6.8 Hz, 1H, OH), 4.03 (s, 3H, OCH3), 3.87 (q, J = 7.0 Hz, 2H, CH2), 2.63 (t, J = 7.0 Hz, 
2H, CH2), 1.92 (tt, J = 7.0, 6.1 Hz, 2H, CH2). Mass calculated for C12H13NO3 [M + H]
+, 220.09 
Found 220.2. The intermediate 73d was used for the next reaction without further 
characterization. 
Diethyl (5-(4-hydroxybutyl)picolinoyl)-L-glutamate (34d). 
Compound 34d (3.35 g, 87%) was prepared using similar catalytic hydrogenation procedure 
to 22d (condition B) from 31d (3.8 g, 10.10 mmol), 10% palladium on activated carbon (4 g) 
in a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.46 (Hexane: EtOAc, 
3:1) 1H NMR (400 MHz, Chloroform-d) δ 8.58 (d, J = 1.9 Hz, 1H, Ar), 8.53 (d, J = 8.5 Hz, 
1H, NH), 8.12 (d, J = 7.8 Hz, 1H, Ar), 7.68 (dd, J = 7.9, 1.9 Hz, 1H, Ar), 4.84 (td, J = 8.3, 4.7 
Hz, 1H, CH), 4.25 (qd, J = 7.1, 1.6 Hz, 2H, CH2), 4.11 (q, J = 7.2 Hz, 2H, CH2), 3.69 (t, J = 
6.2 Hz, 2H, CH2), 2.74 (t, J = 7.6 Hz, 2H, CH2), 2.59 – 2.29 (m, 4H, CH2), 1.75 (q, J = 7.4 Hz, 
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2H, CH2), 1.68 – 1.58 (m, 2H, CH2), 1.32 (t, J = 7.1 Hz, 3H, CH3), 1.23 (t, J = 7.1 Hz, 3H, 
CH3). The intermediate 34d was used for the next reaction without further characterization. 
Diethyl (5-(6-hydroxyhexyl)picolinoyl)-L-glutamate (35d). 
Compound 35d (3.8 g, 90%) was prepared using similar catalytic hydrogenation procedure to 
22d (condition B) from 32d (4.2 g, 10.38 mmol), 10% palladium on activated carbon (4 g) in 
a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.47 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.52 (d, J = 8.5 Hz, 1H, NH), 8.43 (d, J = 1.8 Hz, 1H, 
Ar), 8.10 (d, J = 7.7 Hz, 1H, Ar), 7.67 (dd, J = 7.8, 2.1 Hz, 1H, ar), 4.83 (m, 1H, CH), 4.28 (q, 
J = 7.2, 2H, CH2), 4.11 (q, J = 7.4 Hz, 2H, CH2), 3.64 (t, J = 5.9 Hz, 2H, CH2), 2.69 (t, J = 7.2 
Hz, 2H, CH2), 2.42 (m, 4H, CH2), 1.73 (m, 4H, CH2), 1.69 – 1.61 (m, 4H, CH2), 1.33 (t, J = 
7.1 Hz, 3H, CH3), 1.25 (t, J = 7.1 Hz, 3H, CH3). The intermediate 35d was used for the next 
reaction without further characterization. 
Diethyl (5-(7-hydroxyheptyl)picolinoyl)-L-glutamate (36d). 
Compound 36d (4.23 g, 93%) was prepared using similar catalytic hydrogenation procedure 
to 22d (condition B) from 33d (4.5 g, 10.75 mmol), 10% palladium on activated carbon (2 g) 
in a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.50 (Hexane: EtOAc, 
3:1) 1H NMR (400 MHz, Chloroform-d) δ 8.57 (d, J = 1.9 Hz, 1H, Ar), 8.55 (d, J = 8.5 Hz, 
1H, NH), 8.16 (d, J = 7.8 Hz, 1H, Ar), 7.65 (dd, J = 7.9, 1.9 Hz, 1H, Ar), 4.85 (td, J = 8.3, 4.7 
Hz, 1H, CH), 4.25 (qd, J = 7.1, 1.6 Hz, 2H, CH2), 4.11 (q, J = 7.2 Hz, 2H, CH2), 3.69 (t, J = 
6.2 Hz, 2H, CH2), 2.74 (t, J = 7.6 Hz, 2H, CH2), 2.59 – 2.29 (m, 4H, CH2), 1.76-1.72 (m, 4H, 
CH2), 1.69 – 1.61 (m, 4H, CH2), 1.57 (m, 2H, CH2), 1.33 (t, J = 7.1 Hz, 3H, CH3), 1.25 (t, J = 
7.1 Hz, 3H, CH3). Mass calculated for C22H30N2O6 [M + H]
+, 445.23 Found 445.4. The 
intermediate 36d was used for the next reaction without further characterization. 
Diethyl (6-(5-hydroxypentyl)nicotinoyl)-L-glutamate (51d). 
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Compound 51d (3.83 g, 88%) was prepared using similar catalytic hydrogenation procedure 
to 22d (condition B) from 48d (4.3 g, 11.01 mmol), 10% palladium on activated carbon (2 g) 
in a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.41 (Hexane: EtOAc, 
3:1) 1H NMR (400 MHz, Chloroform-d) δ 8.97 (d, J = 9.1 Hz, 1H, NH), 8.12 (dd, J = 8.0, 2.0 
Hz, 1H, Ar), 7.53 – 7.48 (d, J = 2.1 Hz, 1H, Ar), 7.44 (d, J = 8.3 Hz, 1H, Ar), 4.75 (td, J = 7.9, 
4.6 Hz, 1H, CH), 4.25 (q, J = 7.2 Hz, 2H, CH2), 4.12 (q, J = 9.3 Hz, 2H, CH2), 3.76 (t, 2H, 
CH2), 2.72 (m, 2H, CH2) 2.59 – 2.46 (m, 4H, CH2), 2.39 – 2.18 (m, 2H, CH2), 1.81 – 1.74 (m, 
2H, CH2), 1.68 – 1.55 (m, 2H, CH2), 1.34 (t, J = 7.1 Hz, 3H, CH3), 1.25 – 1.20 (m, 3H, CH3). 
The intermediate 51d was used for the next reaction without further characterization. 
Diethyl (6-(6-hydroxyhexyl)nicotinoyl)-L-glutamate (52d). 
Compound 52d (395 g, 95%) was prepared using similar catalytic hydrogenation procedure to 
22d (condition B) from 49d (4.1 g, 10.14 mmol), 10% palladium on activated carbon (2 g) in 
a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.46 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.91 (d, J = 8.9 Hz, 1H, NH), 8.07 (dd, J = 8.4, 2.1 Hz, 
1H, Ar), 7.54 - 7.48 (d, J = 2.2 Hz, 1H, Ar), 7.37 (d, J = 7.8 Hz, 1H, Ar), 4.59 (m, 1H, CH), 
4.27 (q, J = 7.6 Hz, 2H, CH2), 4.14 (q, J = 9.0 Hz, 2H, CH2), 3.71 (t, 2H, CH2), 2.69 (m, 2H, 
CH2), 2.55 – 2.44 (m, 4H, CH2), 2.39 – 2.20 (m, 2H, CH2), 1.77 – 1.73 (m, 2H, CH2), 1.69 – 
1.51 (m, 4H, CH2), 1.33 (t, J = 7.1 Hz, 3H, CH3), 1.28 (m, 3H, CH3). Mass calculated for 
C21H32N2O6 [M + H]
+, 409.23 Found 409.4. The intermediate 52d was used for the next 
reaction without further characterization. 
 
 
Diethyl (6-(7-hydroxyheptyl)nicotinoyl)-L-glutamate (53d). 
Compound 53d (3.42 g, 87%) was prepared using similar catalytic hydrogenation procedure 
to 22d (condition B) from 50d (3.9 g, 9.32 mmol), 10% palladium on activated carbon (2 g) in 
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a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.48 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.98 (d, J = 9.1 Hz, 1H, NH), 8.14 (dd, J = 7.9, 2.2 Hz, 
1H, Ar), 7.57 - 7.51 (d, J = 2.1 Hz, 1H, Ar), 7.45 (d, J = 8.4 Hz, 1H, Ar), 4.68 (m, 1H, CH), 
4.29 (q, J = 7.3 Hz, 2H, CH2), 4.12 (q, J = 8.8 Hz, 2H, CH2), 3.64 (t, 2H, CH2), 2.71 (m, 2H, 
CH2) 2.53 – 2.44 (m, 4H, CH2), 2.40 – 2.21 (m, 2H, CH2), 1.78 – 1.71 (m, 2H, CH2), 1.64 – 
1.52 (m, 4H, CH2), 1.49 (m, 2H, CH2), 1.31 (t, J = 7.1 Hz, 3H, CH3), 1.26 – 1.19 (m, 3H, CH3). 
The intermediate 53d was used for the next reaction without further characterization. 
Methyl 5-(3-hydroxypropyl)picolinate (74d). 
Compound 74d (2.25 g, 88%) was prepared using similar catalytic hydrogenation procedure 
to 22d (condition B) from 71d (2.5 g, 13.08 mmol), 10% palladium on activated carbon (2 g) 
in a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.51 (Hexane: EtOAc, 
3:1) 1H NMR (400 MHz, Chloroform-d) δ 8.62 (d, J = 2.2 Hz, 1H, Ar), 8.08 (dd, J = 8.1, 0.7 
Hz, 1H, Ar), 7.69 (dd, J = 8.0, 1.1 Hz, 1H, Ar), 4.09 (s, 3H, OCH3), 4.49 (q, J = 7.1 Hz, 2H, 
CH2), 2.88 – 2.77 (m, 2H, CH2), 1.98 – 1.86 (m, 2H, CH2). Mass calculated for C10H14NO3 [M 
+ H]+, 196.10 Found 196.2. The intermediate 74d was used for the next reaction without further 
characterization. 
Methyl 5-(4-hydroxybutyl)picolinate (75d). 
Compound 75d (2.49 g, 81%) was prepared using similar catalytic hydrogenation procedure 
to 22d (condition B) from 72d (3 g, 14.62 mmol), 10% palladium on activated carbon (2 g) in 
a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.47 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.58 (m, 1H, Ar), 8.07 – 8.01 (m, 1H, Ar), 7.72 – 7.60 
(m, 1H, Ar), 4.02 (s, 3H, OCH3), 3.69 – 3.63 (m, 2H, CH2), 2.76 – 2.68 (m, 2H, CH2), 1.79 – 
1.70 (m, 2H, CH2), 1.64 (m, 2H, CH2). Mass calculated for C10H14NO3 [M + H]
+, 196.10 Found 
196.2. The intermediate 75d was used for the next reaction without further characterization. 
Methyl 5-(5-hydroxypentyl)picolinate (76d). 
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Compound 76d (2.51 g, 75%) was prepared using similar catalytic hydrogenation procedure 
to 22d (condition B) from 73d (3.3 g, 15.05 mmol), 10% palladium on activated carbon (2 g) 
in a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.54 (Hexane: EtOAc, 
3:1) 1H NMR (400 MHz, Chloroform-d) δ 8.60 – 8.55 (m, 1H, Ar), 8.10 – 8.04 (m, 1H, Ar), 
7.69 – 7.62 (m, 1H, Ar), 4.01 (s, 3H, OCH3), 3.68 – 3.61 (m, 2H, CH2), 2.76 – 2.67 (m, 2H, 
CH2), 1.76 – 1.66 (m, 2H, CH2), 1.62 (m, 2H, CH2), 1.49 – 1.40 (m, 2H, CH2). The intermediate 
76d was used for the next reaction without further characterization. 
Diethyl (5-(4-oxobutyl)picolinoyl)-L-glutamate (37d). 
Compound 37d (1.62 g, 65%) was prepared using similar DMP oxidation procedure to 22d 
(condition B) from 34d (2.5 g, 6.57 mmol) of DMP (5.57 g, 13.14 mmol) in CH2Cl2 (20 mL). 
TLC Rf = 0.66 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 9.76 (t, J = 7.2 Hz, 
1H, CHO), 8.46 (d, J = 8.5 Hz, 1H, NH), 8.38 (t, J = 2.2 Hz, 1H, Ar), 8.06 (dd, J = 7.9, 4.1 Hz, 
1H, Ar), 7.64 (dt, J = 8.0, 2.3 Hz, 1H, Ar), 4.78 (tt, J = 8.4, 4.1 Hz, 1H, CH), 4.24 – 4.16 (m, 
2H, CH2), 4.08 (q, J = 7.2 Hz, 2H, CH2), 2.70 (t, J = 7.8 Hz, 2H, CH2), 2.49 (td, J = 7.0, 4.4 
Hz, 2H, CH2), 2.44 – 2.26 (m, 4H, CH2), 1.98 – 1.90 (m, 2H, CH2), 1.32 – 1.12 (m, 6H, CH3). 
The intermediate 37d was used for the next reaction without further characterization. 
Diethyl (5-(6-oxohexyl)picolinoyl)-L-glutamate (38d). 
Compound 38d (1.38 g, 68%) was prepared using similar DMP oxidation procedure to 22d 
(condition B) from 35d (2.2 g, 5.39 mmol) of DMP (4.57 g, 10.77 mmol) in CH2Cl2 (20 mL). 
TLC Rf = 0.69 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 9.85 (t, J = 7.1 Hz, 
1H, CHO), 8.56 (d, J = 8.3 Hz, 1H, NH), 8.39 (t, J = 2.3 Hz, 1H, Ar), 8.12 (dd, J = 7.8, 4.2 Hz, 
1H, Ar), 7.77 (dt, J = 7.9, 2.0 Hz, 1H, Ar), 4.81 (tt, J = 8.3, 4.0 Hz, 1H, CH), 4.20 – 4.15 (m, 
2H, CH2), 4.10 (q, J = 7.4 Hz, 2H, CH2), 2.72 (t, J = 7.3 Hz, 2H, CH2), 2.52 (td, J = 6.7, 4.2 
Hz, 2H, CH2), 2.47 – 2.23 (m, 4H, CH2), 2.15 – 2.01 (m, 2H, CH2), 1.95 – 1.87 (m, 4H, CH2), 
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1.33 – 1.14 (m, 6H, CH3). The intermediate 38d was used for the next reaction without further 
characterization. 
Diethyl (5-(7-oxoheptyl)picolinoyl)-L-glutamate (39d). 
Compound 39d (1.19 g, 66%) was prepared using similar DMP oxidation procedure to 22d 
(condition B) from 36d (1.8 g, 4.26 mmol) of DMP (3.61 g, 8.52 mmol) in CH2Cl2 (20 mL). 
TLC Rf = 0.67 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 9.81 (t, J = 6.8 Hz, 
1H, CHO), 8.48 (d, J = 8.1 Hz, 1H, NH), 8.36 (t, J = 2.4 Hz, 1H, Ar), 7.89 (dd, J = 8.0, 3.8 Hz, 
1H, Ar), 7.62 (dt, J = 7.7, 2.1 Hz, 1H, Ar), 4.85 (tt, J = 8.0, 3.8 Hz, 1H, CH), 4.21 – 4.12 (m, 
2H, CH2), 4.07 (q, J = 7.2 Hz, 2H, CH2), 2.70 (t, J = 7.8 Hz, 2H, CH2), 2.48 (td, J = 7.4, 4.4 
Hz, 2H, CH2), 2.47 – 2.23 (m, 4H, CH2), 2.18 – 2.05 (m, 2H, CH2), 1.98 – 1.82 (m, 4H, CH2), 
1.68 (m, 2H, CH2), 1.33 – 1.10 (m, 6H, CH3). Mass calculated for C22H32N2O6 [M + K]
+, 459.2 
Found 459.4. The intermediate 39d was used for the next reaction without further 
characterization. 
Diethyl (6-(5-oxopentyl)nicotinoyl)-L-glutamate (54d). 
Compound 54d (0.99 g, 47%) was prepared using similar DMP oxidation procedure to 22d 
(condition B) from 51d (2.1 g, 5.32 mmol) of DMP (4.52 g, 10.65 mmol) in CH2Cl2 (20 mL). 
TLC Rf = 0.65 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 9.76 (t, J = 7.2 Hz, 
1H, CHO), 9.01 – 8.96 (d, J = 9.1 Hz, 1H, NH), 8.12 (dd, J = 7.8, 2.1 Hz, 1H, Ar), 7.51 (d, J = 
2.4 Hz, 1H, Ar), 7.41 (d, J = 8.2 Hz, 1H, Ar), 4.68 (m, 1H, CH), 4.26 (q, J = 7.2 Hz, 2H, CH2), 
4.13 (q, J = 8.7 Hz, 2H, CH2), 2.86 (t, 2H, CH2), 2.55-2.41 (m, 4H, CH2), 2.35 – 2.19 (m, 2H, 
CH2), 1.78 – 1.71 (m, 2H, CH2), 1.67 – 1.59 (m, 2H, CH2), 1.35 (t, J = 7.1 Hz, 3H, CH3), 1.26 
– 1.21 (m, 3H, CH3). The intermediate 54d was used for the next reaction without further 
characterization. 
Diethyl (6-(6-oxohexyl)nicotinoyl)-L-glutamate (55d). 
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Compound 55d (1.18 g, 53%) was prepared using similar DMP oxidation procedure to 22d 
(condition B) from 52d (2.25 g, 5.51 mmol) of DMP (4.67 g, 11.02 mmol) in CH2Cl2 (20 mL). 
TLC Rf = 0.64 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 9.77 (t, J = 7.1 Hz, 
1H, CHO), 8.98 (s, 1H, NH), 8.07 (dd, J = 8.1, 2.1 Hz, 1H, Ar), 7.32 (d, J = 7.1 Hz, 1H, Ar), 
7.25 (d, J = 8.1 Hz, 1H, Ar), 4.78 (td, J = 7.9, 4.5 Hz, 1H, CH), 4.31 – 4.20 (m, 2H, CH2), 4.18 
– 4.07 (m, 2H, CH2), 2.86 (t, J = 7.7 Hz, 2H, CH2), 2.59 – 2.40 (m, 4H, CH2), 2.37 – 2.11 (m, 
2H, CH2), 1.79 (m, 2H, CH2), 1.73 – 1.64 (m, 2H, CH2), 1.46 – 1.36 (m, 2H, CH2), 1.31 (t, J = 
7.1 Hz, 3H, CH3), 1.27 – 1.20 (m, 3H, CH3). The intermediate 55d was used for the next 
reaction without further characterization. 
Diethyl (6-(7-oxoheptyl)nicotinoyl)-L-glutamate (56d). 
Compound 56d (1.44 g, 60%) was prepared using similar DMP oxidation procedure to 22d 
(condition B) from 53d (2.4 g, 5.68 mmol) of DMP (4.82 g, 11.36mmol) in CH2Cl2 (20 mL). 
TLC Rf = 0.68 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 9.81 (t, J = 7.1 Hz, 
1H, CHO), 8.93 (d, J = 9.1 Hz, 1H, NH), 8.09 (dd, J = 8.1, 2.3 Hz, 1H, Ar), 7.36 (d, J = 7.2 Hz, 
1H, Ar), 7.28 (d, J = 8.3 Hz, 1H, Ar), 4.74 (m, 1H, CH), 4.28 (m, 2H, CH2), 4.20 – 4.11 (m, 
2H, CH2), 2.83 (t, J = 7.5 Hz, 2H, CH2), 2.55 – 2.41 (m, 4H, CH2), 2.39 – 2.14 (m, 2H, CH2), 
1.83 (m, 2H, CH2), 1.75 – 1.68 (m, 2H, CH2), 1.49 – 1.38 (m, 4H, CH2), 1.33 (t, J = 7.1 Hz, 
3H, CH3), 1.26 – 1.22 (t, J = 7.2 Hz, 3H, CH3). The intermediate 56d was used for the next 
reaction without further characterization. 
Diethyl (5-(2-(2-amino-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)picolinoyl)-L-glutamate 
(43d). 
Compound 43d was prepared using the similar procedure to 27d from the aldehyde 
37d (1.62 g, 4.28 mmol) and 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 24d (646 mg, 
2.14 mmol), and 2 N HCl in Et2O solution (0.21 mL, 0.43 mmol). After the workup, the residue 
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40d was used directly in the next step without further characterization. TLC Rf = 0.88 
(hexane/EtOAc 1:1) 
To a solution of 2,6-diaminopyrimidin-4(3H)-one 26d (950 mg, 7.54 mmol) and 
sodium acetate (1.12 g, 13.7 mmol) in water (5 mL) and methanol (5 mL) was added crude 
α-bromo aldehyde 40d (1.96 g). The reaction mixture was stirred at 45 °C for 4 hours to afford 
43d (520 mg, 25% over two steps) as a light pink sticky solid. TLC Rf = 0.31 (CHCl3/MeOH, 
10:1); 1H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H, NH), 10.15 (s, 1H, NH), 8.92 (d, J = 7.9 
Hz, 1H, NH), 8.52 (d, J = 2.2 Hz, 1H, Ar), 7.93 (d, J = 8.0 Hz, 1H, Ar), 7.83 (dd, J = 8.0, 2.2 
Hz, 1H, Ar), 6.35 (d, J = 1.9 Hz, 1H, Ar), 5.97 (s, 2H, 2-NH2), 4.55 (m, J = 8.9, 5.0 Hz, 1H, 
CH), 4.12 (qd, J = 7.0, 1.8 Hz, 2H, CH2), 4.01 (q, J = 7.1 Hz, 2H, CH2), 2.71 (m, 2H, CH2), 
2.60 (s, 2H, CH2), 2.40 – 2.33 (m, 2H, CH2), 2.21 – 2.00 (m, 2H, CH2), 1.22 (t, J = 7.1 Hz, 3H, 




Compound 44d was prepared using the similar procedure to 27d from the aldehyde 
38d (1.38 g, 3.4 mmol) and 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 24d (512.5 mg, 
1.7 mmol), and 2 N HCl in Et2O solution (0.17 mL, 0.34 mmol). After the workup, the residue 
41d was used directly in the next step without further characterization. TLC Rf = 0.90 
(hexane/EtOAc 1:1) 
To a solution of 2,6-diaminopyrimidin-4(3H)-one 26d (728 mg, 5.78 mmol) and 
sodium acetate (862 mg, 10.50 mmol) in water (5 mL) and methanol (5 mL) was added crude 
α-bromo aldehyde 41d (1.65 g). The reaction mixture was stirred at 45 °C for 4 hours to afford 
44d (698 mg, 40% over two steps) as a light pink sticky solid. TLC Rf = 0.33 (CHCl3/MeOH, 
10:1); 1H NMR (400 MHz, DMSO-d6) δ 10.63 (s, 1H, NH), 10.12 (s, 1H, NH), 8.68 (d, J = 8.2 
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Hz, 1H, NH), 8.55 (d, J = 2.4 Hz, 1H, Ar), 7.88 (d, J = 7.9 Hz, 1H, Ar), 7.81 (dd, J = 8.3, 2.2 
Hz, 1H, Ar), 6.27 (d, J = 2.3 Hz, 1H, Ar), 5.93 (s, 2H, 2-NH2), 4.58 (m, J = 8.6, 4.9 Hz, 1H, 
CH), 4.16 (q, J = 7.0 Hz, 2H, CH2), 4.05 (q, J = 7.3 Hz, 2H, CH2), 2.67 (m, 2H, CH2), 2.58 (m, 
2H, CH2), 2.42 – 2.34 (m, 2H, CH2), 2.26 – 2.11 (m, 2H, CH2), 1.68 – 1.56 (m, 4H, CH2), 1.18 
(t, J = 6.8 Hz, 3H, CH3), 1.13 (t, J = 7.3 Hz, 3H, CH3). The intermediate 22d was used for the 
next reaction without further characterization. 
Diethyl (5-(5-(2-amino-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)picolinoyl)-L-
glutamate (45d). 
Compound 45d was prepared using the similar procedure to 27d from the aldehyde 
39d (1.19 g, 2.83 mmol) and 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 24d (427 mg, 
1.41 mmol), and 2 N HCl in Et2O solution (0.14 mL, 0.28 mmol). After the workup, the residue 
42d was used directly in the next step without further characterization. TLC Rf = 0.89 
(hexane/EtOAc 1:1) 
To a solution of 2,6-diaminopyrimidin-4(3H)-one 26d (596 mg, 4.73 mmol) and 
sodium acetate (705 mg, 8.59 mmol) in water (5 mL) and methanol (5 mL) was added crude 
α-bromo aldehyde 42d (1.41 g). The reaction mixture was stirred at 45 °C for 4 hours to afford 
45d (489 mg, 33% over two steps) as a light pink sticky solid. TLC Rf = 0.33 (CHCl3/MeOH, 
10:1); 1H NMR (400 MHz, DMSO-d6) δ 10.61 (s, 1H, NH), 10.11 (s, 1H, NH), 8.77 (d, J = 8.0 
Hz, 1H, NH), 8.53 (d, J = 2.1 Hz, 1H, Ar), 7.92 (d, J = 8.4 Hz, 1H, Ar), 7.86 – 7.81 (m, 1H, 
Ar), 6.33 (d, J = 1.7 Hz, 1H, Ar), 5.96 (s, 2H, 2-NH2), 4.52 (m, J = 8.1, 4.7 Hz, 1H, CH), 4.12 
(q, J = 7.2, 2H, CH2), 4.01 (q, J = 7.3 Hz, 2H, CH2), 2.69 (m, 2H, CH2), 2.56 (m, 2H, CH2), 
2.38 (m, 2H, CH2), 2.13 (m, 2H, CH2), 1.62 (m, 4H, CH2), 1.19 (t, J = 7.0 Hz, 3H, CH3), 1.14 





Compound 60d was prepared using the similar procedure to 27d from the aldehyde 
54d (0.99 g, 2.90 mmol) and 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 24d (368 mg, 
1.22 mmol), and 2 N HCl in Et2O solution (0.12 mL, 0.24 mmol). After the workup, the residue 
57d was used directly in the next step without further characterization. TLC Rf = 0.90 
(hexane/EtOAc 1:1) 
To a solution of 2,6-diaminopyrimidin-4(3H)-one 26d (545 mg, 4.32 mmol) and 
sodium acetate (645 mg, 7.86 mmol) in water (5 mL) and methanol (5 mL) was added crude 
α-bromo aldehyde 57d (1.18 g). The reaction mixture was stirred at 45 °C for 4 hours to afford 
60d (252 mg, 20% over two steps) as a light brown sticky solid. TLC Rf = 0.34 (CHCl3/MeOH, 
10:1); 1H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H, NH), 10.07 (s, 1H, NH), 8.86 (d, J = 8.3 
Hz, 1H, NH), 8.12 (dd, J = 7.7, 2.3 Hz, 1H, Ar), 7.32 (d, J = 7.2 Hz, 1H, Ar), 7.25 (d, J = 7.8 
Hz, 1H, Ar), 6.37 (d, J = 2.3 Hz, 1H, Ar), 5.56 (s, 2H, 2-NH2), 4.71 (td, J = 7.9, 5.0 Hz, 1H, 
CH), 4.31 – 4.20 (m, 2H, CH2), 4.18 – 4.07 (m, 2H, CH2), 2.72 (m, 2H, CH2), 2.58 (m, 2H, 
CH2), 2.37 (m, 2H, CH2), 1.64 – 1.52 (m, 4H, CH2), 1.31 (t, J = 7.1 Hz, 3H, CH3), 1.26 (m, 3H, 




Compound 61d was prepared using the similar procedure to 27d from the aldehyde 
55d (1.18 g, 2.90 mmol) and 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 24d (438 mg, 
1.45 mmol), and 2 N HCl in Et2O solution (0.15 mL, 0.29 mmol). After the workup, the residue 
58d was used directly in the next step without further characterization. TLC Rf = 0.89 
(hexane/EtOAc 1:1) 
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To a solution of 2,6-diaminopyrimidin-4(3H)-one 26d (623 mg, 4.94 mmol) and 
sodium acetate (736 mg, 8.98 mmol) in water (5 mL) and methanol (5 mL) was added crude 
α-bromo aldehyde 58d (1.41 g). The reaction mixture was stirred at 45 °C for 4 hours to afford 
61d (420 mg, 28% over two steps) as a light brown sticky solid. TLC Rf = 0.31 (CHCl3/MeOH, 
10:1); 1H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H, NH), 10.18 (s, 1H, NH), 8.74 (d, J = 8.2 
Hz, 1H, NH), 8.09 (dd, J = 8.1, 2.3 Hz, 1H, Ar), 7.34 (d, J = 7.4 Hz, 1H, Ar), 7.27 (d, J = 7.8 
Hz, 1H, Ar), 6.14 (d, J = 2.1 Hz, 1H, Ar), 5.81 (s, 2H, 2-NH2), 4.56 (td, J = 7.6, 4.7 Hz, 1H, 
CH), 4.27 – 4.18 (m, 2H, CH2), 4.18 – 4.09 (m, 2H, CH2), 2.83 (m, 2H, CH2), 2.57 (m, 2H, 
CH2), 2.42 – 2.36 (m, 2H, CH2), 1.72 – 1.51 (m, 4H, CH2), 1.42 – 1.34 (m, 2H, CH2), 1.32 (t, 
J = 6.8 Hz, 3H, CH3), 1.27 – 1.20 (m, 3H, CH3). The intermediate 61d was used for the next 
reaction without further characterization. 
Diethyl (6-(5-(2-amino-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)nicotinoyl)-L-
glutamate (62d). 
Compound 62d was prepared using the similar procedure to 27d from the aldehyde 
56d (1.44 g, 3.42 mmol) and 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 24d (517 mg, 
1.71 mmol), and 2 N HCl in Et2O solution (0.17 mL, 0.28 mmol). After the workup, the residue 
59d was used directly in the next step without further characterization. TLC Rf = 0.91 
(hexane/EtOAc 1:1) 
To a solution of 2,6-diaminopyrimidin-4(3H)-one 26d (723 mg, 5.73 mmol) and 
sodium acetate (855 mg, 10.42 mmol) in water (5 mL) and methanol (5 mL) was added crude 
α-bromo aldehyde 59d (1.71 g). The reaction mixture was stirred at 45 °C for 4 hours to afford 
62d (470 mg, 26% over two steps) as a light brown sticky solid. TLC Rf = 0.35 (CHCl3/MeOH, 
10:1); 1H NMR (400 MHz, DMSO-d6) δ 10.61 (s, 1H, NH), 10.17 (s, 1H, NH), 8.87 (d, J = 8.2 
Hz, 1H, NH), 8.14 (dd, J = 8.1, 2.2 Hz, 1H, Ar), 7.38 (d, J = 7.1 Hz, 1H, Ar), 7.24 (d, J = 8.1 
Hz, 1H, Ar), 6.38 (d, J = 2.1 Hz, 1H, Ar), 6.01 (s, 2H, 2-NH2), 4.72 (td, J = 7.9, 4.9 Hz, 1H, 
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CH), 4.29 (m, 2H, CH2), 4.15 – 4.10 (m, 2H, CH2), 2.84 (m, 2H, CH2), 2.57 (m, 2H, CH2), 
2.38 (m, 2H, CH2), 1.71 – 1.63 (m, 4H, CH2), 1.42 – 1.36 (m, 4H, CH2), 1.31 (t, J = 7.1 Hz, 
3H, CH3), 1.24 – 1.18 (m, 3H, CH3). The intermediate 62d was used for the next reaction 
without further characterization. 
(5-(2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)picolinoyl)-L-
glutamic acid (13c). 
Compound 13c was prepared using the similar procedure to 28d, from 43d (0.52 g, 1.07 mmol) 
to give 13c (321 mg, 70%) as a brown powder. mp 225 °C. 1H NMR (400 MHz, DMSO-d6) δ 
10.61 (s, 1H, NH), 10.13 (s, 1H, NH), 8.79 (d, J = 8.1 Hz, 1H, NH), 8.52 (d, J = 2.0 Hz, 1H, 
Ar), 7.94 (d, J = 8.0 Hz, 1H, Ar), 7.83 (dd, J = 8.0, 2.2 Hz, 1H, Ar), 6.35 (d, J = 2.0 Hz, 1H, 
Ar), 5.91 (s, 2H, 2-NH2), 4.47 (td, J = 8.8, 4.8 Hz, 1H, CH), 2.71 (d, J = 7.3 Hz, 2H, CH2), 2.63 
– 2.57 (m, 2H, CH2), 2.29 (t, J = 7.4 Hz, 2H, CH2), 2.18 – 1.96 (m, 2H, CH2). Anal. Calcd for 
C21H24N6O6 · 0.3949 H2O: C, 54.41; H, 5.39; N, 18.13. Found: C, 54.35; H, 5.10; N, 18.21.   
(5-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)picolinoyl)-L-
glutamic acid (15c). 
Compound 15c was prepared using the similar procedure to 28d, from 44d (0.70 g, 1.36 mmol) 
to give 15c (392 mg, 63%) as a buff colored powder. mp: 170.2 °C.  1H NMR (400 MHz, 
DMSO-d6) δ 10.60 (s, 1H, NH), 10.08 (s, 1H, NH), 8.81 (d, J = 8.3 Hz, 1H, NH), 8.48 (d, J = 
2.1 Hz, 1H, Ar), 7.95 (d, J = 7.8 Hz, 1H, Ar), 7.85 (dd, J = 8.3, 2.4 Hz, 1H, Ar), 6.38 (d, J = 
2.0 Hz, 1H, Ar), 5.94 (s, 2H), 4.49 (td, J = 8.1, 4.6 Hz, 1H, CH), 2.73 (d, J = 7.1 Hz, 2H, CH2), 
2.65 (m, 2H, CH2), 2.31 (t, J = 7.7 Hz, 2H, CH2), 2.23 – 1.85 (m, 2H, CH2), 1.66 – 1.57 (m, 
4H, CH2). Anal. Calcd for C21H24N6O6 · 0.4455 H2O: C, 54.30; H, 5.40; N, 18.09. Found: C, 




glutamic acid (16c). 
Compound 16c was prepared using the similar procedure to 28d, from 45d (0.49 g, 0.93 mmol) 
to give 16c (330 mg, 75%) as a brown colored powder. mp: 234 °C. 1H NMR (400 MHz, 
DMSO-d6) δ 10.63 (s, 1H, NH), 10.14 (s, 1H, NH), 8.81 (d, J = 7.9 Hz, 1H, NH), 8.54 (d, J = 
2.0 Hz, 1H, Ar), 7.91 (d, J = 8.3 Hz, 1H, Ar), 7.86 (dd, J = 7.5, 2.1 Hz, 1H, Ar), 6.33 (d, J = 
1.9 Hz, 1H, Ar), 6.01 (s, 2H, 2-NH2), 4.45 (td, J = 8.9, 4.1 Hz, 1H, CH), 2.69 (t, J = 7.2 Hz, 
2H, CH2), 2.55 (d, J = 7.8 Hz, 2H, CH2), 2.30 (t, J = 7.5 Hz, 2H, CH2), 2.20 – 1.93 (m, 2H, 
CH2), 1.71 – 1.55 (m, 4H, CH2), 1.37 – 1.25 (m, 2H, CH2). Anal. Calcd for C22H26N6O6: C, 
56.16; H, 5.57; N, 17.86. Found: C, 55.97; H, 5.35; N, 17.67. 
(6-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)nicotinoyl)-
L-glutamic acid (17c). 
Compound 17c was prepared using the similar procedure to 28d, from 60d (0.25 g, 0.51 mmol) 
to give 17c (0.14 g, 64%) as a brown powder. mp: 181.5 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 10.67 (s, 1H, NH), 10.14 (s, 1H, NH), 8.92 (d, J = 8.0 Hz, 1H, NH), 8.05 (dd, J = 7.9, 2.0 Hz, 
1H, Ar), 7.33 (d, J = 7.0 Hz, 1H, Ar), 7.28 (d, J = 8.1 Hz, 1H, Ar), 6.39 (d, J = 2.0 Hz, 1H, Ar), 
6.01 (s, 2H, 2-NH2), 4.51 (m, J = 9.5, 8.0 Hz, 1H, CH), 2.71 (t, J = 7.6 Hz, 2H, CH2), 2.60 (t, 
J = 7.4 Hz, 2H, CH2), 2.43 – 2.32 (m, 2H, CH2), 2.28 – 2.13 (m, 2H, CH2), 2.05 (q, J = 7.6 Hz, 
2H, CH2). Anal. Calcd for C20H22N6O6 · 0.5705 H2O: C, 53.06; H, 5.15; N, 18.56. Found: C, 
52.95; H, 4.77; N, 18.75 
(6-(5-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)nicotinoyl)-
L-glutamic acid (18c). 
Compound 18c was prepared using the similar procedure to 28d, from 61d (0.42 g, 0.82 mmol) 
to give 18c (282 mg, 75%) as a brown powder. mp: 241.7 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 10.62 (s, 1H, NH), 10.13 (s, 1H, NH), 8.84 (d, J = 8.2 Hz, 1H, NH), 8.07 (dd, J = 8.1, 2.2 Hz, 
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1H, Ar), 7.32 (d, J = 7.1 Hz, 1H, Ar), 7.25 (d, J = 8.1 Hz, 1H, Ar), 6.35 (d, J = 2.0 Hz, 1H, Ar), 
5.97 (s, 2H, 2-NH2), 4.47 (td, J = 8.8, 4.8 Hz, 1H, CH), 2.74 (d, J = 7.3 Hz, 2H, CH2), 2.60 – 
2.55 (m, 2H, CH2), 2.32 (t, J = 7.4 Hz, 2H, CH2), 2.19 – 2.11 (m, 2H, CH2), 1.69 – 1.58 (m, 
4H, CH2). Anal. Calcd for C21H24N6O6 · 0.4773 H2O: C, 54.24; H, 5.41; N, 18.07. Found: C, 
54.27; H, 5.12; N, 17.87. 
(6-(5-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)nicotinoyl)-
L-glutamic acid (19c). 
Compound 19c was prepared using the similar procedure to 28d, from 62d (0.47 g, 0.89 mmol) 
to give 19c (294 mg, 70%) as a reddish brown powder mp: 221.6 °C. 1H NMR (400 MHz, 
DMSO-d6) δ 10.59 (s, 1H, NH), 10.11 (s, 1H, NH), 8.91 (d, J = 7.8 Hz, 1H, Ar), 8.09 (dd, J = 
8.0, 1.9 Hz, 1H, Ar), 7.35 (d, J = 7.6 Hz, 1H, Ar), 7.26 (d, J = 8.1 Hz, 1H, Ar), 6.17 (d, J = 2.2 
Hz, 1H, Ar), 5.89 (s, 2H, 2-NH2), 4.53 (td, J = 8.5, 4.3 Hz, 1H, CH), 2.69 (t, J = 7.7 Hz, 2H, 
CH2), 2.52 (d, J = 7.6 Hz, 2H, CH2), 2.30 (t, J = 7.3 Hz, 2H, CH2), 2.20 – 1.98 (m, 2H, CH2), 
1.63 (m, 4H, CH2), 1.36 – 1.25 (m, 2H, CH2). Anal. Calcd for C22H26N6O6 · 0.5848 H2O: C, 
54.93; H, 5.69; N, 17.47. Found: C, 54.86; H, 5.51; N, 17.64. 
General procedure for the synthesis of 67d-69d. 
To a solution of triphenylphosphine (1 eq) in dry methylene chloride (100 mL) was 
added iodine (1 eq) and imidazole (1 eq) at 0 ºC. The resulting solution was stirred for 10 min, 
before a solution of alcohols 74d-76d (1 eq.) in dry methylene chloride (50 mL) was added. 
The reaction mixture was then quenched with sat. aqueous sodium thiosulfite solution after 30 
minutes. The organic layer was separated and washed with brine and dried over Na2SO4. Silica 
gel was then added, and the solvent was evaporated under reduced pressure. The resulting plug 
was loaded on to a silica gel column with ethyl acetate-Hexane as the eluent. Fractions that 
showed the desired spot (TLC) were pooled and the solvent evaporated to dryness to afford 
corresponding iodides. 
 194 
Methyl 5-(3-iodopropyl)picolinate (67d). 
Compound 67d was prepared using above general procedure, from 74d (2.25g, 11.53 mmol), 
iodine (4.39 g, 17.29 mmol), triphenyl phosphine (4.53 g, 17.29 mmol), and imidazole (1.18g, 
17.29 mmol) to afford 67d (3.01 g, 85%) as yellow oil. TLC Rf = 0.88 (Hexane: EtOAc, 3:1); 
1H NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 2.0 Hz, 1H, Ar), 8.00 (d, J = 8.0 Hz, 1H, Ar), 
7.89 – 7.83 (m, 1H, Ar), 3.87 (s, 3H, OCH3), 3.26 (t, J = 6.8 Hz, 2H, CH2), 2.83 – 2.72 (m, 2H, 
CH2), 2.16 – 2.04 (m, 2H, CH2). The intermediate 67d was used for the next reaction without 
further characterization. 
Methyl 5-(4-iodobutyl)picolinate (68d). 
Compound 68d was prepared using above general procedure, from 75d (2.49 g, 11.90 mmol), 
iodine (4.53 g, 17.85 mmol), triphenyl phosphine (4.68 g, 17.85 mmol), and imidazole (1.2 g, 
17.85 mmol) to afford 68d (3.10 g, 82%) as yellow oil. TLC Rf = 0.84 (Hexane: EtOAc, 3:1); 
1H NMR (400 MHz, DMSO-d6) δ 8.58 (m, 1H, Ar), 7.99 (dd, J = 8.0, 0.7 Hz, 1H, Ar), 7.86 – 
7.80 (m, 1H, Ar), 3.87 (s, 3H, OCH3), 3.29 (t, J = 6.9 Hz, 2H, CH2), 2.68 (t, J = 7.6 Hz, 2H, 
CH2), 1.81 – 1.75 (m, 2H, CH2), 1.64 (p, J = 7.4 Hz, 2H, CH2). The intermediate 68d was used 
for the next reaction without further characterization. 
Methyl 5-(5-iodopentyl)picolinate (69d). 
Compound 69d was prepared using above general procedure, from 76d (2.51 g, 11.15 mmol), 
iodine (4.25 g, 16.73 mmol), triphenyl phosphine (4.39, 16.73 mmol), and imidazole (1.14g, 
16.73 mmol) to afford 69d (2.99 g, 80%) as yellow oil. TLC Rf = 0.87 (Hexane: EtOAc, 3:1); 
1H NMR (400 MHz, DMSO-d6) δ 8.61 – 8.56 (m, 1H, Ar), 7.97 (dd, J = 7.9, 0.9 Hz, 1H, Ar), 
7.84 (m, 1H, Ar), 3.89 (s, 3H, OCH3), 3.26 (t, J = 6.6 Hz, 2H, CH2), 2.69 (t, J = 7.9 Hz, 2H, 
CH2), 1.83 – 1.73 (m, 2H, CH2), 1.62 (p, J = 7.6 Hz, 2H, CH2), 1.37 (t, J = 6.8 Hz, 2H, CH2). 




 In a 100 mL, round-bottomed flask, 2-amino-6-methyl-4(3H)-oxopyrimidin 80d (20 g, 0.16 
mmol) was dissolved in H2S04 (100 mL) and cooled to 0 °C, and HNO3(17.6 mL) was added 
dropwise over 30 min. The mixture was warmed to rt, stirred for 3 h, and poured into Et2O 
(1500 mL), and the precipitate was filtered and dissolved in 1 N NaOH. AcOH was added to 
precipitate product, and the solid was collected by vacuum filtration, washed with H2O (2 x 10 
mL), and air-dried overnight in a vacuum oven to yield 26.3 g (97%) of 81d as a pale yellow 
solid: mp > 300 °C, (lit. mp > 300 °C) 1H NMR (400 MHz, DMSO-d6) δ  11.62 (s, 1H, NH), 
6.25 (s, 2H, 2-NH2), 2.24 (s, 3H, CH3). 
N’-[4-[2-(Dimethylamino)ethenyl]-1,6-dihydro-5-nitro-6-oxo-2-pyrimidinyl]-N,N 
dimethylmethanimidamide (82d). 
In a 100 mL two-neck round-bottomed flask under N2 atmosphere and molecular sieve 3 Å 
was added 81d (2.0 g, 11.7 mmol) in dry DMF (25 mL) and DMF dimethyl acetal (7.5 mL, 
70.0 mmol). The mixture was stirred at 100 °C for 24 h and then cooled. The mixture was dried 
under vacuum. Acetone (15 mL) was added and the formed precipitate was filtered and washed 
with acetone (10 mL) furnishing 82d in 90% yield (2.96 g) as an orange solid, mp: 275 °C 
(Lit.351 276-278 °C). 1H NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H, CH), 7.88 (d, J = 12.2 Hz, 
1H, CH), 5.60 (d, J = 12.2 Hz, 1H, CH), 3.24 (s, 3H, CH3), 3.14 (s, 3H, CH3), 2.80–3.10 (m, 
6H, CH3).  
2-Amino-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one (83d). 
In a 500 mL round-bottomed flask were combined 82d (4.6 g, 16.4 mmol), sodium dithionite 
(12.0 g, 69 mmol) and THF/H2O (2:1, 300 mL). The mixture was stirred at room temperature 
for 1 h. The solvent was removed under reduced pressure, then H2O (50 mL) was added and 
the solid formed was filtered and washed with water (2 x 100 mL). The product was purified 
by silica gel chromatography using 2% MeOH in CH2Cl2 as eluent. Compound 83d was 
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obtained in 89% yield (2.99 g) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 11.58 (s, 
1H, NH), 8.51 (s, 1H, CH), 7.19 (t, J = 5.9 Hz, 1H, Ar), 6.09 (t, J = 4.7 Hz, 1H, Ar), 3.13 (s, 
3H, CH3), 3.03 (s, 3H, CH3). 
2-Amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one (66d). 
In a microwave vessel was added 83d (1 g, 4.87 mmol) and NaOH (975 mg, 24.36 mmol) in 
H2O (10mL). The set conditions were 90 °C for 15 min in the Biotage® microwave. This 
procedure was repeated four times and then the crude products were mixed. The solvent was 
evaporated under vacuum and then water (5 mL) was added. The mixture was acidified to pH 
5.0 with glacial acetic acid. The precipitate was affording the desired product 66d in 90% yield 
(660 mg) as a white solid, mp: decomposed at 300 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.43 
(d, J = 5.9 Hz, 1H, Ar), 6.44 (s, 2H, 2-NH2), 5.87 (d, J = 4.9 Hz, 1H, Ar).  
N-(4-Oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)pivalamide (84d). 
To a round bottomed flask were added 66d (660 mg, 4.4 mmol) and pivalic anhydride (10 ml). 
The mixture was refluxed at 110 °C for 4 h. After 4 h, the reaction mixture was cooled in ice 
bath and 100 mL of hexanes was added to precipitate the compound 84d in 85% (880 mg) 
yield as a white solid. Mp: decomposed at 300 °C. TLC Rf = 0.87 (CHCl3:MeOH, 10:1); 
1H 
NMR (400 MHz, DMSO-d6) δ 12.16 (s, 1H, NH), 10.08 (s, 1H, NH), 7.41 (t, J = 2.9 Hz, 1H, 
Ar), 6.36 – 6.32 (m, 1H, Ar), 1.24 (s, 9H, CH3). 
N,N-Dimethyl-N'-(4-methyl-5-nitro-6-oxo-1,6-dihydropyrimidin-2-yl)formimidamide (87d). 
In a 50 mL round bottom flask flushed with nitrogen were combined 81d (4.0 g, 23.6 mmol), 
DMF dimethylacetal (20 mL), and CH2Cl2 (30 mL). The reaction mixture was stirred at rt for 
4 h, the solvent was removed under reduced pressure, the crude product was purified by column 
chromatography on silica gel with 0.5-1% MeOH:CH2C12 as the eluent to yield 3.2 g (60%) 
of 87d as an orange solid. TLC Rf = 0.38 (CHCl3:MeOH, 10:1); mp: 207-209 °C; 
1H NMR 
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(400 MHz, DMSO-d6) δ 12.27 (s, 1H, NH), 8.73 (s, 1H, CH), 3.22 (s, 3H, CH3), 3.09 (s, 3H, 
CH3), 2.28 (s, 3H, CH3). 
(2-(((Dimethylamino)methylene)amino)-4-methyl-5-nitro-6-oxopyrimidin-1(6H)-yl)methyl 
pivalate (89d), ((2-(((dimethylamino)methylene)amino)-6-methyl-5-nitropyrimidin-4-
yl)oxy)methyl pivalate (90d). 
In a two-neck 100 mL round-bottomed flask flushed with argon were placed NaH (0.46 g, 11.5 
mmol, 60% in mineral oil) and DMF(anhyd) 20 mL. To this mixture was added 87d (2.35 g, 
10.4 mmol) slowly. The mixture became viscous and could stir at rt for 1 h. Chloromethyl 
pivalate (2 mL) was added dropwise over 5 min, and the reaction was stirred for 12 h at rt, after 
which time it became fluid. Solvent was removed under reduced pressure, the residue was 
dissolved in CH2Cl2 (50 mL), extracted with 5% AcOH (1 x 30 mL) and H2O (1 x 30 mL), 
dried with MgSO4, and filtered, and the solvent was removed under reduced pressure. The 
crude products were purified by column chromatography on silica gel with CH2C12-0.5% 
MeOH:CH2Cl2 as the eluent to yield 2.27 g (65%) of 89d as a pale yellow solid: mp 134-136 
°C; 1H NMR (400 MHz, Chloroform-d) δ 8.73 (s, 1H, CH), 6.21 (s, 2H, CH2), 3.26 (s, 3H, 
CH3), 3.14 (s, 3H, CH3), 2.37 (s, 3H, CH3), 1.15 (s, 9H, CH3), and 0.53 g (15%) of 90d as a 
pale yellow gum: 1H NMR (400 MHz, Chloroform-d) δ 8.75 (s, 1H, CH), 6.17 (s, 2H, CH2), 
3.23 (s, 3H, CH3), 3.21 (s, 3H, CH3), 2.52 (s, 3H, CH3), 1.17 (s, 9H, CH3). 
4[(2-Dimethylamino)ethenyll-2-[[(N,N-dimethylamino)methylene]amino]-5-nitro-4(3H)-
oxo-3-[(pivaloyloxy)-methyllpyrimidine (91d). 
In a 50-mL round-bottomed flask flushed with nitrogen were combined 90d (2.27 g, 6.6 mmol), 
DMF(anhyd) (20 mL), and DMF dimethylacetal (5 mL). The reaction mixture was stirred for 
12 h at rt, the solvent was removed under reduced pressure, 20% ether/hexanes was added, and 
the solid was filtered and dried under house vacuum. The product was purified by column 
chromatography on silica gel with CH2C12-0.5% MeOH:CH2Cl2 as the eluent to yield 2.48 g 
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(90%) of 91d as yellowish white solid. TLC Rf = 0.85 (CHCl3:MeOH, 10:1); mp: 206-207 °C;
 
1H NMR (400 MHz, Chloroform-d) δ 8.63 – 8.57 (m, 1H, CH), 7.99 (d, J = 12.2 Hz, 1H, CH), 
6.18 (s, 2H, CH2), 5.74 (d, J = 12.2 Hz, 1H, CH), 3.25 (s, 3H, CH3), 3.18 (s, 3H, CH3), 3.11 (s, 
3H, CH3), 2.98 – 2.89 (s, 3H, CH3), 1.16 (s, 9H, CH3). 
2-[(N,N-Dimethylamino)methylenelaminol-4(3H)-oxo-3-[(pivaloyloxy)methyl]-5H-
pyrrolo[3,2-d]pyrimidine (92d). 
In a 100 mL round-bottomed flask were combined 91d (2 g, 5.07 mmol), Na2S2O4 (5.30 g, 
30.42 mmol), and THF:H2O (2:1, 30 mL). The mixture was stirred at rt for 1 h, the solvent was 
removed under reduced pressure, H2O (10 mL) was added, and the solid was collected by 
vacuum filtration and washed with H2O (2 x 10 mL) to yield 1.44 g (89%) of 92d as a white 
powder: mp 266.4 °C; 1H NMR (400 MHz, Chloroform-d) δ 11.82 (s, 1H, NH), 8.56 (s, 1H, 
CH), 7.30 (s, 1H, Ar), 6.20 (s, 2H, CH2), 6.14 (s, 1H, Ar), 3.14 (s, 3H, CH3), 2.97 (s, 3H, CH3), 
1.10 (s, 9H, CH3). 
General procedure for the synthesis of 93d-95d. 
In a two-neck 100 mL round-bottomed flask flushed with argon were placed NaH (1.5 eq) and 
DMF(anhyd). To this mixture was added 92d (1 eq.) slowly. The mixture was allowed to stir 
at rt for 2 h and solution of iodides 67d-69d in DMF (5 mL) were added dropwise over 10 min. 
The mixture was stirred for 2 h, the solvent was removed under reduced pressure, and the crude 
product was purified by column chromatography on silica gel with 3% MeOH:CH2Cl2 as the 
eluent to yield 93-95d as sticky oil. 
Methyl 5-(3-(2-(((dimethylamino)methylene)amino)-4-oxo-3-((pivaloyloxy)methyl)-3,4-
dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl)picolinate (93d). 
Compound 93d was prepared using the above general procedure from 92d (0.7 g, 2.19 mmol), 
NaH (87.7 mg, 2.19 mmol) and 67d (1 g, 3.29 mmol) to afford 93d (550 mg, 50%) as a yellow 
oil. TLC Rf = 0.79 (CHCl3:MeOH, 10:1); 
1H NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 2.2 
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Hz, 1H, Ar), 8.53 (s, 1H, CH), 7.98 – 7.94 (m, 1H, Ar), 7.85 (dd, J = 8.2, 2.2 Hz, 1H, Ar), 7.41 
(d, J = 3.1 Hz, 1H, Ar), 6.22 (s, 2H, CH2), 6.18 – 6.15 (m, 1H, Ar), 4.25 – 4.16 (m, 2H, CH2), 
3.87 (s, 3H, CH3), 3.14 (s, 3H, CH3), 2.85 (s, 3H, CH3), 2.75 (q, J = 8.7, 8.1 Hz, 2H, CH2), 1.98 
– 1.91 (m, 2H, CH2), 1.08 (s, 9H, CH3). The intermediate 93d was used for the next reaction 
without further characterization. 
Methyl 5-(4-(2-(((dimethylamino)methylene)amino)-4-oxo-3-((pivaloyloxy)methyl)-3,4-
dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl)picolinate (94d). 
Compound 94d was prepared using the above general procedure from 92d (1g, 3.13 mmol), 
NaH (125 mg, 3.13 mmol) and 68d (1.5 g, 4.7 mmol) to afford 94d (644 mg, 40%) as a yellow 
oil. TLC Rf = 0.83 (CHCl3:MeOH, 10:1); 
1H NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 1.8 
Hz, 1H, Ar), 8.55 (s, 1H, CH), 7.93 (d, J = 7.8 Hz, 1H, Ar), 7.81 (d, J = 1.7 Hz, 1H, Ar), 7.21 
(d, J = 0.3 Hz, 1H, Ar), 6.22 (s, 2H, CH2), 5.88 (d, J = 2.6 Hz, 1H, Ar), 4.26 (t, J = 6.7 Hz, 2H, 
CH2), 3.85 (s, 3H, CH3), 3.56 (t, J = 4.7 Hz, 2H, CH2), 3.17 (s, 3H, CH3), 1.74 (t, J = 7.2 Hz, 
2H, CH2), 1.51 (m, 2H, CH2), 1.08 (s, 9H, CH3). The intermediate 94d was used for the next 
reaction without further characterization. 
Methyl 5-(5-(2-(((dimethylamino)methylene)amino)-4-oxo-3-((pivaloyloxy)methyl)-3,4-
dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)pentyl)picolinate (95d). 
Compound 95d was prepared using the above general procedure from 92d (0.85 g, 2.66 mmol), 
NaH (106 mg, 2.66 mmol) and 68d (1.33 g, 3.99 mmol) to afford 95d (671 mg, 48%) as a 
yellow oil. TLC Rf = 0.80 (CHCl3:MeOH, 10:1); 
1H NMR (400 MHz, DMSO-d6) δ 8.57 (s, 
1H, CH), 8.54 (d, J = 2.1 Hz, 1H, Ar), 7.96 (d, J = 8.0 Hz, 1H, Ar), 7.79 (dd, J = 8.0, 2.2 Hz, 
1H, Ar), 7.39 (d, J = 3.1 Hz, 1H, Ar), 6.24 (s, 2H, CH2), 6.17 (d, J = 3.1 Hz, 1H, Ar), 4.22 – 
4.14 (m, 2H, CH2), 3.87 (s, 3H, CH3), 3.16 (s, 2H, CH2), 2.99 (s, 3H, CH3), 2.71 – 2.61 (m, 
2H, CH2), 1.71 – 1.56 (m, 4H, CH2), 1.33 (s, 2H, CH2), 1.07 (s, 9H, CH3). The intermediate 




To a 25 mL round-bottomed flask was added 93d (0.55 g, 1.11 mmol), 1N NaOH (9.97 mL, 
9.97 mmol) and MeOH (5 mL), stirred overnight. MeOH was evaporated and reaction was 
acidified to pH 5 using 1N HCl to afford 96d (244 mg, 70%) as a white precipitate.; 1H NMR 
(400 MHz, DMSO-d6) δ 8.51 (d, J = 2.0 Hz, 1H, Ar), 7.94 (d, J = 7.9 Hz, 1H, Ar), 7.84 – 7.74 
(m, 1H, Ar), 7.22 (d, J = 2.9 Hz, 1H, Ar), 5.90 (d, J = 2.8 Hz, 1H, Ar), 5.83 (s, 2H, 2-NH2), 
4.27 (t, J = 6.9 Hz, 2H, CH2), 2.62 (t, J = 7.8 Hz, 2H, CH2), 2.09 (t, J = 7.5 Hz, 2H, CH2). The 
intermediate 96d was used for the next reaction without further characterization. 
5-(4-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl)picolinic acid 
(97d). 
Compound 97d was prepared using similar procedure to 96d from 94d (644 mg, 1.26 mmol) 
to afford 226 mg of target compound as a buff colored precipitate in 55% yield. 1H NMR (400 
MHz, DMSO-d6) δ 8.49 (d, J = 1.9 Hz, 1H, Ar), 7.93 (d, J = 8.0 Hz, 1H, Ar), 7.73 (dd, J = 8.0, 
2.2 Hz, 1H, Ar), 7.20 (d, J = 2.8 Hz, 1H, Ar), 5.88 (d, J = 2.7 Hz, 1H, Ar), 5.82 (s, 2H, 2-NH2), 
4.26 (t, J = 6.9 Hz, 2H, CH2), 2.66 (t, J = 7.7 Hz, 2H, CH2), 1.74 (p, J = 6.9 Hz, 2H, CH2), 1.51 
(q, J = 7.8 Hz, 2H, CH2). Mass calculated for C16H17N5O3 [M + H]
+, 328.14 Found 328.4. The 
intermediate 97d was used for the next reaction without further characterization. 
5-(5-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)pentyl)picolinic acid 
(98d). 
Compound 98d was prepared using similar procedure to 96d from 95d (671 mg, 1.72 mmol) 
to afford 381 mg of target compound as a white precipitate in 65% yield. 1H NMR (400 MHz, 
DMSO-d6) δ 8.54 (d, J = 2.2 Hz, 1H, Ar), 7.95 (d, J = 7.9 Hz, 1H, Ar), 7.78 (dd, J = 8.1, 2.2 
Hz, 1H, Ar), 7.17 (d, J = 2.8 Hz, 1H, Ar), 5.87 (d, J = 2.8 Hz, 1H, Ar), 5.74 (s, 2H, 2-NH2), 
4.21 (t, J = 7.0 Hz, 2H, CH2), 2.72 – 2.60 (m, 2H, CH2), 1.79 – 1.69 (m, 2H, CH2), 1.68 – 1.54 
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(m, 2H, CH2), 1.23 (m, 2H, CH2). Mass calculated for C17H19N5O3 [M - H]
-, 340.14 Found 
340.5. The intermediate 98d was used for the next reaction without further characterization. 
Diethyl (5-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propyl)picolinoyl)-L-glutamate (99d). 
Compound 99d (245 mg, 63%) was prepared as a brown syrup using similar glutamate 
coupling conditions as 29d, from 96d (244 mg, 0.78 mmol), 2-chloro-4,6-dimethoxy-1,3,5-
triazine (164 mg, 0.93 mmol), 4-methylmorpholine (0.1 mL, 0.93 mmol) and diethyl L-
glutamate HCl (237 mg, 1.17 mmol). TLC Rf = 0.51 (CHCl3:MeOH, 10:1). 
1H NMR (400 
MHz, DMSO-d6) δ 8.92 (d, J = 8.2 Hz, 1H, NH), 8.51 (d, J = 2.2 Hz, 1H, Ar), 7.93 (d, J = 8.0 
Hz, 1H, Ar), 7.83 (dd, J = 8.0, 2.2 Hz, 1H, Ar), 5.95 (s, 2H, 2-NH2), 5.93 (d, J = 2.8 Hz, 1H, 
Ar), 4.52 (m, 1H, CH), 4.28 (t, J = 6.9 Hz, 2H, CH2), 4.21 (q, J = 7.1 Hz, 2H, CH2), 4.16 – 4.10 
(m, 2H, CH2), 2.65 (t, J = 7.8 Hz, 2H, CH2), 2.43 – 2.31 (m, 2H, CH2), 2.21 – 1.98 (m, 4H, 
CH2), 1.25 (t, J = 7.1 Hz, 3H, CH3), 1.14 (t, J = 7.1 Hz, 3H, CH3). The intermediate 99d was 
used for the next reaction without further characterization. 
Diethyl (5-(4-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)picolinoyl)-L-glutamate (100d). 
Compound 100d (206 mg, 58%) was prepared as a yellow syrup using similar glutamate 
coupling conditions as 29d, from 97d (226 mg, 0.67 mmol), 2-chloro-4,6-dimethoxy-1,3,5-
triazine (145 mg, 0.83 mmol), 4-methylmorpholine (0.09 mL, 0.83 mmol) and diethyl L-
glutamate HCl (211 mg, 1.04 mmol). TLC Rf = 0.54 (CHCl3:MeOH, 10:1). 
1H NMR (400 
MHz, DMSO-d6) δ 8.90 (d, J = 8.2 Hz, 1H, NH), 8.50 (d, J = 1.9 Hz, 1H, Ar), 7.93 (d, J = 8.0 
Hz, 1H, Ar), 7.83 – 7.77 (m, 1H, Ar), 7.21 (d, J = 2.9 Hz, 1H, Ar), 5.88 (d, J = 2.7 Hz, 1H, Ar), 
5.74 (s, 2H, 2-NH2), 4.53 (m, 1H, CH), 4.26 (t, J = 6.8 Hz, 2H, CH2), 4.11 (q, J = 5.2 Hz, 2H, 
CH2), 4.01 (q, J = 7.1 Hz, 2H, CH2), 3.56 (t, J = 4.7 Hz, 2H, CH2), 2.69 (t, J = 7.8 Hz, 2H, 
CH2), 2.37 (dd, J = 8.1, 5.8 Hz, 2H, CH2), 1.78 – 1.70 (m, 2H, CH2), 1.52 (d, J = 8.0 Hz, 2H, 
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CH2), 1.19 (t, J = 7.2 Hz, 3H, CH3), 1.15 (t, J = 7.2 Hz, 3H, CH3). Mass calculated for 
C25H32N6O6 [M + H]
+, 513.24 Found 513.5. The intermediate 100d was used for the next 
reaction without further characterization. 
Diethyl (5-(5-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)pentyl)picolinoyl)-L-glutamate (101d).    
Compound 101d (386 mg, 66%) was prepared as a brown syrup using similar glutamate 
coupling conditions as 29d, from 98d (381 mg, 1.12 mmol), 2-chloro-4,6-dimethoxy-1,3,5-
triazine (235 mg, 1.34 mmol), 4-methylmorpholine (0.15 mL, 1.34 mmol) and diethyl L-
glutamate HCl (340 mg, 1.67 mmol). TLC Rf = 0.52 (CHCl3:MeOH, 10:1). 
1H NMR (400 
MHz, DMSO-d6) δ 8.90 (d, J = 8.2 Hz, 1H, NH), 8.51 (d, J = 2.1 Hz, 1H, Ar), 7.93 (d, J = 8.0 
Hz, 1H, Ar), 7.81 (dd, J = 8.0, 2.2 Hz, 1H, Ar), 7.16 (d, J = 2.8 Hz, 1H, Ar), 5.87 (d, J = 2.8 
Hz, 1H, Ar), 5.73 (s, 2H, 2-NH2), 4.53 (td, J = 8.8, 5.1 Hz, 1H, CH), 4.21 (t, J = 6.9 Hz, 2H, 
CH2), 4.15 – 4.08 (m, 2H, CH2), 4.03 (p, J = 7.1 Hz, 2H, CH2), 2.67 (q, J = 9.4, 7.5 Hz, 2H, 
CH2), 2.41 – 2.32 (m, 2H, CH2), 2.25 – 2.01 (m, 2H, CH2), 1.85 – 1.70 (m, 2H, CH2), 1.59 (dd, 
J = 15.5, 7.7 Hz, 2H, CH2), 1.24 – 1.22 (m, 2H, CH2), 1.19 (t, J = 7.1 Hz, 3H, CH3), 1.14 (t, J 
= 7.1 Hz, 3H, CH3). Mass calculated for C26H34N6O6 [M + H]
+, 527.26 Found 527.4. The 
intermediate 101d was used for the next reaction without further characterization. 
(5-(3-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl)picolinoyl)-L-
glutamic acid (20c). 
Compound 20c (383 mg, 88%) was prepared using the similar procedure to 28d, from 99d 
(0.49 g, 0.98 mmol) as a brown colored powder. mp 206.1 °C. 1H NMR (400 MHz, DMSO-
d6) δ 8.79 (d, J = 8.1 Hz, 1H, NH), 8.50 (d, J = 2.1 Hz, 1H, Ar), 7.94 (d, J = 8.0 Hz, 1H, Ar), 
7.83 (dd, J = 8.1, 2.1 Hz, 1H, Ar), 7.22 (d, J = 2.9 Hz, 1H, Ar), 5.94 – 5.86 (m, 1H, Ar), 5.80 
(s, 2H, 2-NH2), 4.48 (td, J = 8.7, 4.9 Hz, 1H, CH), 4.28 (t, J = 7.0 Hz, 2H, CH2), 2.64 (t, J = 
7.8 Hz, 2H, CH2), 2.29 (t, J = 7.3 Hz, 2H, CH2), 2.19 – 1.96 (m, 4H, CH2). Mass calculated for 
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C20H22N6O6 [M + Na]
+, 465.16; Found 465.7. HPLC analysis: retention time, 12.75 min; peak 
area, 95.23 %; eluent A, H2O with 0.1% TFA: eluent B, ACN with 0.1% TFA; gradient elution 
(95% H2O to 10% H2O) over 45 min with flow rate of 0.5 mL/min and detection at 245 nm; 
column temperature, rt.  
(5-(4-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl)picolinoyl)-L-
glutamic acid (21c). 
Compound 21c (136 mg, 74%) was prepared using the similar procedure to 28d, from 100d 
(0.21 g, 0.4 mmol) as a brown colored powder. mp 152.1 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 8.77 (d, J = 7.7 Hz, 1H, NH), 8.48 (d, J = 2.1 Hz, 1H, Ar), 7.93 (d, J = 7.8 Hz, 1H, Ar), 7.79 
(dd, J = 8.1, 2.2 Hz, 1H, Ar), 7.20 (d, J = 2.8 Hz, 1H, Ar), 5.88 (d, J = 2.8 Hz, 1H, Ar), 5.77 (s, 
2H, 2-NH2), 4.43 – 4.35 (m, 1H, CH), 4.26 (t, J = 6.7 Hz, 2H, CH2), 2.68 (t, J = 7.7 Hz, 2H, 
CH2), 2.36 – 2.20 (m, 2H, CH2), 2.03 (q, J = 7.2 Hz, 2H, CH2), 1.73 (q, J = 7.1 Hz, 2H, CH2), 
1.57 – 1.45 (m, 2H, CH2). Mass calculated for C21H24N6O6 [M + H]
+, 457.18; Found 457.3. 
HPLC analysis: retention time, 7.93 min; peak area, 97.28 %; eluent A, H2O with 0.1% TFA: 
eluent B, ACN with 0.1% TFA; gradient elution (95% H2O to 0 % H2O) over 17 min with flow 
rate of 0.3 mL/min and detection at 245 nm; column temperature, rt. 
(5-(5-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)pentyl)picolinoyl)-L-
glutamic acid (22c). 
Compound 22c (311 mg, 90%) was prepared using the similar procedure to 28d, from 101d 
(0.39 g, 0.73 mmol) as a brown colored powder. mp 158.0 °C. 1H NMR (400 MHz, DMSO-
d6) δ 8.78 (d, J = 7.8 Hz, 1H, NH), 8.49 (d, J = 2.1 Hz, 1H, Ar), 7.93 (d, J = 7.9 Hz, 1H, Ar), 
7.80 (dd, J = 8.0, 2.1 Hz, 1H, Ar), 7.17 (d, J = 2.8 Hz, 1H, Ar), 5.86 (d, J = 2.8 Hz, 1H, Ar), 
5.78 (s, 2H, 2-NH2), 4.39 (d, J = 7.3 Hz, 1H, CH), 4.21 (t, J = 6.9 Hz, 2H, CH2), 2.65 (t, J = 
7.7 Hz, 2H, CH2), 2.36 – 2.25 (m, 2H, CH2), 2.08 – 1.98 (m, 2H, CH2), 1.74 (t, J = 7.4 Hz, 2H, 
CH2), 1.64 – 1.55 (m, 2H, CH2), 1.21 (m, 2H, CH2). Mass calculated for C22H26N6O6 [M + H]
+, 
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471.19; Found 471.3. HPLC analysis: retention time, 8.07 min; peak area, 98.53 %; eluent A, 
H2O with 0.1% TFA: eluent B, ACN with 0.1% TFA; gradient elution (95% H2O to 0 % H2O) 
over 17 min with flow rate of 0.3 mL/min and detection at 245 nm; column temperature, rt. 
Diethyl (5-bromo-3-fluoropicolinoyl)-L-glutamate (103d). 
Diethyl L-glutamate HCl (2.54 g, 12.50 mmol) was dissolved in DMF (20 mL). In a separate 
flask, 5-bromo-3-fluoropicolinic acid (2.50 g, 11.36 mmol) was dissolved in DMF (20 mL). 
The solution of diethyl L-glutamate HCl in DMF was then added, followed by DIPEA (5.94 
mL, 34.09 mmol) and HATU (4.32 g, 11.36 mmol). The mixture was stirred overnight at room 
temperature, then diluted with EtOAc (200 mL). The organic layer was washed sequentially 
with 50 mL of half saturated sodium chloride, 50 mL 10% citric acid (aq.), 50 mL of half 
saturated sodium chloride, 50 mL of saturated sodium bicarbonate (aq.), 50 mL water and twice 
with 50 mL brine. The organic layer was dried over sodium sulfate, filtered and concentrated 
under reduced pressure. Purification by column chromatography eluting 0-50% 
EtOAc/Hexanes gave the desired product 103d as a clear liquid (3.70 g, 80%).1H NMR (400 
MHz, Chloroform-d) δ 8.51 (d, J = 1.7 Hz, 1H, Ar), 8.27 (d, J = 8.3 Hz, 1H, NH), 7.81 – 7.75 
(m, 1H, Ar), 4.81 (ddd, J = 8.0, 5.4, 2.7 Hz, 1H, CH), 4.26 (q, J = 7.1, 2.2 Hz, 2H, CH2), 4.14 
(q, J = 7.1, 4.1 Hz, 2H, CH2), 2.55 – 2.30 (m, 4H, CH2), 1.35 – 1.30 (t, J = 7.1 Hz, 3H, CH3), 
1.28 – 1.22 (t, J = 7.1 Hz, 3H, CH3). The intermediate 103d was used for the next reaction 
without further characterization. 
Diethyl (3-fluoro-5-(4-hydroxybut-1-yn-1-yl)picolinoyl)-L-glutamate (104d). 
Compound 104d (2.58 g, 69%) was prepared as a brown oil using similar procedure to 23d, 
from 103d (3.7 g, 9.13 mmol) in anhydrous acetonitrile was added palladium chloride (65 mg, 
0.37 mmol), triphenylphosphine (96 mg, 0.37 mmol), copper iodide (278 mg, 1.46 mmol), 
triethylamine (12.73 mL, 91.3 mmol), and but-3-yn-1-ol (0.83 mL, 10.96 mmol). TLC Rf = 
0.54 (Hexane: EtOAc, 3:1) 1H NMR (400 MHz, DMSO-d6) δ 8.53 (d, J = 1.8 Hz, 1H, Ar), 8.21 
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(d, J = 8.1 Hz, 1H, NH), 7.79 – 7.76 (m, 1H, Ar), 4.79 (m, 1H, Ar), 4.26 (q, J = 7.2 Hz, 2H, 
CH2), 4.13 (q, J = 7.1 Hz, 2H, CH2), 3.65 (dd, J = 6.4, 5.5 Hz, 2H, CH2), 2.55 – 2.53 (m, 2H, 
CH2), 2.58 – 2.42 (m, 2H, CH2), 2.39 – 2.09 (m, 2H, CH2), 1.33 (t, J = 7.1 Hz, 3H, CH3), 1.26 
(t, J = 7.1 Hz, 3H, CH3). Mass calculated for C19H23FN2O6 [M + Na]
+, 417.14; Found, 417.3. 
The intermediate 104d was used for the next reaction without further characterization. 
Diethyl (3-fluoro-5-(5-hydroxypent-1-yn-1-yl)picolinoyl)-L-glutamate (105d). 
Compound 105d (2.42 g, 65%) was prepared as a yellowish brown oil using similar procedure 
to 23d, from 103d (3.7 g, 9.13 mmol) in anhydrous acetonitrile was added palladium chloride 
(65 mg, 0.37 mmol), triphenylphosphine (96 mg, 0.37 mmol), copper iodide (278 mg, 1.46 
mmol), triethylamine (12.73 mL, 91.3 mmol), and but-3-yn-1-ol (0.99 mL, 10.96 mmol). TLC 
Rf = 0.52 (Hexane: EtOAc, 3:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.52 (d, J = 1.7 Hz, 1H, 
Ar), 8.25 (d, J = 8.3 Hz, 1H, NH), 7.79 – 7.73 (m, 1H, Ar), 4.85 (m, J = 8.0, 5.4, 2.7 Hz, 1H, 
CH), 4.25 (q, J = 7.1, 2.2 Hz, 2H, CH2), 4.15 (q, J = 7.1, 4.1 Hz, 2H, CH2), 3.82 (t, J = 6.1 Hz, 
2H, CH2), 2.61 (t, J = 7.0 Hz, 2H, CH2), 2.58 – 2.42 (m, 2H, CH2), 2.39 – 2.09 (m, 2H, CH2), 
1.89 (tt, J = 7.1, 6.2 Hz, 2H, CH2), 1.32 (t, J = 7.1 Hz, 3H, CH3), 1.25 (t, J = 7.1 Hz, 3H, CH3). 
The intermediate 105d was used for the next reaction without further characterization. 
Diethyl (3-fluoro-5-(4-hydroxybutyl)picolinoyl)-L-glutamate (106d). 
Compound 106d (2.3 g, 88%) was prepared as a clear oil using similar catalytic hydrogenation 
procedure to 22d (condition B) from 104d (2.58 g, 6.54 mmol), 10% palladium on activated 
carbon (2 g) in a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.47 
(Hexane: EtOAc, 3:1) 1H NMR (400 MHz, Chloroform-d) δ 8.35 (d, J = 8.1 Hz, 1H), 8.27 (d, 
J = 8.2 Hz, 1H), 7.38 (dd, J = 11.5, 1.7 Hz, 1H, Ar), 4.84 (m, J = 8.4, 4.6 Hz, 1H, CH), 4.26 (q, 
J = 7.3 Hz, 2H, CH2), 4.16 (q, J = 7.4 Hz, 2H, CH2), 3.71 (q, J = 7.5 Hz, 2H, CH2), 2.77 (t, J = 
7.7 Hz, 2H, CH2), 2.58 – 2.42 (m, 2H, CH2), 2.39 – 2.09 (m, 2H, CH2), 1.85 – 1.72 (m, 2H, 
CH2), 1.70 – 1.62 (m, 2H, CH2), 1.33 (t, J = 7.2 Hz, 3H, CH3), 1.24 (t, J = 7.2 Hz, 3H, CH3). 
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Mass calculated for C19H27FN2O6 [M + H]
+, 399.19; Found, 399.5. The intermediate 106d was 
used for the next reaction without further characterization. 
Diethyl (3-fluoro-5-(5-hydroxypentyl)picolinoyl)-L-glutamate (107d). 
Compound 107d (1.94 g, 79%) was prepared as a clear oil using similar catalytic hydrogenation 
procedure to 22d (condition B) from 105d (2.42 g, 5.93 mmol), 10% palladium on activated 
carbon (2 g) in a Parr flask, in ethanol/MeOH (150 mL) at 55 psi for 5 h. TLC Rf = 0.44 
(Hexane: EtOAc, 3:1) 1H NMR (400 MHz, Chloroform-d) δ 8.34 (d, J = 8.3 Hz, 1H, Ar), 8.27 
(d, J = 7.9 Hz, 1H, NH), 7.39 (dd, J = 11.2, 2.1 Hz, 1H, Ar), 4.85 (m, 1H, CH), 4.26 (q, J = 6.9 
Hz, 2H, CH2), 4.13 (q, J = 7.1 Hz, 2H, CH2), 3.69 (q, J = 7.5 Hz, 2H, CH2), 2.79 (t, J = 7.5 Hz, 
2H, CH2), 2.56 – 2.41 (m, 2H, CH2), 2.37 – 2.10 (m, 2H, CH2), 1.85 – 1.72 (m, 2H, CH2), 1.70 
– 1.62 (m, 2H, CH2), 1.55 (m, 2H, CH2), 1.32 (t, J = 7.2 Hz, 3H, CH3), 1.26 (t, J = 7.2 Hz, 3H, 
CH3). The intermediate 107d was used for the next reaction without further characterization. 
General procedure for synthesis of 108d-109d and 110d-111d.  
To the alcohols 106d-107d, was added triethylamine (1.5 equivalent) and dichloromethane (25 
mL). The reaction was cooled to 0 ⁰C and purged with nitrogen gas. Under anhydrous 
conditions, methanesulfonyl chloride (1.50 equivalent) was added dropwise over 30 minutes. 
The reaction was stirred at room temperature for 2 hours and the reaction was added into 
sodium bicarbonate solution (25 mL). The water layer was washed thrice with dichloromethane 
(100 mL). The dichloromethane was evaporated to obtain a semi-solid products 108d-109d. 
To the intermediates (108d-109d) in acetone, sodium iodide (1 equivalent) was added and 
refluxed for 8 hours. The reaction mixture was filtered. The filtrate was evaporated to obtain 
110d-111d as yellow oil. 
Diethyl (3-fluoro-5-(4-iodobutyl)picolinoyl)-L-glutamate (110d). 
Compound 110d was prepared using the general method described for the preparation of 108d-
109d and 110d-111d, from 106d (2.3 g, 5.7 mmol), methanesulfonyl chloride (0.67 mL, 8.66 
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mmol) and triethylamine (1.22 mL, 8.66 mmol) to form the intermediate 108d in 82% (2.25g) 
yield. To this sodium iodide was added and the procedure was followed to give 1.3 g (82%) of 
110d as a clear oil; TLC Rf = 0.63 (EtOAc:Hexane, 1:2); 
1H NMR (400 MHz, Chloroform-d) 
δ 8.35 (d, J = 8.4 Hz, 1H, Ar), 8.27 (d, J = 8.1 Hz, 1, NH), 7.42 – 7.35 (m, 1H, Ar), 4.83 (td, J 
= 8.2, 4.9 Hz, 1H, CH), 4.26 (qd, J = 7.1, 2.5 Hz, 2H, CH2), 4.13 (q, J = 7.1 Hz, 2H, CH2), 3.23 
(t, J = 6.6 Hz, 2H, CH2), 2.75 (t, J = 7.5 Hz, 2H, CH2), 2.58 – 2.39 (m, 2H, CH2), 2.39 – 2.10 
(m, 2H, CH2), 1.94 – 1.74 (m, 4H, CH2), 1.33 (t, J = 7.2 Hz, 3H, CH3), 1.25 (t, J = 7.1 Hz, 3H, 
CH3). The intermediate 110d was used for the next reaction without further characterization. 
Diethyl (3-fluoro-5-(5-iodopentyl)picolinoyl)-L-glutamate (111d). 
Compound 111d was prepared using the general method described for the preparation of 108d-
109d and 110d-111d, from 107d (1.94 g, 4.7 mmol), methanesulfonyl chloride (0.55 mL, 7.06 
mmol) and triethylamine (0.99 mL, 7.06 mmol) to form the intermediate 109d in 82% (2.25g) 
yield. To this sodium iodide was added and the procedure was followed to give 1.98 g (86%) 
of 111d as a clear oil; TLC Rf = 0.62 (EtOAc:Hexane, 1:2); 
1H NMR (400 MHz, Chloroform-
d) δ 8.34 (d, J = 8.4 Hz, 1H), 8.29 (d, J = 7.9 Hz, 1H, NH), 7.37 (m, 1H, Ar), 4.75 (td, J = 7.7, 
1H, CH), 4.24 (q, J = 7.1 Hz, 2H, CH2), 4.17 (q, J = 7.3 Hz, 2H, CH2), 3.28 (t, J = 6.6 Hz, 2H, 
CH2), 3.11 (m, 2H, CH2), 2.74 (t, J = 7.4 Hz, 2H, CH2), 2.47 (m, 2H, CH2), 2.34 – 2.15 (m, 2H, 
CH2), 1.91-1.78 (m, 4H), 1.31 (t, J = 7.5 Hz, 3H, CH3), 1.28 (t, J = 7.3 Hz, 3H, CH3). The 
intermediate 111d was used for the next reaction without further characterization. 
Diethyl (5-(4-(2-(((dimethylamino)methylene)amino)-4-oxo-3-((pivaloyloxy)methyl)-3,4-
dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl)-3-fluoropicolinoyl)-L-glutamate (112d). 
In a two-neck 50 mL round-bottomed flask flushed with argon were placed NaH (13.78 mg, 
0.34 mmol) and DMF(anhyd) 25 mL. To this mixture was added 92d (0.1 g, 0.31 mmol) 
slowly. The mixture was allowed to stir at rt for 2 h and solution of iodide 110d (0.24 g, 0.47 
mmol) in DMF (5 mL) were added dropwise over 10 min. The mixture was stirred for 2 h, the 
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solvent was removed under reduced pressure, and the crude product was purified by column 
chromatography on silica gel with 3% MeOH:CH2Cl2 as the eluent to yield 112d (179 mg, 
82%) as a sticky oil. TLC Rf = 0.75 (CHCl3:MeOH, 10:1) 
1H NMR (400 MHz, Chloroform-d) 
δ 8.50 (s, 1H, CH), 8.33 (d, J = 8.4 Hz, 1H, NH), 8.22 (t, J = 1.5 Hz, 1H, Ar), 7.33 (dd, J = 
11.5, 1.7 Hz, 1H, Ar), 7.01 (d, J = 2.8 Hz, 1H, Ar), 6.38 (s, 2H, CH2), 6.23 (dd, J = 2.8, 0.5 Hz, 
1H, Ar), 4.82 (td, J = 8.2, 4.9 Hz, 1H, CH), 4.44 (t, J = 7.0 Hz, 2H, CH2), 4.25 (qd, J = 7.1, 2.5 
Hz, 2H, CH2), 4.12 (q, J = 7.2 Hz, 2H, CH2), 3.15 (s, 3H, CH3), 3.06 (d, J = 0.6 Hz, 3H, CH3), 
2.73 (t, J = 7.8 Hz, 2H, CH2), 2.55 – 2.41 (m, 2H, CH2), 2.40 – 2.09 (m, 2H, CH2), 1.98 – 1.87 
(m, 2H, CH2), 1.71 – 1.63 (m, 2H, CH2), 1.32 (t, J = 7.1 Hz, 3H, CH3), 1.28 – 1.23 (m, 3H, 




Compound 113d was prepared using above procedure from 92d (0.4 g, 1.25 mmol), NaH (50 
mg, 1.25 mmol), and 110d (0.79 g, 1.5 mmol) to give 113d in 80% (715 mg) yield as a yellow 
oil. TLC Rf = 0.77 (CHCl3:MeOH, 10:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.51 (s, 1H, 
CH), 8.35 (d, J = 8.2 Hz, 1H, NH), 8.25 (t, J = 1.6 Hz, 1H, NH), 7.33 (dd, J = 11.3, 1.8 Hz, 1H, 
Ar), 7.01 (d, J = 2.5 Hz, 1H, Ar), 6.39 (s, 2H, CH2), 6.23 (dd, J = 2.7, 0.7 Hz, 1H, Ar), 4.85 (td, 
J = 7.9, 5.1 Hz, 1H, CH), 4.41 (t, J = 7.0 Hz, 2H, CH2), 4.25 (q, J = 6.7 Hz, 2H, CH2), 4.12 (q, 
J = 7.3 Hz, 2H, CH2), 3.15 (s, 3H, CH3), 3.06 (s, 3H, CH3), 2.76 (t, J = 7.4 Hz, 2H, CH2), 2.54 
(m, 2H, CH2), 2.41 - 2.28 (m, 2H, CH2), 1.95-1.78 (m, 2H, CH2), 1.72 – 1.62 (m, 4H, CH2), 
1.32 (t, J = 7.1 Hz, 3H, CH3), 1.28 – 1.23 (m, 3H, CH3), 1.18 (s, 9H, CH3). The intermediate 




fluoropicolinoyl)-L-glutamic acid (23c). 
To a 25 mL round-bottomed flask was added 112d (0.24 g, 0.34 mmol), 1N NaOH (4.12 mL, 
4.12 mmol) and MeOH (5 mL), stirred overnight. MeOH was evaporated and reaction was 
acidified to pH 5 using 1N HCl to afford 23c (133 mg, 82%) as a white precipitate. mp 226.8 
°C; 1H NMR (400 MHz, DMSO-d6) δ 8.74 (d, J = 8.0 Hz, 1H, NH), 8.35 (s, 1H, Ar), 7.71 (dd, 
J = 12.0, 1.6 Hz, 1H, Ar), 7.21 (d, J = 2.8 Hz, 1H, Ar), 5.89 (d, J = 2.8 Hz, 1H, Ar), 5.78 (s, 
2H, 2-NH2), 4.41 (td, J = 8.5, 5.1 Hz, 1H, CH), 4.26 (t, J = 6.8 Hz, 2H, CH2), 2.70 (t, J = 7.6 
Hz, 2H, CH2), 2.31 (t, J = 7.4 Hz, 2H, CH2), 2.03 (m, 2H, CH2), 1.74 (p, J = 6.9 Hz, 2H, CH2), 
1.52 (p, J = 7.6 Hz, 2H, CH2). Mass calculated for C21H23FN6O6 [M + H]
+, 475.2; Found 475.6. 
HPLC analysis: retention time, 7.81 min; peak area, 97.08 %; eluent A, H2O with 0.1% TFA: 
eluent B, ACN with 0.1% TFA; gradient elution (95% H2O to 0 % H2O) over 17 min with flow 
rate of 0.3 mL/min and detection at 245 nm; column temperature, rt. 
(5-(5-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)pentyl)-3-
fluoropicolinoyl)-L-glutamic acid (24c). 
To a 25 mL round-bottomed flask was added 113d (0.48 g, 0.67 mmol), 1N NaOH (8.07 mL, 
8.07 mmol) and MeOH (5 mL), stirred overnight. MeOH was evaporated and reaction was 
acidified to pH 5 using 1N HCl to afford 24c (262 mg, 80%) as a white precipitate. mp 190.3 
°C; 1H NMR (400 MHz, DMSO-d6) δ 8.75 (d, J = 7.9 Hz, 1H, NH), 8.35 (s, 1H, Ar), 7.73 (dd, 
J = 11.9, 1.6 Hz, 1H, Ar), 7.18 (d, J = 2.8 Hz, 1H, Ar), 5.88 (d, J = 2.8 Hz, 1H, Ar), 5.86 (s, 
2H, 2-NH2), 4.41 (td, J = 8.5, 5.1 Hz, 1H, CH), 4.21 (t, J = 7.0 Hz, 2H, CH2), 2.67 (t, J = 7.7 
Hz, 2H, CH2), 2.31 (t, J = 7.4 Hz, 2H, CH2), 2.17 – 1.91 (m, 2H, CH2), 1.75 (p, J = 7.1 Hz, 2H, 
CH2), 1.61 (p, J = 7.7 Hz, 2H, CH2), 1.29 – 1.16 (m, 2H, CH2). Mass calculated for 
C22H25FN6O6 [M + H]
+, 489.1; Found 489.1. HPLC analysis: retention time, 1.15 min; peak 
area, 98.43 %; eluent A, H2O with 0.1% TFA: eluent B, ACN with 0.1% TFA; gradient elution 
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(95% H2O to 0 % H2O) over 17 min with flow rate of 0.3 mL/min and detection at 245 nm; 
column temperature, rt. 
Methyl 5-(5-oxohexyl)picolinate (116d). 
To a solution of methyl 4-bromopicolinate (118d) (1.4 g, 5 mmol, 1 eq) in DMF (20 mL) was 
added hex-5-en-2-one 117d (0.52 mL, 5 mmol, 1 eq), LiCl (212 mg, 5 mmol, 1 eq), LiOAc 
(825 mg, 12.5 mmol, 2.5 eq), Bu4NCl (1.41 g, 5 mmol, 1 eq), Pd(OAc)2 (68 mg, 0.3 mmol, 
0.06 eq) and the mixture was stirred at 70 °C for 4 hours. TLC showed the disappearance of 
the starting material and formation of one major polar spot (hexane/EtOAc). To the reaction 
mixture cooled to room temperature was added ethyl acetate. The resulting solution was 
extracted with H2O and dried over Na2SO4. After evaporation of solvent, the residue was 
loaded on a silica gel column and flash-chromatographed with hexane followed by gradual 
increase in polarity to 100% EtOAc. The desired fractions were pooled, evaporated and the 
residue was dried in vacuo using P2O5 to afford mixture of 119d (720 mg, 60%) as colorless 
syrup. TLC Rf = 0.42 (hexane/EtOAc 3:1) The crude 
1H NMR of the intermediate 119d is 
mentioned in the chemical discussion section. The mixture was taken directly to reduction step.  
To 10% palladium on activated carbon (1:1 wt equiv) in a Parr flask, ethanol was added 
to quench. Methanolic solutions of 119d (0.72 g, 4.3 mmol) were added, and hydrogenation 
was carried out at 55 psi of H2 for 5 h. The reaction mixture was filtered through Celite®, 
washed with MeOH, passed through a short silica gel column (3 cm × 5 cm), and concentrated 
under reduced pressure to give methyl 5-(5-oxohexyl)picolinate (116d) (0.69 g, quant. yield) 
as clear oil. Rf = 0.39 (hexane/EtOAc, 3:1). 
1H NMR (400 MHz, Chloroform-d) δ 8.58 (dd, J = 
2.3, 0.7 Hz, 1H, Ar), 8.08 (dd, J = 7.9, 0.8 Hz, 1H, Ar), 7.67 (dd, J = 8.0, 2.3 Hz, 1H, Ar), 4.02 
(s, 3H, OCH3), 2.73 (t, J = 7.2 Hz, 2H, CH2), 2.53 – 2.46 (m, 2H, CH2), 2.15 (s, 3H, CH3), 1.69 





A mixture of the ketone 119d (591 mg, 2.52 mmol, 1 eq) and 2-Amino-6-
hydrazinopyrimidin-4(3H)-one 115d (356 mg, 2.52 mmol, 1 eq) in 2-methoxyethanol (20 mL) 
was refluxed for 14 h, then cooled to room temperature and filtered. The filtrate was 
concentrated to which 1:1 ether/hexanes were added, and the resulting brownish powder was 
collected by filtration to afford 121d (770 mg, 89%) as a light brown powder. TLC Rf = 0.2 
(CHCl3/MeOH, 5:1); mp 183 °C. 
1H NMR (400 MHz, DMSO-d6) δ 9.95 (s, 1H, NH), 8.72 (s, 
1H, NH), 8.58 (d, J = 2.3 Hz, 1H, Ar), 7.99 (d, J = 8.0 Hz, 1H, Ar), 7.83 (dd, J = 8.0, 2.2 Hz, 
1H, Ar), 5.08 (s, 1H, Ar), 4.44 – 4.38 (m, 2H, CH2), 3.84 (s, 3H, OCH3), 3.68 – 3.64 (m, 2H, 
CH2), 3.30 (s, 3H, CH3), 2.72 (t, J = 7.5 Hz, 2H, CH2), 1.68 – 1.58 (m, 2H, CH2). Mass 
calculated for C17H22N6O3 [M - H]
-, 357.14; Found 357.2.  
Diethyl [(E/Z)-2-Cyano-1-methylvinyl]aminolonate (124d). 
To a suspension of an E/Z mixture of 3-aminobut-2-enenitrile 122d (4 g, 48.72 mmol) in 
MeOH (60 mL) was added diethyl aminomalonate hydrochloride 123d (10.72 g, 50.7 mmol). 
The resulting mixture was stirred at room temperature for 5 h. TLC showed the disappearance 
of the starting materials and the formation of one major spot at TLC Rf = 0.26 (EtOAc/ hexane, 
1:2). The reaction solvent was diluted with ethyl acetate (50 mL), washed with brine (30 mL × 
2), and dried over MgSO4. To the organic solvent 15 g of silica gel was added, and the mixture 
was evaporated to dryness under reduced pressure. This silica gel plug was loaded on a dry 
silica gel column (2 cm × 15 cm) and flash-chromatographed initially with n-hexane and then 
sequentially with 5% ethyl acetate in n-hexane, 10% ethyl acetate in n-hexane, and 15% ethyl 
acetate in n-hexane. Fractions containing the desired product (TLC) were pooled and 
evaporated to afford 9.38 g (80%) of 124d as an off-white solid: mp 51-53 °C; 1H NMR (400 
MHz, DMSO-d6) δ E isomer 4.96 (d, 1 H, J = 7.8 Hz, CH), 4.18–4.24 (m, 4 H, CH2), 3.94 (s, 
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1 H, CH), Z isomer 7.51–7.56 (d, 2 H, J = 7.8 Hz, CH), 5.32 (s, 1 H),; 2.05 (s, 6 H, CH3), 1.18–
1.23 (t, 3 H, J = 6.9 Hz, CH3). 
Ethyl 3-Amino-5-methyl-1H-pyrrole-2-carboxylate (125d). 
 A solution of NaOEt in EtOH (0.5 M, 150 mL) was added slowly to a stirred solution of 124d 
(6 g, 25 mmol) in 120 mL of EtOH. The reaction mixture was stirred for 6 h at 60 °C and 
cooled to room temperature. The solvent was evaporated under reduced pressure. The crude 
product was purified by column chromatography on silica gel with 10% EtOAc/Hexane as the 
eluent to yield 125d (3.17 g, 75%) as an off-white solid: mp 89-92 °C TLC Rf =  0.36 
(EtOAc/Hexane, 1:1); 1H NMR (400 MHz, DMSO-d6) δ 10.21 (s, 1 H, NH), 5.26 (s, 1 H, Ar), 
4.91 (s, 2 H, 2-NH2), 4.12 (q, 2 H, J = 6.4 Hz, CH2), 4.12 (q, 2 H, J = 6.4 Hz, CH2), 2.03 (s, 
3H, CH3), 1.24 (t, 3 H, J = 6.4 Hz, CH3). 
5-(4-(2-Amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl)picolinic 
acid (128d). 
To a solution of ethyl 3-amino-5-methyl-1H-pyrrole-2-carboxylate 125d (0.75 g, 4.5 mmol) in 
dry DMF (10 mL) was added slowly NaH (0.21 g, 5.4 mmol) under nitrogen at room 
temperature. The resulting mixture was stirred for about 15 min when there was no more gas 
produced, and then methyl 5-(4-iodobutyl)picolinate (1.42 g, 4.5 mmol) in DMF (3 mL) was 
added dropwise. The reaction mixture was stirred at room temperature for 4 h, and 20 mL of 
water was added carefully to quench the reaction. The sample was extracted with EtOAc (25 
mL × 4), and the organic phases were combined and dried (Na2SO4). Evaporation of the solvent 
offered a gummy residue, which was used for the next step without purification. 
The gummy residue (∼1.72 mmol) was dissolved in MeOH (20 mL), and 1,3-
bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (0.36 g, 1.72 mmol) was added followed by 
AcOH (0.5 mL, 8.62mmol). The mixture was stirred at room temperature overnight and 
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became a thick paste. NaOMe in MeOH (25%) (2.6 mL, 12.07 mmol) was added, and stirring 
was continued at room temperature overnight. The mixture was neutralized with AcOH and 
the methanol was removed under reduced pressure. To the residue was added water (20 mL), 
and the pH value was adjusted to 10–11 by adding NH3 ·H2O. The solid was collected by 
filtration and washed well with water. The resulting solid was added to 1 N NaOH (2 mL), and 
the mixture was heated at 55 °C for 3 h. The mixture was cooled and neutralized with acetic 
acid to give a precipitate. The solid was collected by filtration and chromatographed and eluted 
with 5% MeOH in CHCl3 (containing 0.5% NH3 ·H2O). Fractions containing the desired 
compound (TLC) were pooled and evaporated to afford 462 mg of 128d (25% for three steps) 
as an off white solid: mp >250 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H, NH), 8.40 
(d, J = 7.6 Hz, 1H, Ar), 8.28 (d, J = 2.2 Hz, 1H, Ar), 7.88 (m, 2H, Ar), 5.74 – 5.66 (m, 3H, 
CH3), 4.25 (qd, J = 7.1, 2.5 Hz, 2H, CH2),  2.70 (d, J = 7.6 Hz, 2H, CH2), 1.66 (d, J = 7.5 Hz, 
2H, CH2), 1.58 (d, J = 8.2 Hz, 2H, CH2). Mass calculated for C17H19N5O3 [M + H]
+, 342.15; 
Found 341.9.   
Diethyl (5-(4-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)picolinoyl)-L-glutamate (129d). 
Compound 129d (122 mg, 64%) was prepared as a dark brown oil using similar glutamate 
coupling conditions as 29d, from 128d (100 mg, 0.5 mmol), 2-chloro-4,6-dimethoxy-1,3,5-
triazine (104 mg, 0.6 mmol), 4-methylmorpholine (0.07 mL, 0.6 mmol) and diethyl L-
glutamate HCl (109 mg, 0.7 mmol). TLC Rf = 0.53 (CHCl3:MeOH, 10:1). 
1H NMR (400 MHz, 
DMSO-d6) δ 8.89 (d, J = 7.6 Hz, 1H, NH), 8.50 (d, J = 2.2 Hz, 1H, Ar), 7.93 (d, J = 7.8 Hz, 
1H, Ar), 7.80 (dd, J = 8.2, 2.1 Hz, 1H, Ar), 5.71 (s, 1H, Ar), 5.69 (2, 2H, 2-NH2), 4.53(m, 1H, 
CH), 4.25 (qd, J = 7.1, 2.5 Hz, 2H, CH2), 4.12 (q, J = 7.2 Hz, 2H, CH2), 4.05 (q, J = 7.0 Hz, 
2H, CH2),  2.70 (d, J = 7.6 Hz, 2H, CH2), 2.36 – 2.29 (m, 2H, CH2), 2.21 (s, 3H, CH3), 2.06 
(dd, J = 13.9, 7.4 Hz, 2H, CH2), 1.66 (d, J = 7.5 Hz, 2H, CH2), 1.58 (d, J = 8.2 Hz, 2H). 1.35 
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(t, J = 7.4 Hz, 3H, CH3), 1.25 (m, 3H, CH3). Mass calculated for C26H34N6O6 [M + H]
+, 527.26; 
Found 527.2. The intermediate 129d was used for the next reaction without further 
characterization. 
(5-(4-(2-Amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)picolinoyl)-L-glutamic acid (26c). 
To a 25 mL round-bottomed flask was added 129d (122 mg, 0.23 mmol), 1N NaOH (0.7 mL, 
0.7 mmol) and MeOH (1 mL), stirred overnight. MeOH was evaporated and reaction was 
acidified to pH 5 using 1N HCl to afford 26c (80 mg, 73%) as a white precipitate. mp 223.3 
°C; 1H NMR (400 MHz, DMSO-d6) δ 8.77 (d, J = 7.6 Hz, 1H, NH), 8.50 (d, J = 2.2 Hz, 1H, 
Ar), 7.93 (d, J = 7.8 Hz, 1H, Ar), 7.80 (dd, J = 8.2, 2.1 Hz, 1H, Ar), 5.74 – 5.66 (m, 3H, 1 Ar 
and 2-NH2), 4.36 (d, J = 7.4 Hz, 1H, CH), 4.24 (t, J = 7.0 Hz, 2H, CH2), 2.70 (d, J = 7.6 Hz, 
2H, CH2), 2.36 – 2.29 (m, 2H, CH2), 2.23 (s, 3H, CH3), 2.06 (t, J = 7.4 Hz, 2H, CH2), 1.66 (d, 
J = 7.5 Hz, 2H, CH2), 1.58 (d, J = 8.2 Hz, 2H, CH2). Mass calculated for C22H26N6O6 [M + H]
+, 
471.2; Found 471.6. HPLC analysis: retention time, 8.13 min; peak area,95.24 %; eluent A, 
H2O with 0.1% TFA: eluent B, ACN with 0.1% TFA; gradient elution (95% H2O to 0 % H2O) 
over 17 min with flow rate of 0.3 mL/min and detection at 245 nm; column temperature, rt. 
5-Bromo-2,4-di-tert-butoxypyrimidine (131d).  
5-Bromo-2,4-dichloropyrimidine (2.28 g, 10.0 mmol) is dissolved in dry THF (50 mL). Then 
a solution of sodium tert-butoxide (2.4 g, 25.0 mmol) in THF (100 mL) is added dropwise at 
rt and the reaction mixture stirred for 5 h. The reaction is quenched with water (50 mL) and 
extracted with EtOAc (3 x 50 mL). Purification by flash chromatography yielded the desired 
product 131d as colorless solid (2.63 g, 87%). mp 63 °C. 1H NMR (400 MHz, Chloroform-d) 
δ 8.25 (s, 1H, Ar), 1.66 (s, 9H, CH3), 1.61 (s, 9H, CH3). 
General procedure for the preparation of benzylic phosphates (132d-136d):  
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To a flask charged with the requisite benzyl alcohols (20 mmol), triethylamine (4.18 mL, 30.0 
mmol), DMAP (244 mg, 2 mmol) and THF (5 mL) was added neat diethyl chlorophosphate 
(2.88 mL, 20 mmol) over a 30 min period at room temperature. An exotherm was observed, 
generally raising the internal temperature to 30- 35 °C. The resultant white, heterogeneous 
mixture was stirred for 5 h before it was poured into a mixture of 2 M KHSO4 (20 mL) and 
water (30 mL). The separated organic phase was then washed with satd. aq. NaHCO3 (30 mL) 
and brine (30 mL), before it was dried over Mg2SO4, filtered and concentrated to leave a crude 
oil. The crude oil was purified by chromatography using appropriate mixtures of 
EtOAc/hexane(determined by TLC analysis) to elute any unreacted benzyl alcohol followed 
by the desired benzylic phosphate. 
3,4-Dimethoxybenzyl diethyl phosphate (132d) 
Following the above general procedure, 132d (3.7g) was obtained as a pale yellow oil (60%) 
from 3,4-dimethoxybenzyl alcohol (3.4 g, 20 mmol). 1H NMR (400 MHz, Chloroform-d) δ 1H 
NMR (400 MHz, Chloroform-d) δ 6.92 (d, J = 1.9 Hz, 1H, Ar), 6.90 (d, J = 8.1 Hz, 1H, Ar), 
6.88 – 6.83 (m, 1H, Ar), 4.98 (d, J = 8.2 Hz, 2H, CH2), 3.90 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 
4.18 – 4.12 (m, 4H, CH2), 1.34 (td, J = 7.1, 1.0 Hz, 6H, CH3). 
4-Methylthiobenzyl diethyl phosphate (133d) 
Following the above general procedure, 133d (2.35 g) was obtained as a pale yellow oil (40%) 
from 4-methylthiobenzyl alcohol (3.1 g, 20 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.24 
– 7.20 (m, 2H, Ar), 7.17 – 7.11 (m, 2H, Ar), 5.21 (d, J = 8.2 Hz, 2H, CH2), 4.16 – 4.08 (m, 4H, 
CH2), 2.53 (s, 3H, CH3), 1.35 (t, J = 7.1 Hz, 6H, CH3). 
3,4-Difluorobenzyl diethyl phosphate (134d). 
Following the above general procedure, 134d (4.01 g) was obtained as a pale yellow oil (70%) 
from 3,4-difluorobenzyl alcohol (2.95 g, 20 mmol): 1H NMR (400 MHz, Chloroform-d) δ 7.10 
(dt, J = 10.3, 8.3 Hz, 1H, Ar), 7.01 (ddd, J = 11.4, 7.6, 2.2 Hz, 1H, Ar), 6.88 (ddt, J = 8.2, 3.9, 
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1.7 Hz, 1H, Ar), 4.98 (d, J = 8.2 Hz, 2H, CH2), 4.18 – 4.11 (m, 4H, CH2), 1.36 (t, J = 7.1 Hz, 
6H, CH3). 
3,4,5-Trifluorobenzyl diethyl phosphate (135d). 
Following the above general procedure, 135d (4.08 g) was obtained as a pale yellow oil (75%) 
from 3,4,5-trifluorobenzyl alcohol (2.95 g): 1H NMR (400 MHz, Chloroform-d) δ 7.05 (t, J = 
7.9 Hz, 2H, Ar), 5.00 (d, J = 8.2 Hz, 2H, CH2), 4.19 – 4.09 (m, 4H, CH2), 1.36 (t, J = 7.1 Hz, 
6H, CH3). 
4-(trifluoromethoxy)benzyl diethyl phosphate (136d). 
Following the above general procedure, 136d (4.4 g) was obtained as a pale yellow oil (68%) 
from 4-(trifluoromethoxy)benzyl alcohol (3.8 g, 20 mmol): 1H NMR (400 MHz, Chloroform-
d) δ 6.88 (dd, J = 8.5, 6.5 Hz, 2H, Ar), 6.76 (dd, J = 8.5, 6.5 Hz, 2H, Ar), 5.01 (d, J = 8.2 Hz, 
2H, CH2), 4.16 (m, 4H, CH2), 1.36 (t, J = 7.3 Hz, 6H, CH3). 
General procedure for the preparation of 137d-141d: 
In a flame-dried microwave vial (20 mL) under nitrogen, 131d (1 eq) is dissolved in DME (3 
mL) and cooled to 0 °C. iPrMgCl (1.3 M in THF, 1.1 eq) is added dropwise via syringe. After 
20 min at 0 °C, CuBr (0.1 eq) and P(OEt)3 (0.2 eq) are added. This mixture is added over 30 
min via cannula to a mixture of benzyl phosphates (1.1 eq) and TBAI (0.1 eq) at 60 °C. The 
reaction mixture is heated at 60 °C for 1 h. The reaction mixture is quenched with saturated 
NH4Cl solution, extracted with ether, and dried (Na2SO4), and the crude product was purified 
by flash chromatography (30% EtOAc/Hexane).  
2,4-Di-tert-butoxy-5-(3,4-dimethoxybenzyl)pyrimidine (137d).  
Following the above general procedure, 137d was obtained as a clear oil (1.1 g, 54 %) from 
131d (1.2 g, 6.25 mmol): 1H NMR (400 MHz, Chloroform-d) δ 7.99 (d, J = 1.7 Hz, 1H, Ar), 
6.92 (d, J = 1.9 Hz, 1H, Ar), 6.90 (d, J = 8.1 Hz, 1H, Ar), 6.88 – 6.83 (m, 1H, Ar), 3.92 (s, 3H, 
OCH3), 3.90 (s, 3H, OCH3), 3.68 (s, 2H, CH2), 1.61 (s, 9H, CH3), 1.55 (s, 9H, CH3). 
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2,4-Di-tert-butoxy-5-(4-(methylthio)benzyl)pyrimidine (138d). 
Following the above general procedure, 138d was obtained as a clear oil (770 mg, 40 %) from 
131d (1.1 g, 5.73 mmol): 1H NMR (400 MHz, Chloroform-d) δ 7.99 (s, 1H, Ar), 7.26 – 7.17 
(m, 2H, Ar), 7.17 – 7.08 (m, 2H, Ar), 3.68 (s, 2H, CH2), 2.48 (s, 3H, SCH3), 1.61 (s, 9H, CH3), 
1.55 (s, 9H, CH3). 
2,4-Di-tert-butoxy-5-(3,4-difluorobenzyl)pyrimidine (139d). 
Following the above general procedure, 139d was obtained as a clear oil (1.03 g, 43 %) from 
131d (1.4 g, 7.3 mmol): 1H NMR (400 MHz, Chloroform-d) δ 7.99 (s, 1H, Ar), 7.05 (dt, J = 
10.3, 8.3 Hz, 1H, Ar), 6.99 (ddd, J = 11.4, 7.6, 2.2 Hz, 1H, Ar), 6.89 (ddt, J = 8.2, 3.9, 1.7 Hz, 
1H, Ar), 3.66 (s, 2H, CH2), 1.61 (s, 9H, CH3), 1.54 (s, 9H, CH3). 
2,4-Di-tert-butoxy-5-(3,4,5-trifluorobenzyl)pyrimidine (140d). 
Following the above general procedure, 140d was obtained as a clear oil (1.77 g, 57 %) from 
131d (1.8 g, 9.37 mmol): 1H NMR (400 MHz, Chloroform-d) δ 8.02 (s, 1H, Ar), 6.80 (dd, J = 
8.5, 6.5 Hz, 2H, Ar), 3.65 (s, 2H, CH2), 1.63 (s, 9H, CH3), 1.56 (s, 9H, CH3). 
2,4-Di-tert-butoxy-5-(4-(trifluoromethoxy)benzyl)pyrimidine (141d). 
Following the above general procedure, 141d was obtained as a clear oil (1.48 g, 60 %) from 
131d (1.43 g, 7.44 mmol): 1H NMR (400 MHz, Chloroform-d) δ 8.02 (s, 1H, Ar), 6.88 (dd, J 
= 8.5, 6.5 Hz, 2H, Ar), 6.76 (dd, J = 8.5, 6.5 Hz, 2H, Ar), 3.65 (s, 2H, CH2), 1.61 (s, 9H, CH3), 
1.56 (s, 9H, CH3). 
General procedure for the preparation of 5-substituted-benzyl pyrimidine-2,4-diamine 
(28c-32c). 
2,4-Di-tert-butoxy-5-substituted-benzyl pyrimidines (137d-141d) were dissolved in 
MeOH (5 mL) then conc. HCl (2 mL) was added dropwise and immediately a precipitate was 
formed. The reaction mixture was stirred 15 min at rt, then the precipitate was filtered off and 
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washed with cold MeOH and dried in vacuo to yield the desired products 5-(substituted-
benzyl)pyrimidine-2,4-(1H,3H)-dione as colorless solids in 80-90% yield. The compounds 
were used for the next step without further purification.   
To a stirred mixture of POCl3 (15 mL) and 5-(substituted-benzyl)pyrimidine-
2,4(1H,3H)-diones in a 25 mL round-bottomed flask with reflux condenser 2 drops of DMF 
were added then the reaction mixture was refluxed for 1 h at 110 °C. Afterwards the reaction 
mixture was poured on ice, extracted with diethyl ether, and the organic layer dried over 
Na2SO4. Purification by flash chromatography yielded 142d-146d as colorless solids. 
Intermediates 142d-146d were suspended in a solution of NH3 in MeOH (10 mL, 7 N) 
in a 10-20 mL microwave vial at 150 °C for 12 h (19-20 bar pressure), then the solvent is 
removed in vacuo. Crude was purified by column chromatography to yield proposed 
compounds (28c-32c) in 30-40% yield over three steps. 
5-(3,4-Dimethoxybenzyl)pyrimidine-2,4-diamine (28c). 
Following the above general procedure, 28c was obtained as a cream white solid (30 %): 1H 
NMR (400 MHz, DMSO-d6) δ 7.51 (s, 1H, Ar), 6.91 (d, J = 1.9 Hz, 1H, Ar), 6.89 (d, J = 8.1 
Hz, 1H, Ar), 6.85 (m, 1H, Ar), 6.12 (s, 2H, 4-NH2), 5.75 (s, 2H, 2-NH2), 3.92 (s, 3H, OCH3), 
3.90 (s, 3H, OCH3), 3.62 (s, 2H, CH2). mp 231-233 °C (lit.
369 233 °C). Anal. Calcd for 
C13H16N4O2: C, 59.98; H, 6.19; N, 21.52. Found: C, 59.75; H, 6.22; N, 21.37. 
5-(4-(Methylthio)benzyl)pyrimidine-2,4-diamine (29c). 
Following the above general procedure, 29c was obtained as a white solid (37 %): 1H NMR 
(400 MHz, DMSO-d6) δ 7.48 (s, 1H, Ar), 7.17 (s, 4H, Ar), 6.10 (s, 2H, 4-NH2), 5.73 (s, 2H, 2-
NH2), 3.56 (s, 2H, CH2), 2.44 (s, 3H, SCH3). mp 211-214 °C. Anal. Calcd for C12H14N4S · 






Following the above general procedure, 30c was obtained as a white solid (40 %): 1H NMR 
(400 MHz, DMSO-d6) δ 7.55 (s, 1H, Ar), 7.38 – 7.22 (m, 2H, Ar), 7.09 – 7.00 (m, 1H, Ar), 
6.16 (s, 2H, 4-NH2), 5.76 (s, 2H, 2-NH2), 3.60 (s, 2H, CH2). mp 189 °C. Anal. Calcd for 
C11H10F2N4: C, 55.92; H, 4.26; N, 23.72; F, 16.08. Found: C, 55.98; H, 4.41; N, 23.54; F, 15.95. 
5-(3,4,5-Trifluorobenzyl)pyrimidine-2,4-diamine (31c). 
Following the above general procedure, 31c was obtained as a buff color solid(36 %): 1H NMR 
(400 MHz, DMSO-d6) δ 7.53 (s, 1H, Ar), 7.40 – 7.33 (t, J = 5.6 Hz, 2H, Ar), 6.13 (s, 2H, 4-
NH2), 5.74 (s, 2H, 2-NH2), 3.62 (s, 2H, CH2). mp 222-224 °C. Anal. Calcd for C11H9F3N4: C, 
51.97; H, 3.57; N, 22.04, F, 22.42. Found: C, 51.63; H, 3.45; N, 21.85; F, 22.08. 
5-(4-(Trifluoromethoxy)benzyl)pyrimidine-2,4-diamine (32c). 
Following the above general procedure, 32c was obtained as a white solid (34 %): 1H NMR 
(400 MHz, DMSO-d6) δ 7.52 (s, 1H, Ar), 7.00 (dd, J = 8.3, 6.1 Hz, 2H, Ar), 6.82 (dd, J = 8.3, 
6.4 Hz, 2H, Ar), 6.11 (s, 2H, 4-NH2), 5.75 (s, 2H, 2-NH2), 3.65 (s, 2H, CH2). mp 264.7 °C. 
Anal. Calcd for C12H11F3N4O: C, 50.70; H, 3.90; N, 19.71; F, 20.05. Found: C, 50.93; H, 4.09; 










This dissertation describes the design and synthesis of selective pjDHFR inhibitors, 
single agents with combination chemotherapy and multiple RTK inhibitory potential and single 
agents with tumor targeting via cellular uptake by Folate Receptors and Proton-Coupled Folate 
Transporter and inhibition of de novo purine nucleotide biosynthesis. The novel compounds 
synthesized as part of this study are listed below: 
1. N-(5-Methoxynaphthalen-2-yl)-N-methylquinazolin-4-amine (1c).  
2. 2-Chloro-N-methyl-N-(4-(methylthio)phenyl)quinazolin-4-amine (2c). 
3. 2-Chloro-N-(4-methoxyphenyl)-N-methylpyrido[3,2-d]pyrimidin-4-amine (3c). 




7. N-(4-Methoxyphenyl)-N-methylpyrido[3,2-d]pyrimidin-4-amine (7c). 
8. 4-(6-Methoxy-3,4-dihydroquinolin-1(2H)-yl)pyrido[3,2-d]pyrimidine (8c). 
9. N-Methyl-N-(4-(methylthio)phenyl)pyrido[3,2-d]pyrimidin-4-amine (9c). 
10. N-(5-Methoxynaphthalen-2-yl)-N-methylpyrido[3,2-d]pyrimidin-4-amine (10c). 
11. 5-Phenoxy-9H-pyrimido[4,5-b]indole-2,4-diamine (11c). 
12. 5-(p-Tolyloxy)-9H-pyrimido[4,5-b]indole-2,4-diamine (12c). 
13. (5-(2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)picolinoyl)-L-glutamic acid (13c). 
14. (5-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)picolinoyl)-L-glutamic acid (14c). 
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15. (5-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)picolinoyl)-L-glutamic acid (15c). 
16. (5-(5-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)picolinoyl)- L-glutamic acid (16c). 
17. (6-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)nicotinoyl)- L-glutamic acid (17c). 
18. (6-(5-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)nicotinoyl)-L-glutamic acid (18c). 
19. (6-(5-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)nicotinoyl)-L-glutamic acid (19c). 
20. 5-(3,4-Dimethoxybenzyl)pyrimidine-2,4-diamine (28c). 
21. 5-(4-(Methylthio)benzyl)pyrimidine-2,4-diamine (29c). 
22. 5-(3,4-Difluorobenzyl)pyrimidine-2,4-diamine (30c). 
23. 5-(3,4,5-Trifluorobenzyl)pyrimidine-2,4-diamine (31c). 
24. 5-(4-(Trifluoromethoxy)benzyl)pyrimidine-2,4-diamine (32c). 
Partially characterized final compounds: 
1. (5-(3-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propyl)picolinoyl)-L-glutamic acid (20c). 
2. (5-(4-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)picolinoyl)-L-glutamic acid (21c). 
3. (5-(5-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)pentyl)picolinoyl)-L-glutamic acid (22c). 
4. (5-(4-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl)-3-
fluoropicolinoyl)-L-glutamic acid (23c). 
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5. (5-(5-(2-Amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)pentyl)-3-
fluoropicolinoyl)-L-glutamic acid (24c). 
6. (5-(4-(2-Amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)picolinoyl)-L-glutamic acid (26c). 
Among these compounds 1c-10c were evaluated as microtubule targeting agents binding 
at the colchicine site of tubulin. Compounds 1c and 7c were also tested for microtubule 
depolymerization and inhibition of tubulin assembly assays. Compounds 3c-10c were tested 
against parental OVCAR-8 and P-gp overexpressing NCI/ADR-RES cell lines. RTK inhibitory 
assays for compounds 1c-10c are underway. 
During this study, a novel synthetic route was successfully optimized for the synthesis of 
target compounds 11c and 12c. Ullmann coupling conditions were explored and successfully 
employed as a key step to obtain the target compounds.  
Biological evaluation of proposed compounds (13c-15c, 20c-22c and 26c) were carried out 
in engineered CHO cell lines that overexpressing RFC, FRα, FRβ, and PCFT. Testing of the 
other compounds (16c-19c and 23c-24c) are underway. Majority of the proposed compounds 
showed improved selectivity compared to the lead compounds. Using traditional bioisosteric 
substitutions and possible conformation restriction (via intra-molecular H-bonding (pyridine 
nitrogen) or stereoelectronic effects (fluorine substitution)), we were able to successfully 
incorporate selectivity and improve potency. Evaluation of compounds 28c-32c are underway 








The tumor inhibitory assays, microtubule depolymerization assays were performed by 
Dr. Susan L. Mooberry (Department of Pharmacology. University of Texas Health Science 
Center at San Antonio, San Antonio, TX 78229). The colchicine binding assays and bovine 
brain tubulin polymerization assays were performed by Dr. Ernest Hamel (Screening 
Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment 
and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, 
Frederick, MD 21702). The biological evaluations of the were performed by Dr. Larry H. 
Matherly (Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute and 
the Cancer Biology Program and Department of Pharmacology, Wayne State University 
School of Medicine) against GARFTase, RFC-expressing PC43-10 cells, FRα-expressing 
RT16 cells, FRβ-expressing D4 cells and hPCFT-expressing R2/hPCFT4 cells. 
Table 16. Antiproliferative and microtubule depolymerizing effects of quinazoline (1c) and 
pyrido[3,2-d]pyrimidine analog (7c). 










1c 2.7 ± 0.5 2.7 1 
7c 30.1 ± 3 272 9 





Table 17. Effects of pyrido[3,2-d]pyrimidine analogs 3c-10c and CA-4 on tubulin assembly 
and colchicine binding. Growth inhibition of parental cell line (OVCAR-8) and Pgp 












colchicine                                                           
binding 
% inhibition (SD) 
Compound activity in a Pgp 
overexpressing cell line
(NCI/ADR-RES) and in a 








OVCAR-8   
IC50 (SD) nM   
NCI/ADR-RES   
IC50 (SD) nM  
2c 0.5 (0.06) 96 (3) 77 (5) 6 (0.7) 3 
3c  0.66 (0.07) 97 (0.06) 85 (2) 4 (1) 3 (1) 
4c  0.62 (0.1) 97 (3) 88 (4) 1 (0) 14 (2) 












7c  1.3 (0.04) 87 (0.6)  ND 68 (20) 39 (2) 
8c  1.6 (0.09) 86 (1) ND 120 (7) 75 (20) 
9c  0.74 (0.1) 
 
82 (3) ND 100 (10) 84 (6) 
10c  0.8 (0.08) 92 (0.007) 63 (4) NT NT 
CA-4 0.54 (0.06) 99 (0.7) 86 (3) 9.0 (1) 5.5 (0.7) 
Paclitaxel - - - 5.5 (2) 3100 (800) 
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Table 18. IC50 Values (nM) for 5-Substituted Pyrrolo[2,3-d]pyrimidine Classical Antifolates 
in RFC-, PCFT-, and FR-Expressing Cell Lines. 
 hRFC hFRα hPCFT KB 
 PC43-10 RT16 R2/hPCFT4 hRFC/hFRα/ 
FRβ/hPCFT 
PMX 26.2 ± 5.5  42 ± 9  8.3 ± 2.7  68 ± 12 
45c 68.8 ± 21.2  72.0 ± 27.1  329 ± 61  68.8 ± 21.2 
46c 56.6 ± 5.8  8.6 ± 2.1  840 ± 90  56.6 ± 5.8 
13c 89.5 336 10.3 497 
14c 546 17.2 96.6 15.9 
15c 55 2.56 65.96 2.51 
 
Table 19. IC50 Values (nM) for 5-Substituted Pyrrolo[3,2-d]pyrimidine Classical Antifolates 
in RFC-, PCFT-, and FR-Expressing Cell Lines. 
 hRFC hFRα hPCFT KB 
 PC43-10 RT16 R2/hPCFT4 hRFC/hFRα/ 
FRβ/hPCFT 
48c 43 50 25.2 6.7 
49c 516 2.13 309 6.8 
50c >1000 26.6 327 6.3 
20c >1000 8 749 10.78 
21c >1000 0.58 >1000 0.75 
22c >1000 9.47 >1000 1.58 
26c >1000 14.12 >1000 227 







Figure 82. Protection studies for compound 14c (AGF315) 
 
 
Figure 83. Protection studies for compound 15c (AGF317) 
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Figure 84. Protection studies for compound 20c (AGF363) 
 
 
Figure 85. Protection studies for compound 22c (AGF370) 
 


















3 6 3  T
3 6 3  G
3 6 3  F F
3 6 3  F A
3 6 3  A IC A + G
3 6 3  A IC A
3 6 3  A + T
3 6 3  A + G
3 6 3  A


















3 7 0  T
3 7 0  G
3 7 0  F F
3 7 0  F A
3 7 0  A IC A + G
3 7 0  A IC A
3 7 0  A + T
3 7 0  A + G
3 7 0  A
 228 
Methods 
Effects of compounds on cellular microtubules: The effect of the compounds on interphase 
and mitotic microtubules were evaluated in A-10 cells using indirect immunofluorescence 
techniques, and the EC50 ((concentration required to cause 50% loss of cellular microtubules)) 
values were calculated from a minimum of three experiments. 
 
Sulforhodamine B (SRB) assay: The cytotoxic and antiproliferative effects of the compounds 
against cancer cells was evaluated using SRB assay. MDA-MB-435 cells were used for 
determining IC50 values (concentration required to cause 50% inhibition of proliferation). 
 
[3H] Colchicine displacement assay: The binding of [3H]colchicine to tubulin was performed 
by the DEAE-cellulose filter technique with a stack of two filters, as described in detail 
previously. In brief, reaction mixtures contained, in a 0.10 mL volume, 1.0 μM purified tubulin, 
5.0 μM [3H]colchicine, potential inhibitor at 5.0 μM, 5% (v/v) dimethyl sulfoxide (the 
compound solvent), and other components previously found to stabilize the colchicine binding 
activity of tubulin for prolonged periods at 37°C. Incubation was at 37°C for 10 min, at which 
time samples were diluted with 2 mL of ice-cold water and poured over the DEAE-filters under 
mild suction, with several rinses of the reaction vessel and of the filtration chamber. The 
amount of radiolabel bound to the filters was determined by liquid scintillation counting, and 
samples containing test compounds were compared to reaction mixtures without compound. 





OVCAR-8, NCI/ADR-RES and HeLa cells 
The OVCAR-8 and the Pgp overexpressing NCI/ADR-RES cell lines were generously 
provided by the Drug Screening group of the Developmental Therapeutics Program, NCI. The 
wild-type and β-III overexpressing HeLa cells were generous gifts, respectively, of Dr. Richard 
F. Ludueña and Dr. Susan L. Mooberry. The OVCAR-8 and NCI/ADR-RES cells were grown 
in RPMI 1640 medium with 5% fetal bovine serum at 37 °C in a 5% CO2 atmosphere for 96 h 
in the presence of varying compound concentrations. The HeLa cells 
were grown in MEM supplemented with Earle’s salts, nonessential amino acids, 2 mM L-
glutamine, and 10% fetal bovine serum at 37 °C in a 5% CO2 atmosphere for 96 h in the 
presence of varying compound concentrations. In all cultures, the DMSO concentration was 
0.5%. Protein was the parameter measured by the sulforhodamine B technique,8 and 
the IC50 was defined as the compound concentration causing a 50% reduction in the increase 
in cell protein as compared with cultures without compound addition. 
 
Cell Lines and Assays of Antitumor Drug Activities. The engineered CHO sublines 
including RFC-, PCFT- and FRα-null MTXRIIOuaR2-4 (R2), and RFC- (PC43-10), PCFT- 
(R2/PCFT4), or FRα- (RT16) and FRβ- (D4) expressing CHO sublines were previously 
described. The CHO cells were cultured in α-minimal essential medium (MEM) supplemented 
with 10% bovine calf serum (Invitrogen, Carlsbad, CA), penicillin (1000 U/mL) streptomycin 
(1000 μg/mL) and 2 mM L-glutamine at 37° C with 5% CO2. All the R2 transfected cells 
(PC43-10, RT16, R2/hPCFT4) were cultured in complete α-MEM media plus 1 mg/mL G418. 
Prior to the cytotoxicity assays (see below), RT16 and D4 cells were cultured for 3 days in 
complete folate free RPMI 1640 (without added folate), plus dialyzed fetal bovine serum (FBS) 
(Sigma-Aldrich) and penicillin/streptomycin. KB human nasopharengeal carcinoma cells were 
purchased from the American Type Culture Collection (Manassas, VA). KB cells were 
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routinely cultured in folate-free RPMI 1640 medium, supplemented with 10% FBS (Sigma-
Aldrich), penicillin-streptomycin solution, and 2 mM L-glutamine. For growth inhibition 
studies, cells (CHO, KB) were plated in 96 well dishes (~2500-5000 cells/well; total volume 
of 200 μl medium) with a range of antifolate concentrations (0-1000 nM). The experiments 
with RT16, D4, and KB cells used folate-free RPMI medium with 10% dialyzed FBS, 
antibiotics and L-glutamine; the medium was supplemented with 2 nM LCV. To confirm FR-
mediated drug uptake, 200 nM folic acid was added to parallel incubations. For experiments 
with R2, PC43-10, and R2/PCFT4 cells, cells were routinely cultured in folate free RPMI 1640 
(pH 7.2)/10% dialyzed FBS with antibiotics and L-glutamine, supplemented with 25 nM LCV. 
Cells were incubated up to 96 h and viable cells were assayed with Cell-Titer BlueTM reagent 
(Promega, Madison, WI), with fluorescence measured with a fluorescence plate reader. 
Fluorescence data were analyzed for calculations of IC50s, corresponding to the drug 
concentrations that resulted in 50% loss of cell proliferation. 
 
FR Binding Assay. [3H]Folic acid binding was used to assess levels of surface FRs. 
Briefly, cells (e.g., RT16 or D4; ∼1.6 × 106) were rinsed twice with Dulbecco’s 
phosphatebuffered saline (DPBS) followed by two washes in acidic buffer (10 mM sodium 
acetate, 150 mM NaCl, pH 3.5) to remove FR-bound folates. Cells were washed twice with ice 
cold HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5 mM 
glucose, pH 7.4; HBS), then incubated in HBS with [3H]folic acid (50 nM, specific 
activity 0.5 Ci/mmol) in the presence and absence of a range of concentrations of unlabeled 
folic acid or antifolate for 15 min at 0 °C. The dishes were rinsed three times with ice-cold 
HBS, after which the cells were solubilized with 0.5 N sodium hydroxide and aliquots 
measured for radioactivity and protein contents. Protein concentrations were measured with 
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Folin phenol reagent. Bound [3H]folic acid was calculated as pmol/mg protein. Relative 
binding affinities for assorted folate/antifolate substrates were calculated as the 
inverse molar ratios of unlabeled ligands required to inhibit [3H]folic acid binding by 50%. 
By definition, the relative affinity of folic acid is 1. 
 
PCFT and RFC Transport Assays. For transport assays, R2/hPCFT4, PC43- 10, and R2(VC) 
CHO cells grown as monolayers were used to seed spinner flasks. For experiments to determine 
the inhibitions of transport by antifolate substrates, cells were collected and washed with DPBS 
and resuspended in 2 mL of physiologic Hank’s balanced salts solution (HBSS) for PC43-10 
cells and in HBS adjusted to pH 7.2 or 6.8 or 4-morpholinepropanesulfonic acid (MES)-
buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose) 
adjusted to pH 6.5, 6.0, or 5.5 for R2/hPCFT4 cells. In either case, uptakes of [3H]MTX (0.5 
μM) were measured over 2 min at 37 °C in the presence and absence of unlabeled antifolates 
(10 μM). Uptakes of [3H]MTX were quenched with ice-cold DPBS. Cells were washed with 
ice cold DPBS (3×) and solubilized with 0.5 N NaOH. Levels of intracellular radioactivity 
were expressed as pmol/mg protein, calculated from direct measurements of radioactivity and 
protein contents of cell homogenates. Protein concentrations were measured with Folin phenol 
reagent. Percent MTX transport inhibition was calculated by comparing level of [3H]MTX 
uptake in the presence and absence of the inhibitors. Kinetic constants (Kt, Vmax) and Kis were 
calculated from Lineweaver-Burke and Dixon plots, respectively. 
 
Protection experiments. IGROV1 cells were plated (2000 cells/well) in folate-free RPMI 
1640 medium with 10% dialyzed FBS, antibiotics, L-glutamine, and 25 nM LCV with a range 
of drug concentrations in the presence of adenosine (60 μM), thymidine (10 μM), AICA (320 
μM) or glycine (130 μM). Cell proliferation was assayed with Cell Titer Blue 
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(Promega) using a fluorescence plate reader. Data are representative of at least triplicate 
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